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A multiscale, agent-based mathematical framework is here used to capture
the multiscale nature of solid tumours. Tumour dynamics and treatment
responses are modelled and simulated in silico. Details regarding cell cy-
cle progression, tumour growth and oxygen distribution are included in the
mathematical framework. Treatment responses to conventional anti-cancer
therapies, such as chemotherapy and radiotherapy, as well as to more novel
drugs, such as hypoxia-activated prodrugs and DNA-damage repair inhibit-
ing drugs, are studied. Uncertainty and sensitivity analyses techniques are
discussed in order to mitigate model uncertainty and interpret model sen-
sitivity to parameter perturbations. This thesis furthermore discusses the
role of mathematical modelling in current cancer research.
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1.1 Personalised cancer practice on various levels, namely Population, Patient, Tu-
mour Prole. On a population macro-level, a population can be categorised into
various subpopulations (for instance based on age, gender or smoking habits),
which in turn can be evaluated and risk-assessed for preventative, detective and
corrective oncology practice. On a central, patient-specic level, cancer care
may be tailored to t the needs, lifestyle and priorities of the patient, in pursuit
of medicine that optimises both treatment outcome and the patient's quality
of life. On a tumour prole level, tumour-specic data can provide information
which may contribute towards disease prognoses and intelligent treatment de-
cisions. Narrowing down cancer care personalisation to tumour level allows for
a bottom-up approach to personalised tumour treatments. . . . . . . . . . . 4
1.2 'Bench-to-bedside' depicts the practice of transferring in vitro and in vivo nd-
ings from the laboratory to a clinical setting. The contemporary mathemati-
cian works on both blackboards and computer keyboards thus we therefore,
analogously, present the term blackboard-to-bedside to describe the action of
translating mathematical and computational intelligence to clinical application. 5
2.1 Time evolution of protein concentrations in one simulated cancer cell (measured
in grams of protein per gram of total cell mass), where the cell cycle length is
25 hours. (a) The opposing dynamics between [CycB] and [Cdh1], which is key
in the used mathematical cell cycle model. (b) Concentrations of the auxiliary
proteins [Pkl1] and p55cdc in its total form [p55cdcT ], and its active form
[p55cdcA]. (c) Cell mass, [mass] over time, where [mass] is halved at the very
start of each cell cycle, i.e. immediately after cell division. . . . . . . . . . . 14
xv
LIST OF FIGURES
2.2 The G1 Delay Factor (G1DF) is incorporated in the model to achieve oxygen-
dependent G1 arrest. The G1DF (dark line) is approximated using results (red
crosses) from a previous mathematical study by Alarcon et al. [1]. . . . . . . 18
2.3 The 1st, 2nd and 3rd order neighbourhood (O.N.) of a parental agent
using (a) the von Neumann convention and (b) the Moore convention. . 20
2.4 The target occupancy (pA) plotted over drug concentration (xA) when the drug
concentration increases on a linear (left) and logarithmic (right) scale. Here
KA, i.e. the drug concentration that yields 50% target occupancy, is xA = 100
(concentration units). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.5 The oxygen enhancement ratio (OER) and the oxygen modication factor (OMF)
plotted over oxygenation value. . . . . . . . . . . . . . . . . . . . . . . . . 35
2.6 The probability S(x, t) that a cell location x at time t in our mathematical
framework survives a radiation dose of 2 Gy, as a function of its cell cycle phase
(see legend) and oxygenation value. The values for α and β are gathered from
a previous study by Kempf et al. [2] and are listed in Table 4.1. . . . . . . . 36
3.1 A schematic representation of the multiscale hybrid mathematical model used
in this study. The model integrates extracellular, intracellular and intercellular
dynamics. This is an on-lattice model and a lattice point may be occupied
by a sensitive (S) or drug resistant (DR) cancer cell shown in black, a blood
vessel cross-section or extracellular space. Various categories of drug resistance
regarded on a cellular resolution are incorporated in the model, these categories
are marked in red and listed in Table 3.4. . . . . . . . . . . . . . . . . . . . 44
3.2 Classication of drug resistance categories occurring in the model. Drug
resistance may be independent of drug presence (orange labels), induced
as a consequence of drug presence (purple labels), or either (orange and
purple labels). Cell acquisition of any DR phenotypical trait (top half)
is here modelled as irreversible and inheritable by any future daughter
cells to the cell in question. . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.3 Partial algorithm for determining primary drug resistance. . . . . . . . 55
3.4 Partial algorithm for determining induced drug resistance. . . . . . . . 56
3.5 Partial algorithm for determining exosome production. . . . . . . . . . 56
xvi
LIST OF FIGURES
3.6 Partial algorithm for determining the spontaneous conversion from a
slow-cycling to a fast-cycling state. . . . . . . . . . . . . . . . . . . . . 57
3.7 Growth of the cancer cell population over time in drug absence, showing
total population (black graph), drug sensitive subpopulation (blue graph)
and drug resistant subpopulation (red graph) incorporating control-case
drug resistance categories (a0) No DR, (b0) Primary DR and (e0) Slow-
Cycling DR. Cases (c0) Drug-induced DR and (d0) Communicated (ICC)
DR are omitted since they produce the same results as (a0) in drug
absence. Each graph shows the average number of cells based on 100
simulations, the standard deviation is demonstrated with error bars. . . 59
3.8 Growth of the cancer cell population over time when drugs are applied
at 500 and 600 hours, showing total population (black graph), drug sen-
sitive subpopulation (blue graph) and drug resistant subpopulation (red
graph). Each row in the gure corresponds to a category of drug resis-
tance (a) to (e) according to the labelling in Table 3.4 ((a) No DR, (b)
Primary DR, (c0) Drug-induced DR, (d0) Communicated DR (e) Slow-
cycling DR), whilst each column corresponds do a specic drug dosage
varying from low (leftmost column) to high (rightmost column), namely
(1) 1C, (2) 2C, (3) 4C and (4) 8C according to the labelling system in
Table 3.5. Each graph shows the average number of cells based on 100
simulations, the standard deviation is demonstrated with error bars. . . 61
3.9 The scaling eciency, demonstrating the relationship between drug dosage and
drug ecacy in terms of number of killed cancer cells. This is for the rst
drug administration at 500 hours for experiments (a1) to (a4) according to the
labelling in Tables 3.4 and 3.5, where no drug resistant phenotypes are present.
Results are based on average values for 100 tests. . . . . . . . . . . . . . . . 62
3.10 Cell-maps of the cancer cell populations at times 500 h (immediately
before rst drug dose), 510 h 600 h (immediately before second drug
dose), 610 h and 700 h (end of simulation). Cases incorporating (a) No
DR and (b) Primary DR are shown for drug dosages of (1) 1C and (4) 8C
according to the labelling in Tables 3.4 and 3.5. White areas correspond
to extracellular space. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
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3.12 Diagram of the drug sensitive subpopulation (blue) and the drug resistant
subpopulation. Various types of drug resistance are incorporated namely
(a) No DR, (b) Primary DR, (c) Induced DR, (d) ICC DR, (e) SC DR.
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(end of simulation) for low drug dosages, (1) 1C, and high drug dosages,
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3.13 Diagram of the ratio between the drug sensitive subpopulation (blue)
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of the tumours (left) expresses drug resistance pre chemotherapy, the
other one (right) does not. Generally in our in silico experiment, drug
resistance that occurs independently of the drug, and thus may precede
chemotherapy, is amplied by high drug dosages (left). Conversely, drug
resistance that is induced by drug presence is accelerated by low to mod-
erate drug dosages (right). . . . . . . . . . . . . . . . . . . . . . . . . . 69
xviii
LIST OF FIGURES
4.1 Cell count over time for tumour spheroids. The in silico data is based on
10 simulations runs, the mean (black line) shows the average value and
the gray ribbon shows standard deviation. In vitro data (red error bars)
are extracted from plots produced by Voissiere et al. [3] using a Java
program [4]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
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ing from comparisons between distributions with perturbed data and a
distribution with calibrated (unperturbed) data. . . . . . . . . . . . . . 163
6.15 Robustness Analysis. Left: Output responses, in terms of percentage
of γH2AX positive (i.e. damaged) cells, and cell count as a result of
perturbations to the input variable ΠD−s. Right: Maximal Â-values
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Mathematical oncology is the exciting research eld in which mathematics meets
traditional cancer research. This chapter motivates the use and development of
mathematical tumour models, and highlights their current and potential contributions
to oncology.
1.1 Mathematical Oncology
Mathematical and computational approaches may constitute a fantastic complement to
classical cancer research, traditionally performed in wet labs and clinics. Due to recent
advances in imaging techniques, the vast accumulation of experimental and clinical data
and available computational power, in silico studies have gradually been entering the
stage of medical research over the last decades [9]. Cancer is a highly complex disease,
and whilst this complexity presents diculties in model formulation, parametrisation
and implementation for the mathematician, this complexity also infers that there is pos-
sible biomedical insight to be gained from mathematical models and their corresponding
in silico experiments. Modelling may unveil new, important information regarding bio-
logical cancer systems and their sub-mechanisms and thus elucidate underlying tumour
processes [10]. The advantages of mathematical and computational oncology are mul-
tifold. Compared to other types of experiments, in silico experiments are both cheap
and quick to perform, highly adaptable and associated with few direct ethical concerns
[11]. Theories formulated in laboratories or clinics can be tested in silico on simulated,
virtual tumours prior to, or in parallel with, classical bench experiments in order to
1
1. INTRODUCTION
validate or guide in vitro and in vivo experiments.
Today, there exists a wide array of mathematical models that are able to capture var-
ious phases of tumour progression and associated mechanisms such as tumour growth,
invasion and metastasis [1217], angiogenesis [1821] and treatment responses [2228].
A comprehensive overview of the eld may be found in a review article by Lowengrub
et al. [29]. Some of these models have successfully conferred with both in vitro and
in vivo experiments or clinical observations [5, 3032], and consequently mathematical
tumour modelling is steadily gaining acceptance in the medical community.
1.2 Mathematics in Personalised Oncology
Personalised medicine is becoming an increasing part of modern cancer care [33, 34].
Patient specic metrics advise contemporary clinical procedure in terms of vaccine rec-
ommendations, screening practice [35] and treatment planning [36]. The aim of person-
alised medicine is to tailor health care specically to the individual patient, in pursuit
of optimal treatment outcome and quality of life. As a strategy, personalised medicine
can be highly benecial in cancer care, as cancer is a disease presenting with high vari-
ability across incidences. It is indeed well established that a one to t all strategy
to prevent, diagnose and treat cancer is a sub-par approach [37]. Ideally, in line with
concepts of personalised medicine, patients should instead be individually evaluated and
matched with appropriate cancer care strategies. The personalisation of medicine can
occur on various levels, as is pictorially illustrated in Figure 1.1. Patient and tumour
metrics gathered from macro-level population data, down to micro-level molecular tu-
mour data, may aid anti-cancer decision making in clinical settings.
On a population level, a population can be categorised and divided into various sub-
populations, which in turn can be evaluated and risk-assessed. Certain subpopulations
express elevated risks of developing particular cancer types, and likewise certain sub-
populations have a predisposition to aggressive disease. This categorisation can be
determined by inexible parameters such as age [35, 36, 38, 39], genetics [38, 40], race
[38] and gender [35, 39] as well as by exible parameters such as smoking habits [41],
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hormone exposure [40], obesity levels [42] and socio-economic factors. The combina-
tion of wide population data and gathered clinical experience can be used to determine
suitable, personalised treatment strategies post tumour detection, and also to evaluate
the need for cancer screening and vaccine administration [43]. For the individual pa-
tient to benet from screenings, screening scheduling should be personalised in order to
enable optimised cancer intervention [41]. By deploying mathematical models, which
incorporate biological knowledge and evolutionary concepts, optimised and personalised
screening recommendations can be achieved [41]. In order to more competently consider
the concerns, quality of life and well-being of a patient, cancer care can be tailored on a
patient-specic level. Post cancer detection, lifestyle, personal priorities and economic
factors all contribute towards determining which treatment strategy is the most appro-
priate for the individual patient [38]. On this central, patient-specic level of treatment
personalisation, the dialogue between patient and clinician is of the essence [38], and it
is important that the patient is well-informed by the clinician.
In parallel, in order to keep the clinician as well-informed as possible, personalised
medicine can be even further detailed and narrowed down to the tumour level [44].
Post tumour detection, disease forecasting and treatment decisions can be informed
by tumour-specic data. Due to the high variability of cancer displayed across disease
incidences, previous research indicates that tumour prognosis and treatment responses
may correlate higher with molecular tumour specics than with larger-scale factors,
such as anatomical tumour origin [33] or metrics quantied on a patient or population
level. Recent advances in bio-marker handling [45, 46], biopsy techniques and medical
imaging enable tumour assessment [47] prior to and throughout treatments regimes.
However, current biopsy procedures may in certain cases be infeasible to perform and
furthermore, tumours are highly evolutive systems whose proles may change after an
evaluation of imaging or biopsy results. Therefore, being able to predict tumour evolu-
tion, progression and treatment response, given tumour-specic input data at an earlier
time point, would present an immensely valuable tool in clinical treatment planning.
Various aspects of tumour growth and treatment responses are currently being investi-
gated in silico by the mathematical oncology community [48]. One of the main, current
missions in the research eld of mathematical and computational oncology is to bridge
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the gap between virtual and physical tumour control, in order for preclinical and clinical
applications to directly benet from recent advances made in the research eld.
Figure 1.1: Personalised cancer practice on various levels, namely Population, Patient,
Tumour Prole. On a population macro-level, a population can be categorised into various
subpopulations (for instance based on age, gender or smoking habits), which in turn can
be evaluated and risk-assessed for preventative, detective and corrective oncology practice.
On a central, patient-specic level, cancer care may be tailored to t the needs, lifestyle and
priorities of the patient, in pursuit of medicine that optimises both treatment outcome and
the patient's quality of life. On a tumour prole level, tumour-specic data can provide
information which may contribute towards disease prognoses and intelligent treatment
decisions. Narrowing down cancer care personalisation to tumour level allows for a bottom-
up approach to personalised tumour treatments.
The phrase bench-to-bedside describes the practice of transferring in vitro and in vivo
ndings from the laboratory to a clinical setting. Now, as the contemporary mathemati-
cian works on both blackboards and computer keyboards and we therefore, analogously,
use the term blackboard-to-bedside to describe the action of translating mathematical
and computational intelligence to clinical application, as is conceptually illustrated in
Figure 1.2. Mathematical modelling has chronologically tailed clinical implementation
of tumour treatment strategies. Historically, this time-lag is validated in the early era
of modern cancer care practice, which preceded advanced technology. However, with
current imaging and biopsy technologies, sophisticated in vitro and in vivo laborato-
ries, accumulating data from experiments and clinics, available computational power
[9] and biological, medical and mathematical knowledge, mathematical oncology to-
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day constitutes an up-to-date complement to traditional cancer research. Modelling
has the potential to both optimise currently available anti-cancer protocols and con-
temporaneously aid preclinical developments of new anti-cancer therapies, thus the
time-lag between clinical applications and mathematical modelling is conceptually be-
ing eliminated. In order to comprehensively transfer insights from blackboard-to-bedside,
actualised collaborations between clinicians, biologists and mathematicians are key [49].
Figure 1.2: 'Bench-to-bedside' depicts the practice of transferring in vitro and in vivo
ndings from the laboratory to a clinical setting. The contemporary mathematician works
on both blackboards and computer keyboards thus we therefore, analogously, present the
term blackboard-to-bedside to describe the action of translating mathematical and compu-
tational intelligence to clinical application.
1.3 Multiscale Models
Cancer is a multiscale process in which subcellular mutations result in aberrations that
are apparent on a cellular scale or on a tissue scale [50]. It follows that multiscale models
may constitute an attractive choice for the mathematical oncologist, and throughout
this thesis we will indeed simulate tumours using mathematical models that can be
classied as multiscale, hybrid, agent-based and on-lattice. Multiscale models refer to
models that incorporate information on multiple scales in space and/or time. By using
multiscale models, we can `zoom in' on details that we consider to be important, and
we can `zoom out' to get an overview of the full modelling scenario at hand [51]. When
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modelling a solid tumour, for example, this entails that we can `zoom in' and look at
subcellular details in individual tumour cells, and then we can `zoom out' again to see
how the tumour is behaving as a whole. Hybrid models are models that incorporate
multiple modelling techniques that can be regarded as contrasting. Such a model might
integrate both mechanistic and phenomenological rules, or both continuous and discrete
variables or both deterministic and stochastic phenomena. This can be very useful in
the eld of mathematical oncology, as biological and biochemical processes involved
in cancer dynamics can be best expressed in various ways. Using a hybrid modelling
technique, we can for example describe the concentration of a drug across a tumour
as a continuous function using a mechanistic diusion equation, whilst regarding cells
as discrete entities [50]. Agent-based models include several agents that may interact
with each other and their environment. Every agent is modelled individually and is
thus distinct from other agents in the system [52]. In an agent based tumour model,
for example, an agent can correspond to one cancer cell or a group of cancer cells. This
naturally allows for heterogeneity amongst tumour cells, which is useful as tumour het-
erogeneity is associated with many implications in anti-cancer treatments (but more on
that later on in the thesis). Combining agent-based models with multiscale and hybrid
modelling approaches allows us to have environmental factors inuence the behaviour
and fate of agents. On-lattice models refer to models that play out on a lattice [50]. In
an agent-based on-lattice model, for example, the movement of all agents is restricted
to the lattice points. A cellular automaton (CA) is a specic type of on-lattice model
that allows a system, containing information about both agents and their environment,
to evolve in time and space. In a CA, the quantity of any scalar eld across the CA
lattice is discretised to have a certain value on a certain lattice point. On-lattice models
have the advantage of being easy to implement when coding for in silico experiments.
In the following chapter, we describe the mathematical framework used throughout this
thesis. This framework is based on a multiscale, hybrid cellular automaton.
Many solid tumours are derived from one cancerous seeding cell, which by detection time
has produced a tumour with subclonal diversity displaying a few dominant subclones
[53]. It has been observed that cells collected from the same tumour may display dier-
ent subclonal [53] and spatio-temporal features inuenced by intracellular, extracellular
and intercellular mechanisms [54]. Consequently, a multitude of tumour metrics will
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vary within a tumour mass [46] and, what is more, this diversity may not be captured
by current diagnostic tools [53]. However, in silico experiments provide a platform on
which to conveniently study implications of spatio-temporal heterogeneities within a
tumour, thus allowing us to observe what is not empirically feasible by other methods.
One strength of multiscale, hybrid cellular automata, in particular, is their inherent
capability to handle cellular, intratumoural variations, providing an opportunity to
conveniently study the eects and implications of these spatio-temporal hetereogenities
within a tumour. Accordingly, several multiscale models have recently been developed
in order to fully capture the spatio-temporal, multiscale nature of tumour dynamics
[6, 5557]. Such models allow for intratumoural cross-scale integration of intracellular,
extracellular and intercellular concepts, providing comprehensive modelling frameworks






In this thesis, a multiscale mathematical framework is used to capture the multiscale
nature of cancer. The framework, that is introduced in this chapter, is applied in the
studies described in Chapters 3, 4 and 5.
2.1 The Cellular Automaton
The mathematical framework used throughout this thesis is, at its core, multiscale,
hybrid cellular automaton (CA) in which a cancer cell population, or a tumour, is sim-
ulated on a square lattice that extends in two or three dimensions in space. Cellular
automata organically enable spatio-temporal dynamics and intratumoural heterogene-
ity. Taking an agent-based approach, each cell (or group of cells) is modelled as an
individual agent with individually computed intracellular features. Extracellular mech-
anisms such as oxygen and drug delivery across the lattice are regulated by mechanistic
partial dierential equations. Using well-formulated modelling rules, intracellular, ex-
tracellular and intercellular mechanisms can be integrated in the mathematical frame-
work. A lattice point in the CA may be occupied by an agent (i.e. a cancer cell or
a group of cancer cells) or an environmental feature such as extracellular solution (in
vitro), or a blood vessel or extracellular space (ECM) (in vivo). Although the ECM
comprises multiple components, such as collagen, elastin and bronectin, we here make
a well-established [58], simplifying modelling choice to not distinguish between these
components. In our cellular automaton, a lattice point can at most be occupied by one
agent, and thus the spatial step-size on the lattice is chosen to correspond to the size
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of an agent, corresponding to the smallest entity on the lattice. For example, when
one agent corresponds to one cancer cell, then the spatial step size (∆x) corresponds to
the cell diameter. The time-step progression of the cellular automaton (∆t) is dened
by the event of shortest length in the modelling scenario at hand. Note that, if any
numerical methods are incorporated in the modelling scenario at hand, (∆x) and (∆t)
and must ensure that the solutions computed by the numerical methods are stable.
2.2 Cell Cycle Models
The cell cycle is the process that drives the duplication of cells and, by extension, the
growth of a cancer cell population or a tumour. The cell cycle mechanism can be par-
titioned into four sequential phases, namely the gap 1 (G1), synthesis (S), gap 2 (G2)
and mitosis (M) phase. A cell's DNA duplicates in the synthesis phase and chromosome
segregation and cell division occur in the mitosis phase [59]. The mitoses phase ends
with the cell duplicating. In order to replicate its DNA and divide, a cell requires time
to grow and double its protein and organelle mass between synthesis and mitoses. This
happens in the intermediate gap phases G1 and G2. If some extracellular or intracellular
conditions are unfavourable for cell cycle progression, a cell may delay its reproduction
progress by (reversibly) exiting the G1 phase of the cell cycle to enter an inactive, qui-
escent phase (G0) [6]. Note that although quiescent cells are not cycling, they are not
completely inactive, in fact they require energy to actively control their interior state [7].
A cell's current cycle phase signicantly impacts its treatment responses to certain
drugs and radiotherapy, as discussed later on in this chapter. Therefore, cell cycle details
are included in our agent-based mathematical framework and the cell cycle progression
for each agent (e.g. cancer cell) is tracked. There exists a number of mathematical
cell cycle models to choose from, some of which are mechanistic and some of which are
phenomenological, some of which are deterministic and some of which are stochastic.
The modeller must decide which cell cycle model is the most appropriate to use for
the modelling scenario at hand. Factors that inuence the choice of cell cycle model
include: goals and hypotheses of the experiment, desired level of details in the model,
availability of data and allowed complexity in the mathematical and computational
framework. In this thesis, three dierent types of cycle models are used. Specically,
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in Chapter 3 we use a mechanistic cell cycle model described by a system of ordinary
dierential equations, in Chapter 4 we use a phenomenological model driven by a cell
cycle clock and in Chapter 5 we use a stochastic model in which a cell progresses
through the cell cycle via various cell cycle states (represented as nodes) connected
by stochastic paths. Common for all three of these models is that they include some
stochastic parameter, individually selected for each agent, that ensures that all cells do
not cycle synchronously. This allows for cell cycle phase heterogeneity amongst cells.
Also common for the three cell cycle models is that a cell's potential (and reversible)
exit from the G1 phase of the cell cycle into the G0 state is based on extracellular
conditions as explained in Section 2.3, and is thus not intrinsically described by the
mathematical expressions used to compute cell cycle progression.
2.2.1 A Mechanistic Cell Cycle Model
In the mechanistic cell cycle model used in Chapter 3 in this thesis, the cell cycle is gov-
erned by a regulatory molecular network described by a system of ordinary dierential
equations (ODEs) (Equation 2.1) [6] in which the dependent variables are ve dierent
protein concentrations and cell mass (mass). The ve proteins are namely the Cdk-
cyclin B complex (CycB), the APC-Cdh1 complex (Cdh1), the p55cdc-APC complex
in its total form (p55cdcT ), the p55cdc-APC complex in its active form (p55cdcA) and
the Plk1 protein in its active form (Plk1). The ODE that regulates the cell cycle reads
d[CycB]
dt







































where the growth rate coecient µ is stochastically picked for each individual cell
in order to enable heterogeneous cell cycle lengths amongst cells [6]. The binary vari-
able [HIF ] (occurring in Equation 2.1a) represents the hypoxia inducible transcription
factor-1 (HIF-1) pathway. This factor is only activated if the cell is classied as hy-
poxic [6], hence [HIF ] = 1 in hypoxic cells and [HIF ] = 0 in normoxic cells. Oxygen
distribution, and by extension hypoxia, is governed by extracellular regulations as is
described in Section 2.4, thus the system of ODEs integrates intracellular dynamics
with extracellular dynamics. The variables and parameters in Equation 2.1 are listed in
Table 2.1, and are chosen to be appropriate for mammalian cell lines, specically cancer
cells with a doubling time of around 25 hours [6].
In the mathematical model used in Chapter 3, a cancer cell is categorised as being
in either the G1 phase or in the collective S-G2-M phase of the cell cycle and the Cyclin
B concentration of a cell is used as a marker to determine cell cycle progression. A
cell leaves the G1 state to enter the collective S-G2-M state when [CycB] increases,
i.e. when [CycB](t + ∆t) > [CycB](t), where t denotes time and ∆t is the time step.
Cell division occurs when the cell exits S-G2-M phase to enter the G1 phase, and this
happens when the threshold value [CycB]thr = 0.1 is crossed from above [6, 60]. Post
cell division, the mass of the cell is halved, simulating one cell dividing into two cells
[60].
Component Rate constants (h−1) Dimensionless parameters
[CycB] k1 = 0.12, k′2 = 0.12 [HIF1] =
{
1 if K̂ ≤ 0.1,
0 otherwise
k′′2 = 4.5, [p27/p21]= 1.05
[Cdh1] k′3 = 3, k
′′
3 = 30, k4 = 105 J3 = 0.04, J4 = 0.04
[p55cdcT ] k′5 = 0.015, k
′′
5 = 0.6, k6 = 0.3 J5 = 0.3, n = 4
[p55cdcA] k7 = 3, k8 = 1.5 J7 = 0.001, J8 = 0.001, [Mad]= 1
[Plk1] k9 = 0.3, k10 = 0.06
[mass] µ = µ+ + εµ̂ ε is randomised, ε ∈ [−1, 1]
Table 2.1: Parameters for the nondimensionalised form of Equation 1. As described in
Section 2.4, K̂ denotes oxygenation value.
The value m∗ occurring in Equation (1f) denotes the maximum mass that a cell
may reach, should it not be allowed to divide for some biological reason. Follow-
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ing previous work by Tyson and Novak [60], m∗  max([mass](x, t)), specically
m∗ = 10 · [mass](xnb, tnb), where [mass](xnb, tnb) corresponds to the mass of a new-
born cell. The average growth rate constant µ+ = 25 hours and µ̂ = 3 hours are
here chosen to produce cell cycle lengths between 22 hours and 28 hours for cells that
are well oxygenated, i.e. cells that have the [HIF ] component occurring in Equation
2.1a switched o (i.e. set to zero). The [HIF ] component is activated (set to one)
in hypoxic cells, this activation delays the cell cycle progression and yields a cell cycle
length increase of approximately 20%.
The cell cycle model here discussed is based on previous work by Tyson and Novak,
who produced a series of papers describing the underlying mechanisms of cell cycle
progression and cell cycle regulation in mathematical terms [6062]. By identifying key
proteins involved in controlling and driving the cell cycle, they managed to condense
the complex biological process, that is the cell cycle, into a six-component regulatory
molecular network [60]. The opposing and oscillating nature between Cyclin-dependent
protein kinases (Cdks) and the anaphase-promoting complex (APC) plays a central role
in cell cycle regulation and yields a hysteresis feedback loop. Cyclin B ([CycB]) is part
of the Cdk family whilst Cdh1 is part of the APC. As is demonstrated in Figure 2.1a,
the cell cycle control system consists of two steady states, namely the G1-phase state
and the S-G2-M-phase state. [CycB] is low, whilst [Cdh1] is high in the G1 state and,
conversely, [CycB] is high, whilst [Cdh1] is low in the S-G2-M state. Other auxiliary
molecules are included in the model to enable appropriate lagging transitions between
these two steady states. Auxiliary molecule concentrations over time are illustrated in
Figure 2.1b. At the start of a cell cycle, the system will tend towards a G1 steady
state and at the end of the cell cycle the system will tend towards a S-G2-M steady
state. Details are provided by Tyson and Novak [60]. As shown in Figure 2.1c, cell
mass, [mass], doubles over the course of a cell cycle and is later reset, i.e halved, at cell
division.
Descriptive remarks regarding each equation occurring in the system of ordinary




Figure 2.1: Time evolution of protein concentrations in one simulated cancer cell (mea-
sured in grams of protein per gram of total cell mass), where the cell cycle length is 25
hours. (a) The opposing dynamics between [CycB] and [Cdh1], which is key in the used
mathematical cell cycle model. (b) Concentrations of the auxiliary proteins [Pkl1] and
p55cdc in its total form [p55cdcT ], and its active form [p55cdcA]. (c) Cell mass, [mass]
over time, where [mass] is halved at the very start of each cell cycle, i.e. immediately after
cell division.
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I Remarks regarding Equation (2.1a) :
d[CycB]
dt
= k1 − (k′2 + k′′2 [Cdh1] + [p27/p21][HIF ])[CycB].
Cdks are necessary for DNA replication, and accordingly Cdk activity is high in the
S-G2-M state. Conversely, Cdk activity is low in the G1 state. The rate of change
of the Cdk [CycB] is governed by synthesis and reduction, where the reduction is
considered to be partly independent of other molecules in the system, and partly
induced by the presence of [Cdh1] and the two proteins p21 and p27. p21 and p27
are known to inhibit Cdks, they are here merely treated as parameters via the
factor [p27/p21] that is activated in hypoxic cells only via the [HIF ] component
[6].











The p55cdc-APC in its total (p55ctcT ) and active form (p55cdcA) is also part
of the APC. The [Cdh1] time derivative obeys Michaelis-Menten type equations,
where the occurring J-constants are Michaelis constants. Here, [CycB] inhibits
[Cdh1] activity whilst [p55cdcA] promotes it. The [CycB]-derived inactivation of
[Cdh1] is assumed to occur in the cell nucleus, hence [CycB] will accumulate in the
nucleus and it follows that [CycB] will increase with cell mass, thus the [mass]
factor is incorporated in the second term that describes the suppressing eect
that [CycB] has on [Cdh1]. For newborn cells, [mass] is minimal, however as
the cell cycle progresses, [mass] increases, consequently promoting [CycB] whilst
demoting [Cdh1].
I Remarks regarding Equation (2.1c) :
d[p55cdcT ]
dt









[p55cdcT ] syntheses occurs naturally throughout the cell cycle but it is also syn-
thesised in the S-G2-M phase by [CycB], as is appropriately described by a Hill
function. However, p55cdc is not active once newly synthesised, and instead this
activation is described in Equation (1d).









In the model, [Plk1] is included to transform p55cdc into its active form [p55cdcA].
Tyson and Novak [60] describe [Plk1] as a hypothetical enzyme driving [p55cdcT ]
activation, and this eect is incorporated with Michaelis-Menten equations. Fur-
thermore, [Mad] represents a family of checkpoint genes, here treated as a pa-
rameter, which are able to deactivate [p55cdcA], should DNA synthesis or chro-
mosomes alignment not be completed rapidly enough to allow correct cell cycle
advancement.
I Remarks regarding Equation (2.1e) :
d[Plk1]
dt
= k9[mass][CycB](1− [Plk1])− k10[Plk1].
[Plk1] decreases naturally whilst [CycB] enhances [Plk] activity. It is here, again,
apparent that the [mass] component boosts eects of [CycB].










The dependent variable [mass] will double over the course of one cell cycle, fol-
lowing an adapted logistic equation.
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2.2.2 A Phenomenological Cell Cycle Clock Model
In the phenomenological cell cycle model used in Chapter 4, progression through the
cell cycle is governed by a cell cycle clock. Thus in our agent-based framework, every
agent is attributed an individual clock that drives and tracks cell cycle progression. To
achieve asynchronous cycling amongst cancer cells, every cell i is assigned an individual,
stochastic doubling-time τi, corresponding to the time it takes for a cell to complete one
cell cycle under well-oxygenated conditions. Specically, we here pick τi is from a nor-
mal distribution with a mean value µ and a standard deviation σ. The choice of using
a normal distribution is motivated by the fact that cell duplication yields imperfect cell
copies that are almost, but not perfectly, synchronised. The choice of distribution from
which to pick τi may ideally be motivated by experimental data, and can be adjusted
if appropriate.
The fraction of time spent in each of the four cell cycle phases G1, S, G2 and M in
well-oxygenated cells are respectively denoted ΘG1, ΘS , ΘG2 and ΘM . The Θ-fractions
sum up to one so that
ΘG1 + ΘS + ΘG2 + ΘM = 1. (2.2)
The values Θj , for j=G1, S, G2, M are here approximations gathered from literature
to represent typical lengths of rapidly cycling human body cells, with a doubling time
of roughly 24 hours, and respectively have the values 11/24, 8/24, 3/24 and 1/24 [63].
Thus, under well oxygenated conditions, the total amount of time that agent i spends
in cell cycle phase j becomes Θj · τi. Low cellular oxygenation values have, however,
been shown to stall cell cycle progression by inducing G1 arrest in particular [1]. Recall
that in the mechanistic cell cycle model presented in Section 2.2.1, the G1 phase is
inherently elongated under hypoxic conditions [6]. For this phenomenological clock-type
model, however, there is no mechanistic functionality driving G1-arrest under hypoxic
conditions so, we therefore introduce an auxiliary function to achieve oxygen-dependent
17
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G1 Delay Factor (G1DF)
Figure 2.2: The G1 Delay Factor (G1DF) is incorporated in the model to achieve oxygen-
dependent G1 arrest. The G1DF (dark line) is approximated using results (red crosses)
from a previous mathematical study by Alarcon et al. [1].
G1 arrest. We call this function the G1 Delay Factor (G1DF ) where,
G1DF (K̂(x, t)) =





if 1% ≤ K̂(x, t) ≤ 10.5%,
1 otherwise.
(2.3)
and K̂ here denotes the oxygenation (in units of mmHg). The G1DF approximates
how much the G1 phase is expanded as a function of oxygenation.
As illustrated in Figure 2.2, the piece-wise function G1DF is an approximation that
is chosen to match data points extracted from a mathematical study by Alarcon et al.
[1], in which a mechanistic Tyson-Novak cell cycle model is extended to incorporate
the action of the p27 protein which delays cell cycle progression and is upregulated
under hypoxia. The time that agent i spends in the G1 phase is thus now given by
G1DF (K̂) · ΘG1τi. Lengths of other cell cycle phases are here modeled to be non-
oxygen dependent.
2.2.3 A Stochastic Cell Cycle Clock Model
Biological systems and mechanisms inherently display a level of stochasticity, the cell
cycle included [5, 64]. As thoroughly described in Chapter 5, and pictorially illustrated
in Figure 5.2, cancer cells are correlated with high replication stress and thus during
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the cell cycle, some cancer cells will need to repair themselves before progressing to
subsequent events in the cell cycle [5]. To account for the fact that not every cell will
progress though the cell cycle the same way, the cell cycle can be modelled as consisting
of several sub-events represented by nodes in a graph, and between the nodes are several
paths, or edges. Building on the cell cycle model describes in Section 2.2.2, a cell cycle
clock here determines when a cell progresses to a subsequent cell cycle state, and a
stochastic `dice roll' determines which path the cell takes. A stochastic cell cycle model
approach is useful when we want to incorporate cell cycle sub-events that some, but not
all, cells experience.
2.3 Cell Division and Tumour Growth
In our framework, when a cell has completed the mitoses (M) phase of its cell cycle, it
duplicates and produces a secondary cell, namely a daughter cell, on a random lattice
point in its spherical neighbourhood. In order to achieve approximately spherical-like
tumour growth on a square lattice, the model stochastically alternates between placing
daughter cells in Moore and von Neumann neighbourhoods [6]. The 1st, 2nd and 3rd
order neighbourhood (O.N.) of a parental agent using (a) the von Neumann convention
and (b) the Moore convention are illustrated in Figure 2.3. A daughter cell is allowed
to be placed on up to ν order neighbourhoods of its mother cell, where lower order
neighbourhoods are strictly prioritised. Thus the rst order neighbourhood must be
lled before cells can be placed in the second order neighbourhood and so on. The value
of ν depends on the modelling scenario at hand. When simulating in vitro monolayer
cell cultures, there is often no spatial constraint or lack of nutrients that would hinder
a cell from dividing, in which case ν can be set to Innity, or half of the lattice size
to ensures that the cells are restricted to the simulated lattice. In vitro cell spheroids
and in vivo tumours, however, often consist of a quiescent core with G0 cells enclosed
by a shell of proliferating cells [3, 5]. This heterogeneity of cycling and non-cycling
cells can be replicated in our model by only allowing daughter cells to be placed on
up to ν order neighbourhoods, where ν is nite and can, ideally, be calibrated from
experimental data. A G1 cell that is not allowed to divide, due to the lack of space
within its νth order neighbourhood, is set to be in state G0 [6]. This is a reversible
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Figure 2.3: The 1st, 2nd and 3rd order neighbourhood (O.N.) of a parental agent using
(a) the von Neumann convention and (b) the Moore convention.
process, as a G0 cell may re-enter the G1 phase of the cell cycle should space become
available again as a result of, for example, anti-cancer targeting.
2.4 Oxygen Dynamics
Solid tumours typically contain a hypoxic core [7]. Hypoxia occurring in solid tumours
can broadly be categorised into two subtypes, namely chronic hypoxia and transient
hypoxia. Chronic hypoxia occurs in the microenvironment as a result of permanent
diusion limitations, whilst transient hypoxia is perfusion limited and brought on by
interim oxygen shortages caused by temporary shut downs of blood vessels or alterations
in oxygen ux [65]. Cells experiencing hypoxia may alter their protein synthesis in order
to adapt to low oxygen conditions and conserve energy, resulting in reduced proliferation
rates [66]. Moreover, radiotherapy responses are reduced in hypoxic tumour regions as
later discussed in Section 2.6.2. Due to the prevalence and implications of intratumoural
hypoxia, oxygen dynamics are included in our mathematical framework in which the
distribution of oxygen across the CA lattice is modelled using a mechanistic partial
dierential equation (PDE). Oxygen is produced on lattice points that are labeled as
oxygen source points. Depending on the model scenario at hand, these oxygen source
points can for example be blood vessels or lattice boundaries. In our mathematical






= ∇ · (DK(x, t)∇K(x, t)) + rKm(x, t)− φKK(x, t)cell(x, t), (2.4)
coupled with no-ux boundary conditions. DK(x, t) here denotes the oxygen diusion
coecient which is higher in lattice points occupied by cells than in unoccupied lat-
tice points [6]. The function cell(x, t) is binary and equal to one if the lattice point is
occupied by a cancer cell, and zero otherwise. Similarly, the binary function m(x, t)
is one if the lattice point x is an oxygen source point at time t, and zero otherwise.
Furthermore, rK is the oxygen production coecient and φK denotes cellular oxygen
consumption. Hence the rst term in Equation 2.4 describes oxygen diusion, the sec-
ond term describes oxygen production and the third term describes oxygen consumption.
The no-ux boundary conditions, and the non-xed oxygen production and con-
sumption rates, will cause the total amount of oxygen on the lattice to uctuate over
time. In order to express the oxygenation levels of lattice points in units of mmHg, we





where maxnK(n, t) denotes the maximal K(x, t)-value, out occurring on the lattice
at time t [67] and h is a scaling factor that should ideally be calibrated by experimental
data. If a cell has a scaled oxygen value such that K̂(x, t) ≤ 10 mmHg, it is classied
as hypoxic [6]. In the mathematical framework, the K̂(x, t)-value inuences G1-arrest
and responses to radiotherapy amongst other things.
2.5 Drug Dynamics
2.5.1 Some Basic Concepts in Pharmacology
Pharmacology can be described as `The study of how drugs aect functionalities of liv-
ing systems' and, in turn, a drug can be dened as substance (that is not a nutrient nor
an essential dietary constituent) of which the chemical structure is known, that induces
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a biological eect in a living organism once said living organism is subjected to the
drug [7, 68, 69]. Drug chemicals can be either synthetic or natural, i.e. man-made or
obtained from ora or fauna. Moreover, a medicine has the purpose of achieving some
therapeutic eect and may (but does not necessarily) contain one or multiple drugs, of-
ten in combination with other substances such as solvents and stabilisers that facilitate
medicine administration. In order to achieve pharmacological responses, drug molecules
must chemically inuence one or more cell constituents. In other words, drug molecules
need to bind to these cell constituents, which are often referred to as `drug targets'
or just `targets', in order for pharmacological responses to be achieved in a biological
system [7]. The most common targets include receptors and enzymes, however many
anti-tumour drugs directly target the DNA. Receptors are protein molecules that re-
spond to endogenous chemical signals, and enzymes are protein molecules that catalyse
chemical reactions without getting consumed in the process [68].
When drugs are administered to a living organism, the number of molecules in the
organism signicantly exceeds the number of drug molecules [7]. This means that if the
drug molecules were to be randomly distributed across the living organism as a whole,
the chance of drug molecules binding to particular targets would be minimal. Drugs
must therefore be able to somehow target specic cells or tissues in the body in order
to be useful in therapeutic settings. The binding site specicity of a drug describes how
good the drug is at selectively binding to its intended targets, without binding elsewhere
[7, 68]. Complete binding site specicity can, however, not be achieved in practice. Drug
binding to unintended targets may induce unwanted biological eects that can manifest
as side eects in therapeutic settings. Drugs with low potency are often administered in
higher doses, and this increases the likelihood of drug molecules binding to unintended
targets. If a target (such as a receptor) is occupied by a drug molecule, this may, but
does necessarily, alter the behavior of the receptor. If the target behaviour is indeed
altered, we say that the target is activated. Note that drug binding and drug activation
are two separate steps involved in the process of drugs producing biological eects. The
anity of a drug describes the drug's tendency to bind to targets whilst the ecacy
describes the tendency of a bound drug molecule to activate targets [7, 68]. A drug
can be classied as a, full or partial, agonists or an antagonists. For an agonist, the
drug molecules bind to targets and, in most cases, activate biological responses. On the
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other hand, for an antagonist, the drug molecules bind to target receptors but do not
activate biological responses [7, 68]. A drug's potency depends both on its anity and
ecacy, but in most cases highly potent drugs have high anity. Full agonists have
maximal ecacy and partial agonists have high (but not maximal) ecacy whilst full
antagonists have negligible (zero) ecacy. The agonist/antagonist classication can be
conceptually understood by the below schematics,











where A denotes a ligand (i.e. any chemical, such as a drug, that binds to receptors),
R denotes target receptors and A binds to R to form the complex AR [7].
2.5.2 Drug Binding and Drug Activation







Now, if we regard a system with a total number of target receptors Ntot, of which
NA receptors are occupied by molecules of ligand A, then there are Ntot − NA free
target receptors available in the system. More precisely, we here let NA correspond
to the steady state number of occupied receptors, and we let xA denote the ligand
concentration. If we assume that the number of added drug molecules (NĀ), is much
greater than the number of available target receptors in the system (Ntot), so that
NĀ >> Ntot, then the ligand concentration xA can assumed to be unaected by the
number of bound molecules, NA. Hence xA can be assumed to be constant [7]. The
Law of Mass Action dictates that the rate of a chemical reaction is proportional to the
product of the concentrations of the substances that are reacting [7]. Using the law of
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mass action, the forward and backward reactions in Equation 2.6 can thus be obtained
as
Forward reaction rate: k+1
(
xA · (Ntot −NA)
)
,
Backward reaction rate: k−1NA.
At steady state there is an equilibrium, so the rate of the forward reaction must equal
the rate of the backward reaction, hence,
k+1
(
xA · (Ntot −NA)
)
= k−1NA. (2.7)





xA · (Ntot −NA)
[l/mol]. (2.8)
The reciprocal of the anity constant is referred to as the equilibrium dissociation





xA · (Ntot −NA)
NA
[mol/l] (2.9)
which depends on both the drug and the target receptor. Since the equilibrium dissoci-
ation constant is measured in units of concentrations (e.g. [mol/l]) it is more intuitive
to use than the anity constant. Further, the occupancy, pA, describes the fraction of











this is the Hill-Langmurir equation that describes how the target occupancy is related
to the drug concentration [7]. When plotting the occupancy pA(xA) over a linearly
increasing drug concentration xA, the characteristic shape of a rectangular hyperbola is
obtained. Alternatively, if the drug concentrations increases on a logarithmic scale, the
pA(xA)-curve takes a sigmoidal shape [68, 70], as is demonstrated in Figure 2.4. If more
than one drug is present, things get slightly more intricate but that is outside the scope
of this thesis. From the above equation (Equation 2.10), it is clear that if xA = KA,
then pA = 0.5.
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Figure 2.4: The target occupancy (pA) plotted over drug concentration (xA) when the
drug concentration increases on a linear (left) and logarithmic (right) scale. Here KA,
i.e. the drug concentration that yields 50% target occupancy, is xA = 100 (concentration
units).
Typical drug binding curves used in experimental settings graph the amount of drug
bound over drug concentration, this can be directly measured using radioactive atoms
[7]. If we are instead interested in assessing the biological eect or response, not just the
drug binding, then we can graph drug eect in [%] over concentration (in vitro) or the
drug response in [%] over drug dose (in vivo). An eect or response of 100% corresponds
to the maximal eect or response achievable by the drug, denoted Emax. EC50 andED50
respectively denote the drug concentration and drug dose required to achieve half of the
maximum eect, i.e. 0.5 · Emax. A modeller may quantitatively formulate what Emax
corresponds to in the specic scenario at hand. Using the Hill-Langmurir Equation,
and the simplifying assumption that drug eect is proportional to target occupancy,
we arrive at the Emax model [7072], a ubiquitous model in pharmacodynamics which






In line with previous discussion, the Emax model achieves a sigmoidal drug response
curve. To achieve steeper growth curves, the Emax model can be expanded to the
sigmoidal Emax model [70], in which a coecient (termed the hill-coecient and here
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We can use the sigmoidal Emax model in our mathematical framework to compute
how cells respond to local drug concentrations. If appropriate, a term +E0 can be
added on the right-hand side of Equation 2.12 to represent a base eect in the absence
of drugs [73].
2.5.3 Cancer Drugs
Cancer cells are merely damaged, corrupted human body cells and consequently, this
makes them more dicult to selectively target in vivo than for example bacteria, be-
cause microorganisms dier from healthy human body cells in ways that cancer cells,
naturally, do not. Cancer drugs must, however, somehow be able to mainly target can-
cer cells, not all human body cells and thus we need to dierentiate between cancer
cells and healthy human body cells in some way. One way to make this dierentiation
is by noticing that cancer cells are relatively proliferative whilst most human body cells
are in a non-cycling state. Many conventional anti-cancer drugs take advantage of this
fact and thus target all cycling cells, or more specically mechanisms involved in the
cell cycle and cell division process [7, 74, 75]. The premise is that this will mainly
attack cancer cells whilst keeping enough human body cells untargeted to validate drug
administration [7, 76]. This explains why common chemotherapy side-eects are associ-
ated with the types of human body cells that are constantly dividing and cycling, such
as hair cells associated with the side-eect alopecia. There exists multiple anti-cancer
drugs, approximately 80 of which are used in British clinics, often in combination with
other drugs or anti-cancer treatments [70]. In this thesis, we will investigate the eect of
three, rather dierent, anti-cancer drugs in silico. In Chapter 3, we consider treatments
with traditional chemotherapeutic drugs. In Chapter 4, we investigate the eects of
hypoxia-activated prodrugs (HAPs), that act as `Trojan Horse' drugs being, conceptu-
ally, harmless until they reach hypoxic (tumour) regions in which warheads are released.
Finally, in Chapter 5 we study drugs that target cellular DNA-damage responses, and




When drugs are administered in vivo, the stages involved in drug disposition are com-
monly categorised using the ADME acronym, where the letters stand for: Absorption
of drugs from the drug administration site, Distribution of drugs within the body,
Metabolism of drugs and Excretion of drugs [7, 69, 77]. In vivo, drug molecules are
dispositioned via bulk ow and diusion. Bulk ow describes the process in which the
drugs are transported over long distances via, for example, the bloodstream or the cere-
brospinal uid. Over short distances, however, the drug molecules are transported via
diusion. The diusion is highly aected by the chemical structure of the drug, whilst
the bulk ow transportation is not [7]. The diusion rate of a drug is predominately
aected by the molecular size of the drug and, more specically, the diusion coecient
of a drug is inversely proportional to the square root of the molecular weight of the drug,
so that large molecules diuse more slowly than do small molecules [7]. In many cases,
drugs can be assumed to be well stirred with a uniform drug distribution within some
regarded body compartment, and it is the inter-body compartment drug movement
that determines how long a drug will be present in the body post drug administration.
Drug elimination describes the irreversible process of drug removal from the body. It is
achieved by metabolism and excretion. Metabolism refers to the chemical build-up and
break down of drugs, and excretion refers to elimination of drug from the body via some
excretory route and elimination transporter, e.g. kidneys and urine [7]. In many cases
when describing drug elimination, we can use rst order kinetics which means that the
rate of drug elimination is directly proportional to the drug concentration. First order
kinetics results in exponential drug decay. As a comparison, zero order kinetics means
that the drug is eliminated at a constant rate. In our mathematical framework, the








+ p(x, t)− ηCC(x, t), (2.13)
and DC(x, t) denotes the diusion coecient, p(x, t) is a supply term and ηC is a




2.6.1 Eects of Radiation in Biological Materials
Today, the majority of cancer patients receive radiotherapy in some form [78]. When
biological materials are exposed to radiation, they absorb energy from the radiation.
This energy absorption can cause an electron in some atom or molecule in the biolog-
ical material to get excited to a higher energy level (excitation) or to get ejected from
its atom or molecule (ionisation) [79]. Dierent types of radiation are being used in
clinical settings, but in this work we will focus on X-rays, a form of electromagnetic,
ionising radiation (IR). X-rays are produced in electrical devices using the kinetic en-
ergy from high energy electrons [79]. X-rays themselves do not damage cell targets
(DNA molecules), but when energy from X-rays is absorbed by the biological material,
this results in the production of fast-moving charged particles that do have the ability
to damage cell targets [79]. IR-induced DNA damage can be grouped into two main
categories: (i) damage by direct action of radiation and (ii) damage by indirect action
of radiation [79]. Direct damage occurs when an electron, that has been ejected from
some atom or molecule in the biological material as a result of ionising radiation, directly
interacts with DNA molecules. Indirect damage occurs when the ejected electron reacts
with other molecules in the cell, that in turn interact with DNA molecules and thus
indirectly cause DNA damage [80]. These `other molecules' are most commonly water
molecules, since cells consist of roughly 80% water [79]. When radiation interacts with
water molecules in the cell, free radicals are formed, and the amount of free radicals
formed is furthermore dose-dependent [81]. Free radicals are atoms or molecules that
each have an unpaired valence electron, making them highly reactive and thus prone to
reacting with (in this case) DNA molecules. Reactions between free radicals and cellular
DNA may result in alterations of the molecular DNA structure, which may induce cell
death or the impairment of some cell functions. It is estimated that two thirds of the
total X-ray induced DNA damage is caused by indirect actions of radiation [79].
A DNA molecule famously consists of two strands, wrapped in double-helical struc-
ture, that are connected by bases. It is the sequence of the four occurring bases (adenine,
guanine, thymine and cytosine) that stipulate the genetic code. Each strand is, further-
more, held together by sugar and phosphate groups. Radiation can produce multiple
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types of DNA lesions in cells, some of which are easy for (mammalian) cells to self-
repair, and some of which are not [79]. In the context of clinical radiotherapy, DNA
strand breaks are the most impactful type of such DNA lesions [79]. They occur when
the sugar-phosphate `scaolding' in the DNA strands gets damaged and disruptions in
the DNA helix consequently occur. Two main types of strand breaks can take place:
single-strand breaks (SSBs) and double-strand breaks (DSBs) [79]. SSBs occur when
one of the strands in a local region of the DNA double-helix breaks, whilst DSBs occur
when both of the strands in a local region of the DNA double-helix break. Note the
word local here, as cells can handle two strand breaks occurring on opposite strands
located more than approximately ten base pairs (or 4 nm) apart as two SSBs [79]. Cells
are better at repairing SSBs than they are at repairing DSBs, because post SSBs cells
can use the undamaged, opposite strand as a template to ensure speedy and accurate
DNA repair, something that can not be done for DSBs. Incorrect DNA repair causes
genetic, and likely harmful, alterations of DNA molecules. In addition to being more
easily self-repaired than DSBs, SSBs are also less biologically impactful and it follows
that DSBs are the main cause of IR-induced cell death, despite the fact that the number
of IR-induced SSBs by far exceeds the number of IR-induced DSBs following a typical
radiotherapy dose. As an example, a radiation dose of 1 Gy yields approximately 1000
SSBs but only 40 DSBs [79].
2.6.2 Inuence of Oxygen on Radiotherapy Responses
It is well established that in mammalian cells, IR-induced DNA damage is boosted by
the presence of oxygen [82]. If the same radiation dose is delivered to two biological
systems that are identical, save from the fact that one of the systems is hypoxic whilst
the other system is well-oxygenated, the response (in terms of number of killed cells)
will be greater in the well-oxygenated system. This can be explained by the fact that
cellular oxygenation values aect the chemical process of IR-induced DNA radicals [83].
DNA radicals are formed when IR-induced free radicals interact with DNA molecules
in a cell [83]. DNA radicals are typically short-lived but in the presence of oxygen,
however, these short-lived DNA radicals are likely to bind to an oxygen molecule to
form a stable DNA peroxide, thus rendering the DNA damage permanent (or x). This
is referred to as the oxygen xation hypothesis [79]. If, on the other hand, molecular
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oxygen is sparse then it is unlikely that a DNA radical will bind to an oxygen molecule,
and thus the DNA radical has a higher probability of chemically reducing back to its
original (undamaged) DNA form. The oxygen xation hypothesis is claried in Example
2.6.2.
I Example 2.6.2: Consider a high energy electron (e−) in the biological material
resulting from x-ray exposure. If this electron strikes a water molecule (H2O), then
this water molecule may split into a proton (p+) and a hydroxyl radical (OH∗)
that can react with DNA (DNA-H) to form a DNA-radical (DNA*). If molecular
oxygen (O2) is available, then oxygen may bind to the DNA-radical to form a
peroxy radical (DNA-OO*), which entails permanent DNA damage. On the other
hand, if there is no molecular oxygen available, the DNA radical (DNA*) can be
restored, i.e. repaired, to its original, undamaged form (DNA-H) [84].
It should also be noted that hypoxia may cause epigenetic and molecular cellular
alterations that may modify radio-sensitivity in additional ways [85]. From the above
discussion we have learnt that biological materials are the least radio-sensitive when
completely oxygen deprived, and empirical results show that radio-sensitivity over oxy-
genation levels have a general sigmoidal trend [79]. To furthermore quantify the inuence
of oxygen on IR responses, a dose ratio, namely the oxygen enhancement ratio (OER)





where DN2 is some IR dose in nitrogen, and Dair is the IR dose needed to achieve
the same response in air. The subscript m in OERm here stands for maximum, as we
are comparing radiotherapy responses in two extreme scenarios, specically in nitrogen
(with no oxygen) and in air (with plentiful oxygen). If the radiation response is evaluated
in terms of a survival fraction of cells, or the number of DSBs, then OERm takes the
value of approximately 3 ± 0.5 for most eukaryotic cells. However, if the response is
instead evaluated in terms of the number of SSBs, the OER value has a wider range of
possible values [82], but since DSBs are the main cause of IR-induced cell death we here
consider the value 3 ± 0.5 to be a good enough approximation to use in radiotherapy
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models in our mathematical framework. In order to describe the oxygen-dependence of
radio-sensitivity, the oxygen enhancement ratio (OER) can be used where,
OER(K̂) =
OERm · K̂ +Km
K̂ +Km
. (2.15)
Here, Km = 3 mmHg is the oxygenation value achieving half of the maximum ratio
and, as previously discussed, OERm = 3 [67]. As is illustrated in Figure 2.5, Equation
2.15 yields the empirically observed sigmoidal curve.
2.6.3 The Linear-Quadratic Model
The linear-quadratic (LQ) model is ubiquitous in radiotherapy modelling. It describes




where α and β are cell-line specic radio-sensitivity parameters. The LQ model is
used both in laboratories for analysing and predicting in vitro and in vivo experiments,
and in clinical settings [79, 86]. If the surviving fraction S in Equation 2.16 is plotted on
a log-scale over the radiation dose D, then the response curve typically takes a quadratic
(or a `shouldered') shape. This curve is dominated by the α-parameter for low D-values
and by the β-parameter for high D-values. The curvature can be described by the ratio
α/β. For high α/β-ratios, the curve is dominated by the linear term with coecient α
and thus assumes a fairly linear shape. On the other hand, for low ratios α/β the curve
has a more quadratic shape. If radiation is given in multiple fractions, cells have time
to repair sub-lethal damage in between doses, specically, this repair usually takes 6-24
hours [86]. If n fractions with radiation dose d are given, such that nd = D, then the




2) = e−(αD+βD·d). (2.17)
Now, since D · d = D ·D/n < D2, the fractional LQ-model (Equation 2.17) will in-
herently result in a higher survival fraction S than the single-dose LQ model (Equation
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2.16) given some dose D.
The current formalisation of the LQ model (Equation 2.16) does not have one single
derivation, but is instead a result of contributions from multiple empirical and theoret-
ical studies performed over several decades during the last century [86]. In the early
20th century, just a few years after the discovery of X-rays in 1895 [87], mathematical
studies were performed that described in vitro radiation responses in simple organisms
such as yeast, bacteria and viruses [86]. These studies reported exponential response
curves when plotting survival fraction over radiation dose, and thus it was hypothesised
that IR exposure causes a number of damaging events (or hits) proportional to the
administered dose D. A cell was thought of as having one single sensitive target, and if
such a target was hit by radiation, the cell would simply die [86]. If one assumes the
hits to be Poisson distributed, with a mean value corresponding to the radiation dose
D, then this `Single Target  Single Hit' model yields an expression for cell survival as
S = Phit(0, D) = e
− D
D0 , (2.18)
where Phits(0, D) denotes the probability that there are exactly 0 hits on a target
when a dose D is administered. D0 here denotes the dose causing on average one hit
per cell.
I Remark 2.6.3: Recall that the Poisson distribution is a discrete probability
distribution that describes the probability that a certain number of events occur
in some xed (here time) interval, when the events occur at a constant rate and
independently of other events. Generally, the probability to observe k events in
some (time) interval is given by




where λ is the expected number of occurrences. Hence, for the special zero-events
case, P (0) = e−λ.
Later on, in the 1950s, in vitro experiments with more complicated organism were
carried out, now using cancer and non-cancer mammalian cell-lines. It was observed
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that mammalian cells are signicantly more IR sensitive than are viruses and bacteria.
Moreover, the empirically produced response curves were now shouldered, rather than
exponential (like the ones previously observed in vitro for the simpler organisms) [86].
As a result, the `Single Hit  Single Target' concept was modied in order to explain this
shouldered response curve, and Both `Single Hit  Multiple Targets' and `Multiple Hits
Â Single Target' models were explored. In `Single Hit  Multiple Targets' models, a
cell is regarded as having multiple, specically m, radio-sensitive targets that all need
to be hit in order for the cell to die. If these targets are denoted i where i = 1, 2, ...,m
then, with the average number of hits per target being D/D0, the probability that a
target i gets hit is given by
1− Phit i(0, D) = 1− e
− D
D0 , (2.20)
hence the probability that all targets 1, 2, ...,m in a cell are hit is given by
(
1− Phit 1(0, D)
)(









and thus the probability that the cell survives, i.e. fewer than m of its targets are
hit, is
S = 1− (1− e−
D
D0 )m. (2.22)
Equation 2.22 yields a shouldered response curve for `Multiple Hit  Single Target'
models. Similar result-trends were obtained for `Single Target  Multiple Hits' models
for radiation dosages within the range typically studied, but for dosages outside the typ-
ical range these models produced response curves that did not agree with experimental
data [86]. This prompted the exploration of `Multiple Target  Multiple Hits' models
but theses required more parameters and were thus more dicult to t to experimental
data. In the meanwhile, studies using the `Single Hit  Multiple Targets' model reported
a wide array of m-values, i.e. number of targets. For example, m = 2 was reported for
HeLa cells but in other studies the m-value was found to be up to two orders of magni-
tude larger [86]! Consequently, m was, and is still, instead considered to be an empirical
factor describing the specic system at hand, and models other than `Hit(s)  Target(s)'
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models were developed using alternatives to this Target theory. This resulted in sev-
eral LQ-like models being suggested with various motivations. In 1966, Sinclair wrote
down the LQ-model (Equation 2.16) based on empirical observations, and in the 70s,
theoretical motivations for the linear-quadratic response-curve were published. It was
suggested that the linear part corresponds to single track events whilst the quadratic
part corresponds to multiple track events. In abstract models, a cell was thought of
as either dying directly from IR-induced DNA damage or by progressing through sub-
lethal stages in order to eventually die, and in mechanistic models, DSBs were said to
be inicted by damage resulting from either one single particle or multiple particles [86].
When simplied, the abstract and mechanistic model both suggest linear-quadratic re-
sponse curves [86].
Besides being veriable in laboratories and theoretically supported, the LQ model
has proven applicable in clinical settings [86], making it the rst choice radiotherapy-
model for many mathematical oncologists. In the mathematical framework used in this
thesis, we are working with agent-based models in which each agent has an individual
response to IR. Thus the LQ-model (Equation 2.16) is here modied to describe the
probability that one agent (e.g. one individual cell) survives a radiation dose D. Cellular
responses to radiotherapy are dependent on oxygenation status [88], cell cycle progres-
sion [89, 90], and cell-line characteristics [2]. To honour this, the survival probability of
an agent in lattice point x at time t is here given by
S(x, t) = e−D([OMF ]α(x,t)+D[OMF ]
2β(x,t)), (2.23)
where D is the radiation dose, n is the number of administered radiation fractions
and α and β are cell-line specic sensitivity parameters [23]. To include cell cycle
sensitivity, α and β are here cell cycle dependent [2], and the oxygen modication
factor (OMF) is incorporated to include oxygen sensitivity [91]. The OMF function is
a scaled version of the OER function (Equation 2.15), suitable for stochastic models,












Figure 2.5: The oxygen enhancement ratio (OER) and the oxygen modication factor
(OMF) plotted over oxygenation value.
where K̂x,t denotes the oxygenation value (in units of mmHg) in lattice point x at
time t, and the values for Km and OERm are previously dened under Equation 2.15.
The OER and OMF functions are illustrated in Figure 2.5. The survival probability of
a cell exposed to a typical clinical radiotherapy dose 2 Gy is plotted in Figure 2.6, as a
function of oxygenation and cell cycle phase, where the sensitivity parameters α and β
are chosen to correspond to those of typical cancer cell lines [2].
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Figure 2.6: The probability S(x, t) that a cell location x at time t in our mathematical
framework survives a radiation dose of 2 Gy, as a function of its cell cycle phase (see
legend) and oxygenation value. The values for α and β are gathered from a previous study




Cancer cells can be, or become, resistant to chemotherapeutic drugs. In this chapter we
investigate what happens when cancer cell populations, comprising both susceptible and
resistant cancer cells, are subjected to various chemotherapy treatments plans.
3.1 Chapter Summary
Tumour recurrence post chemotherapy is an established clinical problem and many can-
cer types are often observed to be increasingly drug resistant subsequent to chemother-
apy treatments. Drug resistance in cancer is a multipart phenomenon which can be
derived from several origins and in many cases it has been observed that cancer cells
have the ability to possess, acquire and communicate drug resistant traits.
In this chapter, the in silico framework described in Chapter 2 is adapted in or-
der to study drug resistance and drug response in cancer cell populations exhibiting
various drug resistant features. The framework is based on an on-lattice hybrid multi-
scale mathematical model and is equipped to simulate multiple mechanisms on dierent
scales that contribute towards chemotherapeutic drug resistance in cancer. This study
demonstrates how drug resistant tumour features may depend on the interplay amongst
intracellular, extracellular and intercellular factors. On a cellular level, drug resistant
cell phenotypes are here derived from inheritance or mutations that are spontaneous,
drug-induced or communicated via exosomes. Furthermore intratumoural heterogeneity
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and spatio-temporal drug dynamics heavily inuences drug delivery and the develop-
ment of drug resistant cancer cell subpopulations. Chemotherapy treatment strategies
are here optimised for various in silico tumour scenarios and treatment objectives.
We demonstrate that optimal chemotherapy treatment strategies drastically depend
on which drug resistant mechanisms are activated, and that furthermore suboptimal
chemotherapy administration may promote drug resistance.
3.2 Introduction
Chemotherapy is one of the major anticancer therapies, it is widely used both by it-
self and as part of multimodality treatment strategies. In most cases chemotherapy
is eective, however the existence, or the development, of chemotherapeutic drug re-
sistance in tumours continues to be a major problem in chemotherapeutic treatments,
often leading to tumour recurrence post treatment [9298]. Clinical and experimental
observations suggest that cancers are often increasingly drug resistant subsequent to
chemotherapy exposure [98101] and moreover cancer cells have the ability to posses,
acquire and communicate drug resistant traits, enabling them to survive in the presence
of chemotherapeutic drugs [95]. The existence of drug resistant phenotypes in cancer
cell populations signicantly impacts the ecacy and successfulness of chemotherapy
[102104].
The emergence of drug resistant cancer cells in tumours results in multiple subpop-
ulations comprising drug sensitive (S) and drug resistant (DR) cells [102]. Furthermore
cancer cell populations may evolve according to Darwinian principles [105] and cells
that acquire drug resistance during chemotherapy have been observed to be increasingly
metastatic [99], consequently DR subpopulations can reach signicant proportions de-
spite initially accounting only for a small fraction of some cancer cell population [95]. S
and DR subpopulations that coexist synergistically compete for resources such as space
and nutrients [105, 106], this competition inuences the tumour environment and yields
intratumoural heterogeneity. In clinical cases where tumour eradication is implausible,
chronic control treatments can be proposed in which tumours are continuously managed
and prohibited from reaching lethal proportions [95, 106, 107], long-term chemother-
apy treatments are however linked to high frequency drug resistance [108, 109]. Since
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DR subpopulations are more t than S subpopulations to survive in the presence of
drugs, repeated or prolonged chemotherapy administration may amplify this tness dif-
ferentiation. Indeed Duan et al. [102] performed in vitro and in vivo experiments to
conclude that in absence of drugs, sensitive cells are more t than drug resistant cells
and conversely, in presence of drugs DR subpopulations dominate as S subpopulations
are reduced [102]. Thus drug resistant cells may thrive in micro-environments con-
taining chemotherapeutic drugs, and a large DR subpopulation may result in disease
recurrence post chemotherapy [110]. Ensuring that the DR subpopulation does not
dominate the S subpopulation is of importance as such an outcome would render the
tumour uncontrollable by chemotherapy [106]. This suggests that deliberately maintain-
ing a subpopulation of drug sensitive cells may constitute a strategic countermeasure in
tumour control schemes [111]. Duan et al. investigated the plausibility of this proposed
strategy in vivo by comparing two cell populations exposed to chemotherapeutic drugs
[102]. The rst of these cell populations comprised drug resistant cells only, and the
second population contained a combination of both drug resistant and sensitive cells.
Their study conrmed that the second, combined, cell population was controllable by
chemotherapy for a longer time period than the rst, drug resistant, cell population
[102].
Drug resistance is a multipart phenomenon which can be derived from several origins,
in fact a cancer cell or tumour may express drug resistance in various ways [95, 111, 112].
Drug resistance may arise due to micro-environmental or intrinsic cell factors [113] and
cells can acquire drug resistance by for example amplifying drug target molecules, acti-
vating DNA-repair, inducing drug transporters or altering their drug metabolism [112].
Phenotypical variations in cells, such as drug resistance, can be inherited or acquired
and further, cells may be resistant to one specic drug or to multiple drugs, the latter
phenomenon is known as multidrug resistance (MDR) [95, 105, 108, 114]. Early work
performed by Luria and Delbrück on bacteria indicated that virus resistant mutations
occur independently of the virus itself, thus indicating the existence of primary virus re-
sistance [115]. These ndings have since been adapted to oncology [93, 95], and primary
drug resistance, that is drug resistance that occurs independently of the drug presence,
is an accepted phenomenon arising from cell mutations. However, drug presence has
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been demonstrated to speed up the development of DR subpopulations [116] and can-
cer cells may acquire drug resistance by altering their genetic or epigenetic structure in
order to evade drug eects [93]. Such alterations are induced by drug presence and may
include dislodging drug receptors or overexpressing and modifying target molecules [93].
Heat shock proteins (Hsps) are molecular chaperones, continuously present in eukary-
otic cells, yielding cytoprotective cell eects [99, 117]. Via their chaperoning actions
they enable cells, both healthy and cancerous, to adapt to extracellular variations and
maintain homeostasis whilst subjected to external stresses such as, maybe most impor-
tantly, hyperthermia but also hypoxia and anoxia, toxins and the presence of harmful
chemical agents such as chemotherapeutic drugs [99, 101, 117, 118]. In healthy cells, the
upregulation of Hsps can protect cells from for example high temperatures [99], however
in cancerous cells Hsp upregulation may protect cells from drug eects [99, 101], thus
enabling cells to survive under otherwise lethal conditions [117]. By extension Hsps have
been linked to resistance to chemotherapeutic drugs [99] such as cisplatin, doxorubicin
[101] and bortezomib [118].
Typical chemotherapy drugs target cells in active cell cycle phases, thus quiescent
cells parry drug eects [96] and similarly slow-cycling cells are intrinsically more drug
resistant than fast cycling cells [110, 119] as they are more likely to evade drug attacks.
Slow-cycling cells have been linked to cancer stem cell-like (CSC-like) cells [96], they
are important drivers for tumours due to their increased drug-survival rate and ability
to serve as reserve stem cells [110, 119]. CSC-like cells have been depicted to display
various traits including being slow-cycling, migratory and non-adhesive [92]. Rizzo et
al. [100] demonstrated in vivo in mouse tails that a subpopulation of CSC-like cells
indeed may benet from drug presence when competing for resources with other cell
populations. Thus slow-cycling cells have been identied to reinforce tumours, hence to
eradicate cancer cell populations containing a subpopulation of slow-cycling cells it is
crucial to target both slow-cycling and fast-cycling cells [119]. Intercellular communi-
cation is vital for multicellular organisms and cells may communicate with each other
using chemical signalling, direct physical contact or, as discussed here, sending and re-
ceiving exosomes [109, 120]. Out of these listed information mediators, exosomes are
of particular interest as they are detectable, cell type-specic and able to travel long
distances [109, 120]. This implies that they could potentially constitute therapeutic
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targets or biomarkers and thus be used to impede or signal cancer [109, 120]. Exosomes
constitute subcellular `molecule parcels' that cells may utilise to dispose of non-essential
materials [120], however perhaps more interestingly, they also facilitate long-distance
intercellular communication by transporting information from sender cells to recipient
cells [109, 121, 122]. These molecule-parcels contain biomolecules such as proteins,
mRNA and DNA which may provide recipient cells with information that can be used
to alter phenotypical attributes, in order to increase tness [120]. Exosomes are a type
of extracellular vesicle (EV) [123] and recent studies have identied EVs as key players
in cancer development as they can inuence tumour growth and metastasis by commu-
nicating oncogenic information [120]. EVs have also been assumed to be a part of the
process that converts non-malicious cells into cancerous, and of optimising the balance
between CSCs and non-CSCs [120]. Thus in response to chemotherapeutic drugs, cancer
cells may not only develop individual drug resistance, but furthermore they may render
other cells drug resistant by secreting exosomes to communicate and share drug resis-
tant traits [123]. Exosomes may induce both destructive and protective cell responses,
in fact the role of EVs depends on the regarded scenario [124]. In this study pathogenic
exosomes only are modelled.
Mathematical models of tumour growth and treatment response may further can-
cer research by contributing insight into tumour dynamics, elucidating and validating
clinically and experimentally recognised phenomena and guiding in vitro and in vivo
experiments [95, 103, 105107, 125]. Computational approaches to simulate biological
systems are an important part of theoretical biology and may provide insights into bi-
ological phenomena [126]. In silico experiments have the advantage of cheaply being
able to reproduce biological systems that span long time periods faster than real-time
[105] and they can be used to nd optimal treatment scheduling [11, 127]. Various such
mathematical models of tumour growth, treatment response and drug resistance have
previously been proposed [95, 128134]. Roose et al. presented a comprehensive re-
view of models of avascular tumour growth [133] and Lavi et al. compiled an extensive
report discussing previous work on mathematical models of drug resistance in cancer
[95]. To name a few such models, Monro et al. [106] presented a continuum model
in which tumour growth follows Gompertzian dynamics and drug resistant mutations
occur proportionately to the tumour growth rate, in accordance with Luria Delbrück
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models. They concluded that increased drug administration may in fact reduce the sur-
vival length of a patient. Powathil et al. [132] used the Compucell3D framework [135]
to investigate two coexisting subpopulations, specically one fast-cycling and one slow-
cycling, in the presence of drugs to demonstrate intrinsic drug resistance of slow-cycling
cells. There currently exists a number of hybrid discrete-continuum mathematical mod-
els that account for the multiscale nature of cancer [50], these models can be used to
study tumour behaviour in response to multimodality treatment schemes [136142].
Several modelling attempts have been made to address the multiscale aspects of cell
growth by incorporating details such as vascular dynamics, oxygen transport, hypoxia,
cell division and other intracellular features in order to study tumour dynamics and
treatment response [19, 57, 143, 144]. Recently, Powathil et al. [6, 145] developed a
hybrid multiscale cellular automaton, integrating cell cycle dynamics and oxygen distri-
bution to study cell cycle-based chemotherapy delivery in combination with radiation
therapy. As an important step towards personalised medicine, Caraguel et al. [146]
managed to create virtual clones of in vivo tumours in mice using multiscale hybrid
modelling. The tumour growth of various mouse tumours successfully agreed with the
tumour growth of their respective virtual clones. Details of other multiscale cancer
models are available in a review by Deisboeck et al. [56]. The mathematical models
that are referenced in this section are categorised and summarised in Table 3.1 (where
models from review papers have been omitted for brevity).
In the present in silico study, we propose a hybrid multiscale mathematical model
that incorporates multiple types of drug resistance. In silico experiments are performed
in order to study chemotherapeutic drug response in heterogeneous cancer cell popula-
tions hosting various types of drug resistant phenotypes pre, peri and post chemother-
apy.
3.3 Model and in silico Framework
In this study, we expand on the mathematical framework presented in Chapter 2 to in-
corporate multiple types of mechanisms that elicit drug resistance in cancer cells. Specif-
ically, the CA used in this study can be categorised as a hybrid multiscale on-lattice
model [50], incorporating a non-uniform micro-environment, extracellular dynamics, in-
tracellular dynamics, intercellular dynamics and various categories of drug resistance
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Panetta et al. [130] (1996) X X X X
Macklin et al. [19] (2009) X X X
Monro et al. [106] (2009) X X X X
Owen et al. [143] (2009) X X X X
Perfahl et al. [144] (2011) X X X X X
Caraguel et al. [146] (2016) X X X X
Perez-Velazquez et al. [131] (2016) X X X X X X
Powathil et al. [147] (2016) X X X X X X
Lorz et al. [129] (2017) X X X X
Table 3.1: A table of mathematical models (referenced in Chapter 3.2) that include
various aspects of cancer growth. A check mark (X) indicates that the referenced model
uses/includes/is what is specied in the respective columns.
regarded on a cellular resolution. The CA model uses partial dierential equations
(PDEs), ordinary dierential equations (ODEs) extracted from a regulatory molecular
network, as well as stochasticity and phenomenological rules formulated by observations
from biological experiments and clinical reports. An overview of the model schematics
are illustrated in Figure 3.1 and details are provided throughout this section. The CA
here extends in two spatial dimensions, specically a 100 by 100 square grid is utilised
to simulate a physical tissue slab of (2 mm)2. This agrees with biological dimensions
and each grid point is either occupied by a cancer cell or a blood vessel cross section, or
it is empty (i.e. occupied by extracellular matrix only) [6]. At the start of the in silico
experiment, one initial cancer cell is planted at the centre of the grid, over time this
cell divides to give rise to a population of cancer cells and eventually chemotherapeutic
drugs are applied to the system. Blood vessels are non-equidistantly scattered across
the grid, they are assumed stationary and perpendicular to the two-dimensional tissue
slab. Thus blood vessel cross sections live on the grid, where they act as source points





Figure 3.1: A schematic representation of the multiscale hybrid mathematical model used
in this study. The model integrates extracellular, intracellular and intercellular dynamics.
This is an on-lattice model and a lattice point may be occupied by a sensitive (S) or drug
resistant (DR) cancer cell shown in black, a blood vessel cross-section or extracellular space.
Various categories of drug resistance regarded on a cellular resolution are incorporated in
the model, these categories are marked in red and listed in Table 3.4.
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3.3.1 Intratumoural Heterogeneity
Tumours are dynamic and should therefore be modelled as such [112], they are also
heterogeneous and may constitute multiple distinguishable subpopulations [105, 112].
Intratumoural heterogeneity has been observed to promote drug resistance [103, 112]
and hinder successful tumour prediction, thus by extension intratumoural heterogene-
ity complicates intelligent chemotherapy administration [105]. A tumour can express
intratumoural heterogeneity in various ways and on multiple scales. For example nu-
trient concentrations, cell cycle dynamics and drug resistant traits may vary amongst
cells in a tumour [103, 105]. Phenotypical attributes, such as drug resistant traits,
may be acquired or inherited [105] and moreover stochasticity occurs naturally in bi-
ological processes. Hence various phenotypical subpopulations may arise in a cancer
cell population, even if the population originates from one single cell [112]. To eec-
tively treat tumours one should thus account for intratumoural heterogeneity, including
the potential uprising of drug resistant subpopulations [105]. Our model accounts for
intratumoural heterogeneity on various scales, details are provided in the following sub-
sections. On a cellular level, each cell has an individual cell cycle length and individual
drug resistant traits. On an extracellular level, the spatio-temporal micro-envrironment
is highly dynamic, each cell has its own neighbours and moreover the blood vessels
are non-equidistantly placed that oxygen and drug concentrations vary asymmetrically
across the grid.
3.3.2 Intracellular Dynamics
The cell cycle mechanism is here partitioned into four sequential main phases, namely
the gap 1 (G1), synthesis (Syn), gap 2 (G2) and mitosis (M) phase. (Note that we, in this
chapter, use the abbreviation `Syn' do denote the synthesis phase as the abbreviation `S'
is reserved to denote drug sensitive cells). We here use the regulatory molecular network,
described by the ODE system (Equation 2.1 in Chapter 2) to model the cell cycle
progression of each individual cell. Cancer cells are thus here categorised as being in
either the G1 phase or in the collective Syn-G2-M phase of the cell cycle, or alternatively
cells can exit the cell cycle and enter the quiescent phase G0 [6]. When cell division
occurs at time step tcd in the model, a daughter cell is placed on a grid point in the
spherical neighbourhood of the parental cell, located in point xparent. At cell division the
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mass of the parent cell is halved so that [mass](xparent, tcd) = 12 · [mass](xparent, tcd−1)
[60]. Grid points in lower order neighbourhoods are prioritised in this process, however
up to third-level neighbourhoods are regarded. Each cell may divide until there is no
unoccupied grid point on which to place a daughter cell, when this occurs a cell enters
the quiescent phase G0. A cell may however re-enter the cell cycle if its neighbourhood
is freed up and space is made available. Whilst in a quiescent phase cells are assumed
to be drug immune in our model, this is because classical chemotherapy drugs target
molecules that are over-expressed in specic cell cycle phases, for example the drug
cisplatin aects the G1 phase of the cell cycle [6, 148].
3.3.3 Extracellular Dynamics
As is previously described in Chapter 2.4, extracellular dynamics is modelled using
PDEs describing oxygen and drug distribution. Oxygen is continuously produced at
each time step on the blood vessels cross sections from which it is distributed across the
grid according to the following diusion-reaction equation [6],
∂K(x, t)
∂t
= ∇ · (Dk(x, t)∇K(x, t)) + rk(x, t)m(x)− φkK(x, t)cell(x, t), (3.1)
where K(x, t) denotes oxygen concentration in location x at time t, Dk(x, t) is the
oxygen diusion coecient, rk(x, t) is the oxygen production rate and φk is the oxygen
consumption rate. The variables m(x) and cell(x, t) are binary so that m(x) = 1 if
there is a blood vessel in location x and m(x) = 0 otherwise. Likewise cell(x, t) = 1
if there is a cell in location x at time t and cell(x, t) = 0 otherwise. No-ux boundary
conditions are applied, such boundary conditions coupled with the oxygen production
at each time step will cause the total oxygen in the system to uctuate over time.
Thus in accordance with previous work by Powathil et al. [67], the absolute hypoxic
threshold value will be dierent at each time step in the simulation, whilst the relative,
or scaled, hypoxic threshold value will remain the same over time. This approach yields
a spatial oxygen distribution at each time step which can be used to evaluate hypoxia.
Physically, a cell is here classied as being hypoxic if its partial pressure of oxygen
(pO2) is 10 mm Hg or less [149]. Following Powathil et al. [6], a grid point in the
implementation is dened to be hypoxic if it has a relative oxygen concentration of
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less than 0.1, where an oxygen concentration of 1 is normalised at the grid point with
the highest oxygen concentration on the grid. Oxygen diuses slower over grid points
occupied by cancer cells than elsewhere and suciently high oxygen concentrations
promote rapid cell proliferation, whilst hypoxia hinders cell cycle advancement. These
hypoxic eects are incorporated in the model via the [HIF ] parameter occurring in
Equation 2.1 [6]. Chemotherapy drugs are similarly administered via blood vessel cross
sections, however drugs are instantaneously produced at one single time step per drug
administration. Drugs diuse according to
∂C (x, t)
∂t
= ∇· (Dc(x, t)∇C (x, t))+rc(x, t)m(x)−φcC (x, t)cell(x, t)−ηcC (x, t), (3.2)
using no-ux boundary conditions. Here C (x, t) denotes drug concentration in location
x at time t, Dc(x, t) is the drug diusion coecient, rc(x, t) is the drug production
rate, φc is the drug consumption rate and ηc is the drug decay rate. Chemotherapy
drugs diuse faster across extracellular space than inside the tumour [6]. Provided that
the cell is in the drug-targeted cell cycle phase and that the cell is not explicitly drug
resistant, a cell in location x at time t is killed if the drug concentration C (x, t) is such
that C (x, t) ≥ κ, where κ is the lethal threshold drug concentration. When a cell dies,
its grid point x becomes empty. Parameters occurring in the PDEs are listed in Section
3.3.3.1.
3.3.3.1 Parameters for Oxygen and Drug Distribution
Parameter Symbol Value Reference
Oxygen diusion coecient Dk 2.5 · 10−5 [cm2s−1] [150]
Oxygen supply rate rk 8.2 · 10−3[s−1] [151]
Oxygen consumption rate φk 2 · 10−1 [s−1] computed(1)
Cisplatin diusion coecient Dc 7.6 · 10−6 [cm2s−1] computed(2)
Cisplatin consumption rate φc 0 (negligible) [6]
Cisplatin decay rate ηc 1.316 [h−1] estimated from [152]
Table 3.2: Parameters for Equations 3.1 and 3.2. (1) φk is computed using the
relationship L =
√
D/φ [6]. (2) Dc is computed using the relationship Dc/Dk =√
molecular weight of O2/
√
molecular weight of drug [7], where molecular weight are gath-
ered from the PubChem data base [8].
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The drug decay rate ηc is estimated to match the half-life time of cisplatin which
has been reported as 31.6±6 minutes [152]. Cisplatin supply is here modelled as instan-
taneous and thus equal to rc at the two time steps conferring with drug administration
(t= 500 hours and t= 600 hours) and zero for all other time steps. Here, rc is estimated
and scaled according to the chosen drug dosage so that
Ni · C = rc · (number of blood vessels), (3.3)
hence rc corresponds to the amount of drug produced at one blood vessel cross
section at one time step. Here i = 0, 1, 2, 3, 4 and Ni = 0, 1, 2, 4, 8 in accordance with the
possible drug dosages explored in the in silico experiment which are 1C, 2C, 4C and 8C.
C and κ are parameterised so that 1C kills half of the cell population in absence of any
included drug resistant mechanisms, more specically, here C= 104 (equal to the number
of grid points) and κ = 0.18. Since C is equal to the number of grid points, all cancer
cells would die immediately from drug exposure if drugs were produced homogeneously
across the grid, as such a scenario would yield a drug concentration C (x, t) = 1 > κ ∀x.
3.3.4 Drug Resistance
In this study, drug resistance is regarded on a cellular resolution, thus subcellular me-
chanics are simplied and drug resistance is categorised into cellular-level categories
as illustrated in Figure 3.2. In the model drug resistance is rstly categorised as be-
ing either explicit or implicit. Explicit drug resistance occurs when a cell possesses
any subcellular trait that directly protects it from drug eects, rendering it immune to
some drug. Conversely, a cell displays implicit drug resistance when it is shielded from
drug impact due to some indirect reason such as being slow-cycling or spatially located
in a region of low drug concentration (location mediated DR). Explicit drug resistant
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traits can be induced or inherited [153, 154] and also, cells may perform phenotypical
alterations in response to intercellular interactions [112]. Therefore we here categorise
drug resistance as being induced, primary or communicated. Induced drug resistance
is activated in cells as a defensive response to drug presence whilst primary drug resis-
tance is caused by cell mutations occurring independently of drugs [153, 154]. Cancer
cells in which drug resistance has been induced may communicate and spread their drug
resistant traits to other cancer cells via intercellular communication (ICC) in an eort
to secure species survival [109, 120, 123]. Using hybrid modelling, the various categories
of drug resistance are here modelled in dierent ways in order to easily reproduce bio-
logical phenomena in a way that is consistent with available clinical and experimental
observations and data. In our model, drug resistance obeys rules formulated from previ-
ous ndings from in vitro and in vivo results. Also incorporated are stochastic methods,
as stochasticity occurs naturally in biological processes and may generate dierent cell
phenotypes [112]. For all categories of phenotypical drug resistance, it is assumed that
once a cell has established a drug resistant trait, its ospring will inherit that trait.
This is in accordance with evolutionary Darwinian principles, as DR subpopulations
are more t to survive in drug presence than are S subpopulations [155]. Furthermore,
the micro-environment inuences drug transport across the tumour and impeded drug
delivery by poor diusion is indeed one of the primary reasons for treatment failure [95].
Thus drug ecacy and cytotoxic cell death is aected by the micro-environment, since
drugs may not reach target cells. This may occur if the drug diusion is impeded by
dense population regions, or if the target cells are spatially located far away from drug
source points, here blood vessels. To study how a heterogeneous micro-environment
impacts drug resistance and drug response, blood vessels are non-equidistantly located
across the in silico domain. Moreover, the speed of molecules such as oxygen, drugs
and exosomes, depends on the medium that the molecules in question are traversing
[6, 109]. This section provides information regarding the modelling of various drug re-
sistant categories. Numerical values of the parameters introduced in this section are
listed in the Section 3.3.4.5, along with schematic representations of algorithms used
in the model and a sensitivity investigation of critical parameters which demonstrates
that our results are robust in regards to these parameters. Thus our qualitative nd-
ings, concerning drug response in cancer cell populations hosting various types of drug
resistance, hold for variations of the chosen parameters.
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Figure 3.2: Classication of drug resistance categories occurring in the model. Drug
resistance may be independent of drug presence (orange labels), induced as a consequence
of drug presence (purple labels), or either (orange and purple labels). Cell acquisition of
any DR phenotypical trait (top half) is here modelled as irreversible and inheritable by
any future daughter cells to the cell in question.
3.3.4.1 Primary Drug Resistance
Cells display primary drug resistance independently of drug presence, thus primary drug
resistance may precede chemotherapy [95, 115, 154]. The in silico setup in our study is
analogous to Luria and Delbrück's [115] in vitro experiment, however here bacteria and
virus have been exchanged for cancer cells and chemotherapy drugs respectively. Luria
and Delbrück [115] stated that there was a probability per unit time that a sensitive cell
would mutate into a, here drug, resistant phenotype. Thus in accordance with Luria and
Delbrück models [115], primary explicit drug resistance is here modelled by stochastic
cell mutations occurring at cell division. More specically the chance of mutation is
given by the mutation rate αpri, which corresponds to the probability of mutation per
cell cycle. The parameter αpri is assumed to be small, so that drug resistant mutations
are rare and moreover the probability that a mutated cell will revert back to a sensitive
state is negligible and set to zero [115]. Hence, in our model, each daughter cell that is
produced has a chance αpri of being explicitly drug resistance before being placed on
the grid.
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3.3.4.2 Induced Drug Resistance
Drug presence has been demonstrated to speed up the development of DR subpop-
ulations in cancers [116] and multiple studies have shown that cancer cells display
altered epigenetic features following chemotherapy [153]. Cancer cells may become
drug resistant after exposure to chemotherapy, the underlying cause of such induced
drug resistance is assumed multifactorial [154]. Factors that may contribute to induced
drug resistance include decreased apoptotic response, increased DNA-repair post drug-
mediated damage, cell cycle alterations and reduced drug accumulation [154]. These
factors may work concurrently and jointly towards establishing drug resistance in cells
[154]. Hsps aid signalling pathways promoting cell growth and sustainability [99], and
may induce anti-apoctic cancer cell properties [117]. Three members of the Hsp family
that have been under scrutiny are namely Hsp27, Hsp70 and Hsp90, which have all
been linked to promoting breast cancer tumours [99] and shown in vivo to contribute
towards chemotherapeutic drug resistance [101]. In cancer cells, Hsps are plentiful and
moreover administration of chemotherapeutic drugs has been observed to alter Hsp ex-
pression and increase Hsp activity [117]. Hsps may reside in both the cytoplasm and
the cell nucleus, Vargas-Roig et al. demonstrated in vivo that chemotherapy drugs may
modify the proportion of Hsps in dierent cell compartments [101], in fact drug admin-
istration resulted in increased nuclear expression, and decreased cytoplasmic expression
of Hsp27 and Hsp70 [101]. Hsp27 promotes cell migration and dierentiation in vivo
[99] and elevated Hsp27 levels have been correlated to doxorubicon resistance and cor-
respond to high tumorigenicity whilst low Hsp27 levels suppress tumour functions such
as angiogenesis and proliferation of endothelial cells [99]. Hsp70 is linked to tumour
growth and yields anti-apoptotic eect in tumours [99] and in breast cancer cells, a
high proportion of nuclear Hsp70 is correlated to drug resistance [101]. Hsp90 is as-
sociated with regulating the cell cycle and controlling metastasis and proliferation [99]
and high Hsp90 levels are linked to decreased survival rates in breast cancer patients
[99]. Inhibiting Hsp27, Hsp70, Hsp90 has been hypothesised as part of future treatment
plans [117, 118] and moreover Hsp70 has been suggested as a factor to prognostically
evaluate the risk of disease recurrence [99]. The heat shock factor 1 protein (HSF1) reg-
ulates Hsps [118, 156], and HSF1 overexpression is linked to poor prognosis in breast,
lung and colon cancers, an increase in intratumoural cancer stem cells proportions and
chemotherapeutic drug resistance [156]. Specically, cells with high HSF1 levels have
51
3. DRUG RESISTANCE
displayed increased paclitaxel resistance [156]. Although cellular Hsp expression and
activity have been linked to anti-cancer drug resistance, the details of these mecha-
nisms are yet to be elucidated [101]. Thus in the mathematical model discussed in this
chapter, details concerning such underlying mechanisms of acquired drug resistance are
omitted and we simply recognise the fact that if a cell has been exposed non-lethal drug
levels for a certain amount of time, it can develop resistance to that drug. Furthermore,
clinically, cancers are usually treated with combination therapies which makes it di-
cult to deduce rigorous information regarding how induced drug resistance is developed
in cells as a response to one particular drug [157]. Due to this multifactorial nature
of induced drug resistance, which involves various subcellular alterations occurring in
response to drug presence in the micro-environment, in the model a cell obtains induced
explicit drug resistance once it has been exposed to a high enough drug concentration
for a suciently long time. Thus if a cell has experienced a minimum drug concentration
χind for τ time units, drug resistance is induced in the cell.
3.3.4.3 Communicated Drug Resistance via Exosomes
Srinivasan et al. [109] investigated exosome kinetics in lymphatic ow in vitro and
in vivo using near infrared imaging. In the in vitro study, they found that planted
exosomes from the HEY cell line, being spherical with a diameter of around 70 nm,
travelled more eectively than size and density matched beads across lymphatic en-
dothelial cells (LECs). This indicates that exosomes travel purposefully as opposed
to randomly. Srinivasan et al. [109] reported an eective permeability for exosomes
across the lymphatic endothelium in the order of 0.2 µm/s and moreover exosomes were
transported twice as fast across areas with cells compared to areas with no cells. Exo-
somes were observed to move rapidly in vivo, indeed they travelled 10 cm in a mouse
tail within 2 minutes [109]. Studies also show that there is a correlation between the
micro-environment and exosome activity, as exosome secretion and uptake is promoted
in low-pH regions [120]. Further, hypoxic regions are associated with drug resistance
[158] which is partly explained by elevated exosome secretion in such regions [123]. Here,
exosomes are modelled using phenomenological rules formulated from experimental ob-
servations, incorporating stochasticity. Exosomes are modelled as discrete `molecule
parcels'. Once per cell cycle each cell that has acquired drug or exosome induced drug
resistance has a chance αex of producing and secreting such a molecule parcel which is
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sent o in a random direction. The rst sensitive cell that the exosome hits is dubbed
the recipient cell, upon receiving the exosome the recipient consumes the parcel to gain
drug resistance. Exosome production and uptake times are incorporated in the travel
time and thus modelled as instant, using data from Srinivasan et al. [109], we choose
a propagation speed of 0.2 µm/s which is equivalent to 1 grid point (20 µm) per 100 s
when travelling across cells, and half of this speed when travelling across extracellular
space. The chance of exosome production αex is signicantly higher in hypoxic regions
in order to account for increased exosome activity in such regions [123].
3.3.4.4 Cell Cycle Mediated Drug Resistance by Slow-Cycling Cells
Slow-cycling cells are distinguishable in vitro [119] and Srinivasan et al. [110] demon-
strated that fast and slow-cycling cells may coexist in a tumour. Many chemothera-
peutic drugs, such as cisplatin, attack only cells in a certain phase of the cell cycle by
targeting proteins overexpressed in the corresponding phase, leaving other cells unaf-
fected [6, 148]. Since the half-life times of common chemotherapy drugs are signicantly
shorter than the average cell cycle length of standard eukaryotic cells [6], slow-cycling
cells are implicitly more resistant to chemotherapy as they are likely to evade drug
impact whilst being in a prolonged untargeted cell cycle phase. Consequently, if there
exists a subpopulation of slow-cycling cells in a tumour, this subpopulation is more
likely to survive chemotherapy and proliferate post treatment, despite having a slower
production rate. Such a slow-cycling subpopulation may comprise CSC-like cells, as
slow-cycling cells have been linked to cancer stem cells [96], which in turn have been
conferred with reduced sensitivity to chemotherapeutic drugs [156]. Previous research
indicates that cancer cells may obtain stem-cell like traits [159], in fact non-stem cancer
cells may convert into CSC-like cells seemingly spontaneously, as demonstrated in vivo
by Chaer et al. [160]. Micro-environmental factors, such as oxygen supply, may inu-
ence such conversions however here cell conversion into a slow-cycling state is modelled
as independent of the micro-environment. The [HIF] parameter, occurring in Equa-
tion 2.1, which is switched on in hypoxic cells only does however increase the cell cycle
length of all cells, fast-cycling and slow-cycling, and thus in the model, oxygen levels ef-
fect cell-cycle lengths. Slow-cycling cells are multidrug resistant as they are resistant to
any drug that targets only a subset of cell cycle phases. In the model, we assume that
slow-cycling conversion occurs spontaneously, independently of drug presence. More
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specically, once per cell cycle there is a chance αSC that a sensitive, fast-cycling cell
will spontaneously convert into a slow-cycling state. Here slow-cycling cells are assumed
to have a cell cycle length that is roughly twice as long as a sensitive cell [132]. The
chance of conversion from a slow-cycling, implicitly drug resistant state back into a
fast-cycling state is assumed negligible in accordance with previously discussed Luria
Delbrück models [115] and Darwinian principles and thus set to zero. Furthermore,
the in silico experiment spans 700 hours only, and the chance that a cell converts and
re-converts is assumed negligible in the model. Once a cell is randomly selected to
convert into a slow-cycling state, the individual growth rate factor µ of the regarded
cell, occurring in Equation 2.1, is updated in order to achieve slower cell-cycle progres-
sion and by extension a longer cell-cycle length. Daughter cells to slow-cycling cells are
assigned appropriate growth rates associated with slow-cycling cells at creation. In the
model, slow-cycling cancer cells dier from normal cancer cells in that their value µ in
Equation 2.1f is doubled.
3.3.4.5 Parameters and Algorithms for Drug Resistance
The chosen parameter values used for simulating drug resistance in the in silico frame-
work are listed in Table 3.3, where in hypoxic regions αex is increased to 2αex.
αpri χind τ αex αSC
0.01 κ/10 30 minutes 0.07 0.07
Table 3.3: Parameters concerning drug resistance used in the in silico framework. αpri
denotes the probability that a cell that is placed on the lattice is drug resistant (when
simulating scenarios involving primary drug resistance). χind and τ respectively denote
the drug concentration and time required to induce drug resistance in a cell (when simula-
tion drug induced drug resistance). αex denotes the probability that a drug resistant cell
will produce an exosome that induces drug resistance in a nearby cell (when simulating
communicated drug resistance). αSC denotes the probability that a cell will convert to a
slow-cycling state (when simulating slow-cycling mediated drug resistance).
The results in this study are qualitative, when varying the parameters in this ta-
ble, as done in Appendix A1, the obtained qualitative results are robust in regards to
chemotherapy response. Here, τ is chosen to be 30 minutes as this is close to the half-life
time of cisplatin. αpri, χind, αex and αSC are parameterised to be low and yield ap-
proximately the same ratio between the sensitive subpopulation and the drug resistant
subpopulation, across all the dierent investigated in silico scenarios, 10 hours after the
rst drug administration when the lowest drug dose is applied. (In other words, all tests
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named (b1), (c1), (d1) and (e1), according to the labelling system declared in Tables
3.4 and 3.5, comprise roughly the same composition of sensitive and drug resistant cells
10 hours post drug administration). This is in order to allow for easy comparisons, in
regards to drug response evaluations, amongst tests. Partial algorithms for incorporat-
ing various types of drug resistance in our mathematical framework are listed below.
Primary drug resistance: Each time cell division occurs there is a chance that
a drug resistant cell will be produced. In the model, when cell division occurs it is said
that a mother cell produces a daughter cell. If the mother cell is drug resistant (DR), the
daughter cell will inherently be drug resistant. However, if the mother cell is sensitive
(S), the daughter cell may or may not be drug resistant according to a stochastic `dice
roll'. At each cell division, a value α ∈ [0, 1] is randomised, and if α ≤ αpri then the















Figure 3.3: Partial algorithm for determining primary drug resistance.
Induced drug resistance: If a cell has experienced a minimum drug concentration
χind for τ time units, drug resistance is induced in the cell. Thus in the model, each cell
has its own counter, countern, which increments each time step that celln experiences
a drug concentration χ = C (x, t) ≥ χind. This is schematically illustrated in Figure
3.4. If drug resistance has been produced in a mother cell, it produces drug resistant
daughter cells.
Communicated drug resistance via exosomes: Once per cell cycle, each cell
that has acquired drug resistance by induced drug resistance (see the above section)
or communicated drug resistance (as described in this section) has a chance αex of
producing and secreting an exosome. In the model, a value α ∈ [0, 1] is randomised, if

























Figure 3.4: Partial algorithm for determining induced drug resistance.
is produced and sent o in a random direction. The rst sensitive cell that the exosome
hits becomes drug resistant, as schematically shown in Figure 3.5. Mother cells that
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Figure 3.5: Partial algorithm for determining exosome production.
Cell-cycle mediated drug resistance by slow-cycling cells: Once per cell
cycle there is a chance that a sensitive, fast-cycling (FC) cell will spontaneously convert
into a slow-cycling (SC), drug resistant state. To check if such conversion occurs, a
value α ∈ [0, 1] is randomised. If α ≤ αSC then the cell converts, otherwise it does not,
as demonstrated in Figure 3.6. Slow-cycling (SC DR) mother cells yield slow-cycling
(SC DR) daughter cells.
3.3.5 Implementation
The CA is implemented in C/C++ using a high performance computational framework.
Ordinary dierential equations are solved using a fourth order Runge-Kutta method
and partial dierential equations are solved using explicit second-order nite dierence
schemes. A owchart of the programming code is available in Appendix A1. Prior to
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Figure 3.6: Partial algorithm for determining the spontaneous conversion from a slow-
cycling to a fast-cycling state.
commencing the in silico experiment, the micro-environment is implemented and thus
blood vessel cross sections are scattered in a non-equidistant fashion across the grid,
this is in order to emphasise and study the eects of spatio-temporal oxygen and drug
heterogeneity. One initial cancer cell is then planted at the centre of the grid, from this
originating cell the cancer cell population will grow. Tumour growth is simulated over
700 hours, where it has been concluded that 700 hours is a suciently long simulation
time to study the drug resistance and drug response in the system. Here, a time step
size ∆t = 10−3 hours, is used in accordance with the appropriate nondimensionalisation
of the oxygen parameters occurring in Equation 3.1 [6]. Cisplatin, a chemotherapy drug
which here is modelled to attack G1 cells only, is administered in two instances at 500
and 600 hours. For each such instance, drugs are produced on all blood vessels at one
single time step. The total amount of drug produced at one time step, on all blood
vessels, corresponds to the drug dosage, which can be varied to study various cases.
Specically, here the studied drug dosage are: (1) 1C, (2) 2C, (3) 4C or (4) 8C, as
listed in Table 3.5. The dosage 1C is parametrised so that, in the absence of drug
resistant phenotypes amongst the cells, 1C kills half of the total cell population shortly
after the rst drug administration at 500 hours. By doubling the drug dosage once,
twice or thrice to 2C, 4C or 8C respectively a higher cell kill is achieved. However, the
relationship between the drug dosage and the number of cells killed is not linear, as is
further discussed in Section 3.4.1.1. For the xed chemotherapy schedule at 500 and 600
hours, the administered drug dosages are varied and the size of the sensitive and drug
resistant cell subpopulations are computed pre, peri, and post chemotherapy. Cell-maps
are produced in order to display cell population topology over time, these cell-maps are
visualised in ParaView [161]. Five dierent in silico experiments are here performed,
corresponding to ve dierent categories of drug resistance namely (a) to (e) listed in
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Label Drug Resistance Category
a No drug resistance (No DR)
b Primary drug resistance (Primary DR)
c Induced drug resistance (Induced DR)
d Induced and, via exosomes, communicated drug resistance (ICC DR)
e Cell cycle mediated drug resistance by spontaneous conversion to slow-
cycling cells (SC DR)
Table 3.4: The labelling of drug resistance categories occurring in the model.
Label Drug dosage





Table 3.5: The labelling of drug dosages used in the implementation. For non-zero drug
dosages the labelling system is such that label ` corresponds to drug dosage 2`−1.
Table 3.4. Each experiment is performed 100 times, subsequently average values and
standard deviations are reported. A sensitivity investigation of critical parameters is
performed in order to conrm that our results are robust in regards to small parameter
variations, this is available in the Appendix A1.
3.4 Results and Discussion
3.4.1 Results
In absence of chemotherapeutic drugs, the growth of the DR subpopulation in our in
silico experiment is proportional to the growth of the S subpopulation, as demonstrated
by the graphs in Figure 3.7. This is in accordance with previous mathematical models
and experimental results [95, 106, 115].
3.4.1.1 No Drug Resistance
Once chemotherapy is applied to the in silico setup, the cancer cell population decreases
in response to drugs. This is especially clear when no drug resistant phenotypes exist,
the cancer cell population then rapidly reduces after drug administration. However
population growth quickly resumes, and the size of such populations eventually reaches,
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(a0)
Figure 3.7: Growth of the cancer cell population over time in drug absence, showing total
population (black graph), drug sensitive subpopulation (blue graph) and drug resistant
subpopulation (red graph) incorporating control-case drug resistance categories (a0) No
DR, (b0) Primary DR and (e0) Slow-Cycling DR. Cases (c0) Drug-induced DR and (d0)
Communicated (ICC) DR are omitted since they produce the same results as (a0) in drug
absence. Each graph shows the average number of cells based on 100 simulations, the
standard deviation is demonstrated with error bars.
and surpasses, the pre-chemotherapy population size. This is evident in graphs (a1)
through to (a4) in Figure 3.8, and especially clear for high chemotherapy dosages where
the size of the cell population cycles between being large immediately before drug ad-
ministration and being small directly after drug administration. Rottenberg and Borst
[98] demonstrated similar cyclic behaviour in mouse tails in vivo. Increasing the drug
dosage trivially kills more cancer cells, however tumour topology and spatial heterogene-
ity signicantly aects drug transport. Moreover, due to intratumoural heterogeneity
in regards to the cell cycle, some cells will be shielded from the drug simply by being in
an untargetted cell cycle phase. This multiscale heterogeneity aects the relationship
between drug dosage and drug ecacy, where drug ecacy here corresponds to the
number of cells killed by the drug. Graphs (a1) to (a4) in Figure 3.8 demonstrate the






where ki denotes the number of cells killed in experiment i and Ni denotes the di-
mensionless drug dosage coecient used in experiment i. Thus here, i = 1, 2, 3, 4 and
respectively Ni = 1, 2, 4, 8. If the relationship between drug dosage and drug ecacy
was linear, doubling the drug dosage would mean doubling the number of cancer cells
killed. In such an ideal case, it would hold that εi = 1∀i, however this is not the case,
as illustrated in Figure 3.9 which shows the scaling eciency for the rst drug admin-
istration at 500 hours. Hence in a clinical setting, the harm that may follow increased
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toxicity from higher drug dosages may not be worth the modest increase in killed can-
cer cells. The cell-maps in Figure 3.10 further highlight how the spatial heterogeneity
aects drug delivery and consequently where the drug concentrations are high enough
for cell kills to occur.
3.4.1.2 Primary Drug Resistance
When a cancer cell population expresses primary drug resistance, two subpopulations,
comprising sensitive and drug resistant cells, already coexist prior to chemotherapy.
Once administered, chemotherapy eliminates cells belonging to the S subpopulation
whilst leaving the DR subpopulation unharmed. Hence increasing the drug dosage, and
consequently killing more sensitive cells, enables the DR subpopulation to ourish as it
gains access to more resources such as space and oxygen. Graphs (b1) through to (b4)
in Figure 3.8 show that such DR subpopulations indeed benet from high drug environ-
ments. Over all, our results show that chemotherapeutic treatments yield poor results if
there exists a subpopulation of drug resistant cells prior to commencing treatment, this
supports clinical observations depicting that primary drug resistance gravely reduces
the successfulness of chemotherapy and inuences the choice of treatment regime [93].
In our experiment, the primary DR subpopulations grow outward in radial strands pre
chemotherapy, as illustrated in cell-maps (b1) and (b4) in Figure 3.10. This geome-
try is explained by the model, in which primary drug resistant mutations occur at cell
division, prior to placing the cell on the grid. Moreover drug resistant cells produce
drug resistant ospring, thus radial strands are formed as the cancer cell population
grows. This DR subpopulation will spread from these strands, which consequently will
widen post drug administration. On the other hand, subpopulation S will spread from
regions containing sensitive cells that survived drug eect. Such sensitive survivor cells
are clustered in regions of low drug concentrations, typically located far away from
blood vessels and enclosed by other cancer cells, as drugs travel more slowly over dense
population regions.
3.4.1.3 Induced Drug Resistance
For simulations incorporating induced drug resistance, the DR subpopulation arises post
chemotherapy. Here, drugs diuse more slowly over cancer cells than over extracellular
space. Therefore, once the initial eect of chemotherapy has eliminated the majority
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Figure 3.8: Growth of the cancer cell population over time when drugs are applied at 500
and 600 hours, showing total population (black graph), drug sensitive subpopulation (blue
graph) and drug resistant subpopulation (red graph). Each row in the gure corresponds
to a category of drug resistance (a) to (e) according to the labelling in Table 3.4 ((a) No
DR, (b) Primary DR, (c0) Drug-induced DR, (d0) Communicated DR (e) Slow-cycling
DR), whilst each column corresponds do a specic drug dosage varying from low (leftmost
column) to high (rightmost column), namely (1) 1C, (2) 2C, (3) 4C and (4) 8C according
to the labelling system in Table 3.5. Each graph shows the average number of cells based
on 100 simulations, the standard deviation is demonstrated with error bars.
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Figure 3.9: The scaling eciency, demonstrating the relationship between drug dosage
and drug ecacy in terms of number of killed cancer cells. This is for the rst drug
administration at 500 hours for experiments (a1) to (a4) according to the labelling in
Tables 3.4 and 3.5, where no drug resistant phenotypes are present. Results are based on
average values for 100 tests.
of the sensitive cancer cells, and the tumour has disintegrated into clusters of surviving
cancer cells, drug resistant cells are typically located on boundaries between cancer
cells and extracellular space, as illustrated in cell-maps (c1) and (c4) in Figure 3.11.
On these boundaries drug resistance is induced since the cells are exposed to high, but
non-lethal, drug concentrations for a suciently long time. From these points of origin
the DR subpopulation spread. By increasing the amount of chemotherapy, the cells that
are exposed to this intermediate, high but non-lethal, drug concentration is reduced.
Hence higher chemotherapy dosages do not only kill more cells overall, but reduces the
amount of drug resistant phenotypes, as demonstrated by graphs (c1) to (c4) in Figure
3.8, this result applies to a cancer cell population in a conned space.
3.4.1.4 Communicated Drug Resistance via Exosomes
The eect of ICC is demonstrated by comparing experiment (c) Induced drug resistance,
to experiment (d) Induced and, via exosomes, communicated drug resistance. This can
be done by regarding graphs (c1) to (c4) and (d1) to (d4) in Figure 3.8 and cell-
maps (c1), (c4), (d1), (d4) in Figure 3.11. These gures show that the communicative
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exosome component amplies the eect of induced drug resistance alone. The number of
oncogenic exosomes produced increases with the number of drug resistant cells. In low
to moderate drug environments, many exosomes are thus produced, as there exists many
cells which have acquired induced DR in accordance with the results in Section 3.4.1.3.
Conversely, in very high drug regimes fewer cells will survive to acquire induced drug
resistance and consequently fewer oncogenic exosomes will be produced. Exosomes have
been hypothesised as possible treatment targets, and our results indicate that reducing
the exosome activity would aid the S subpopulation, as less cells would convert from
sensitive to drug resistant. Here, hypoxic cells secrete more exosomes than do normoxic
cells. This results highlights one of the benets of targeting hypoxic tumour regions,
as doing so may reduce exosome activity and by extension hinder communicated drug
resistance.
3.4.1.5 Cell Cycle Mediated Drug Resistance by Slow-Cycling Cells
Slow-cycling cells are more likely to evade drug eects, as shown in graphs (e1) to
(e4) in Figure 3.8 where, after each drug attack, the DR slow-cycling subpopulation
displays a higher survivor rate. High chemotherapy dosages increase this eect, and thus
benet the DR subpopulation. Since the conversion to slow-cycling cells is modelled
as spontaneous, implicit drug resistance may precede chemotherapy. Furthermore, this
spontaneity means that at every cell cycle, each fast-cycling cell has the same chance
αSC of converting to a slow-cycling state. Thus pre chemotherapy the DR subpopulation
will be point-wise scattered across the cell population, and post chemotherapy the DR
subpopulation will spread from these source points, as illustrated in cell-maps (e1) and
(e4) in Figure 3.11.
3.4.1.6 Cell-Map Topology
Each drug resistance category in our model corresponds to a typical cell-map topology
and vice-versa, as shown in Figures 3.10 and 3.11. The location of the subpopulations
S and DR depends on the category of drug resistance regarded, as does the location
of regions with high cell-kill numbers. These cell-maps are useful for conveying spatial
heterogeneity, which is of importance since intratumoural heterogeneity is known to
heavily inuence drug eciency [6]. Any sensitive cell, or cell cluster, that is surrounded
by a band of other cells will be partly shielded from drug eects, as drugs travel slowly
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over dense population regions. Further, any quiescent sensitive cell, or cell cluster, that
is surrounded by a band of explicitly drug resistant cells is eternally safe from drug
presence in our in silico setup. This is because such a sensitive cell, or cell cluster,
will never meet the necessary condition to re-enter the cell cycle as this requires free
neighbourhood space. Thus, even sensitive cell may be protected from drug eect, this
is an example of location mediated implicit drug resistance.
3.4.2 Discussion
Our study shows that drug response in cancer cell populations is crucially inuenced by
the drug resistant phenotypes amongst the cells. We here demonstrate, in silico, that the
eect of chemotherapy is heavily dependent not only on the mere existence of drug re-
sistant cells, but also the type of drug resistance displayed and micro-environmental fac-
tors. Clinically, this implies that optimal chemotherapy scheduling and dosages depend
on tumour specic data, including information regarding drug resistance and tumour
environment. Indeed our results show that some types of drug resistant phenotypes
thrive in low drug settings, whilst other ourish in high drug settings.
Before proceeding to discuss optimal drug dosages, one must dene what consti-
tutes as successful chemotherapy. Is the aim perhaps to (i) reduce the cancer cell
population as much and quickly as possible or to (ii) be able to control the tumour
long-term using chemotherapy? Case (i) may be relevant when chemotherapy is used
in combinations with other treatments, for example when neoadjuvant chemotherapy is
used prior to radiation treatment or surgery. Conversely, Case (ii) may be applicable
when chronic chemotherapeutic treatment strategies are used, as can be done when it
is implausible to completely eliminate a tumour. In such cases it is vital to suppress
any DR subpopulation in order to keep the tumour manageable by chemotherapy. For
Case (i), Figure 3.12 provides the data needed to discuss intelligent treatment strategy.
This diagram trivially shows that high chemotherapy dosages are the most eective
to rapidly eradicate cancer cells. However, what is not shown in our result, but is of
clinical importance, is that high drug dosages are coupled with high toxicity which may
be harmful to patients. Moreover our results show that the relationship between drug
dosage and drug ecacy scales poorly, which is worth considering in a clinical setting.
The increase in toxicity following from an increased drug dosage may not validate the
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Figure 3.10: Cell-maps of the cancer cell populations at times 500 h (immediately before
rst drug dose), 510 h 600 h (immediately before second drug dose), 610 h and 700 h (end
of simulation). Cases incorporating (a) No DR and (b) Primary DR are shown for drug
dosages of (1) 1C and (4) 8C according to the labelling in Tables 3.4 and 3.5. White areas
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Figure 3.11: Cell-maps of the cancer cell populations at times 500 h (immediately before
rst drug dose), 510 h 600 h (immediately before second drug dose), 610 h and 700 h
(end of simulation). Cases incorporating (c) Induced DR, (d) ICC DR and (e) SC DR are
shown for drug dosages of (1) 1C and (4) 8C according to the labelling in Tables 3.4 and
3.5. White areas correspond to extracellular matrix.
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outcome in terms of tumour reduction. In Case (ii) there is a balance, and sometimes a
trade-o, between eliminating sensitive cells and aiding the drug resistant cells. Indeed
killing of sensitive cells paves the way for any drug resistant phenotypes. Hence admin-
istering low chemotherapy dosages sometimes constitutes a wiser treatment strategy
as it delays the uprising of a drug resistant subpopulation. Evolutionary theory and
the interaction between S and DR subpopulations may thus play a role in designing
intelligent treatment strategies. Figure 3.13 shows the ratio between S and DR subpop-
ulations at dierent times. This diagram demonstrates that drug resistant phenotypes
that arise independently of drug presence benet from high drug dosages. However,
in silico, the opposite is true here for drug-induced drug resistant phenotypes, which
prosper in low drug conditions. Ideal chemotherapeutic tumour treatments would in-
volve rapidly reducing tumour size whilst minimising drug resistance, thus meeting the
requirements of both Cases (i) and (ii). However, our results indicate that when using
chemotherapy only, there is a trade-o between tumour reduction and the suppressing
of drug resistant phenotypes in some cases, thus the objectives of Cases (i) and (ii)
may conict.
The aim of this study is to qualitatively model drug response in cancer cell pop-
ulations hosting drug resistant individuals. Drug resistance is here modelled from a
collective of biological experiments, biological theory and clinical observations, and thus
does not confer strictly with one cell line or one experiment. However, the developed in
silico framework can be parametrised and calibrated appropriately for a cell-line specic
study (as shown in a recent paper [31]), should relevant biological data become available
in detail. Our in silico framework is equipped to handle various mechanisms concerning
drug resistance, these mechanisms can be appropriately included or excluded in order
to study a certain cell-line or a certain tumour scenario.
3.5 Conclusion
Enhanced chemotherapeutic drug resistance post-chemotherapy is an established clinical
problem, this study provides insight into drug resistance and drug response in cancer
cell populations on a cellular resolution. Our results show that, whilst chemotherapy is
an eective way to reduce tumours, suboptimal drug dosages may contribute towards
drug resistance and, by extension, tumour reinforcement. Thus, in accordance with
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Figure 3.12: Diagram of the drug sensitive subpopulation (blue) and the drug resistant
subpopulation. Various types of drug resistance are incorporated namely (a) No DR, (b)
Primary DR, (c) Induced DR, (d) ICC DR, (e) SC DR. Results are shown at times 500 h
(immediately before the rst drug dose), 510 h, 600 h (immediately before the second drug
dose), 610 h and 700 h (end of simulation) for low drug dosages, (1) 1C, and high drug
dosages, (4) 8C according to the labelling in Table 3.5. Each diagram shows the average
value based on 100 simulations.
Figure 3.13: Diagram of the ratio between the drug sensitive subpopulation (blue) and
the drug resistant sub-population. Various types of drug resistance are incorporated namely
(a) No DR, (b) Primary DR, (c) Induced DR, (d) ICC DR, (e) SC DR. Results are shown
at times 500 h (immediately before the rst drug dose), 510 h, 600 h (immediately before
the second drug dose), 610 h and 700 h (end of simulation) for low drug dosages, (1) 1C,
and high drug dosage, (4) 8C according to the labelling in Table 3.5. Each diagram shows
the average value based on 100 simulations.
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Figure 3.14: Tumours exposed to chemotherapeutic drugs given in low (top) or high
(bottom) dosages, the latter dosage option kills more cancer cells. One of the tumours (left)
expresses drug resistance pre chemotherapy, the other one (right) does not. Generally in
our in silico experiment, drug resistance that occurs independently of the drug, and thus
may precede chemotherapy, is amplied by high drug dosages (left). Conversely, drug
resistance that is induced by drug presence is accelerated by low to moderate drug dosages
(right).
Nietzschean philosophy, chemotherapy that does not kill a tumour may indeed make it
stronger. Generally we found that drug resistance presenting independently of the drug,
which thus may precede chemotherapy, is amplied by high drug dosages. However,
drug resistance that is induced by drug presence is accelerated by low to moderate drug






Hypoxia-Activated Prodrugs are bioreductive prodrugs convert to cytotoxic agents upon
reaching hypoxic (tumour) regions. Thus they, theoretically, act as Trojan horses,
being essentially harmless until warheads are released in tumours. In this chapter we
investigate treatments combining hypoxia-activated prodrugs and radiotherapy.
4.1 Chapter Summary
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not
only overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful
in vitro and in vivo, HAPs are yet to achieve successful results in clinical settings. It
has been hypothesised that this lack of clinical success can, in part, be explained by
the insuciently stringent clinical screening selection of determining which tumours are
suitable for HAP treatments [162].
We here demonstrate that both the intra-tumoural oxygen landscape and treatment
scheduling of HAP-radiation combination therapies inuence treatment responses in
silico. Our in silico framework is based on an on-lattice, hybrid, multiscale cellular au-
tomaton spanning three spatial dimensions. The mathematical model is parameterised





Oxygen concentrations vary across solid tumours and, although tumours present with
high diversity across patients [163], hypoxic regions are prevalent tumour features
[66, 88, 164170] commonly provoked by inadequate oxygen supply and high tumour
growth rates [85]. Hypoxia signicantly impacts tumour dynamics, treatment responses
and, by extension, clinical outcomes [165, 168, 171]. Hypoxia may alter cellular expres-
sions of genomes, proteins and epigenetic traits [85], and such hypoxia-induced alera-
tions may cause hypoxic cancer cells to be more resistant to apoptosis [172]. Hypoxia
may also alter the metabolism of cells [172] and promote angiogenesis by activating asso-
ciated genes [173]. Thus hypoxia both protects and progresses solid tumours [171, 172].
Accordingly, severe tumour hypoxia is associated with tumours that are dicult to
treat and, by extension, poor prognoses for patients [85, 166]. It is well established
that hypoxic regions in solid tumours express reduced sensitivity to radiotherapy and
a plethora of chemotherapeutic drugs [65, 85, 165168, 170, 172175]. Hypoxic cancer
cells in a solid tumour are naturally located far away from active oxygen sources, i.e.
blood vessels [166], and therefore drug molecules that are of large size or tightly bound
to cell components may not reach hypoxic tumour cells at all [173]. Moreover, genes
associated with chemo-resistance may be upregulated by hypoxia [162]. Hypoxia is also
regarded to be one of the main factors contributing to radiotherapy failure [173], as is
previously explained in Section 2.6.2. IR-induced DNA damage, especially in the form
of double strand breaks, is more easily self-repaired by the cell under hypoxic conditions
[79].
Due to their severe impact on conventional anticancer therapies, such as chemother-
apy and radiotherapy, hypoxic cancer cells, and their central mediators [85], have for
the last decades been considered to be important treatment-targets [163, 173]. Mul-
tiple ways to handle tumour hypoxia have been explored. One approach to combat
intratumoural hypoxia is to increase the tumour oxygenation as part of a neoadjuvant
treatment [162]. A second approach to overcome hypoxia is to selectively target hypoxic
cancer cells only for treatment-sensitising or eradication [88]. A third and conceptually
elegant approach to not only overcome, but better yet, exploit intratumoural hypoxia is
realised by hypoxia-activated prodrugs (HAPs) [173]. HAPs are bioreductive prodrugs
that reduce, and thus convert, into cytotoxic agents upon reaching hypoxic (tumour)
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regions [65, 172]. Theoretically, they act as Trojan horses, being essentially harmless
until they are converted into warheads in target regions, i.e. hypoxic (tumour) cells.
The tumour-targeting ability of HAPs is based on the premise that oxygen concentra-
tions in hypoxic tumour regions reach exceptionally low levels, and that such low oxygen
levels are not found elsewhere in the surrounding body tissue [172]. Indeed physoxia,
that is the term used to describe oxygen levels found in normal tissue, ranges between
10 and 80 mmHg, and a cancer cell is commonly classied as hypoxic if it has a partial
pressure of oxygen (pO2) value of 10 mmHg or less [66]. Solid tumours commonly dis-
play regions that are even more hypoxic, where pO2 values may drop below 5 mmHg
[66]. Consequently, HAPs theoretically constitute a means to eectively target hypoxic
tumour cells. This also means that toxic drug eects can be localised to tumours, and
that the remaining host system can in great part be spared from harmful toxicity caus-
ing unwanted side eects.
HAPs transform into activated drugs (AHAPs) via reductive metabolism [164, 173]
in suciently hypoxic environments, and the AHAPs can achieve cytotoxic eects in
cells [103]. Freely available redmolecular oxygen inhibits this bioreduction, and thus
HAPs remain (for the most part) intact in well-oxygenated environments [172]. Once
activated, AHAPs may diuse into local surroundings. Thus, via bystander eects,
AHAPs may infer damage to cells in which the HAP-to-AHAP bioreduction did not
occur, however a few recent studies dispute the impact of these bystander eects on the
overall treatment outcome [176]. In the mathematical model described in this study, the
dispersion of HAPs and AHAPs obey mechanistic diusion equations, and the reach of
AHAPs can easily be modied by altering coecients in the AHAP diusion equation.
Thus the inuence of bystander eects on the treatment outcome is allowed to range
from negligable to highly inuential.
Multiple HAPs have been evaluated for their clinical potential, both as monother-
apies and as part of combination therapies [85, 167]. Class I HAPs are activated in
moderately hypoxic environments whilst Class II HAPs require more severe hypoxia
to undergo the HAP to AHAP bioreduction [177]. One such Class II HAP is evofos-
famide, or TH-302, which has been tested in clinical Phase I-III trials [85, 162]. TH-302
bioreduces to its activated form, bromo-isophosphoramide mustard (Br-IPM), in hy-
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poxic tumour regions, and Br-IPM is a DNA-crosslinking agent [176]. Multiple in vitro
and in vivo studies have validated this drug's preclincal success and, by extension, its
clinical feasibility [103, 165, 166, 168, 169, 171, 175, 178182]. Multimodality treatment
strategies combining HAPs, particularly Class II HAPs, with ionising radiation (IR)
may be particularly promising [167, 168, 181] as the two therapies conceptually com-
plement each other: HAPs target hypoxic tumour regions whilst radiotherapy is most
eective against well oxygenated tumour regions. Thus, in principal, HAP-IR combi-
nation treatments have the ability to produce multifaceted attacks on tumours.
Despite HAPs being conceptually promising and successful in laboratories, this suc-
cess has not yet been mirrored in clinical trials [85, 162, 163]. It is hypothesised that
this unsuccessful Bench-to-Bedside translation is partly due to an insuciently strin-
gent clinical screening practice of selecting tumours that are suitable for HAP treat-
ments [162]. It is likely that some of the tumours enrolled in clinical trials have been
insuciently hypoxic to benet from treatment plans involving HAPs [163]. To investi-
gate this hypothesis, we here propose a mathematical modelling angle to simulate how
spatio-temporal tumour features may impact HAP ecacy and how scheduling inu-
ences the outcome of multimodality HAP-IR treatments.
Today, mathematical modelling constitutes an indispensable complement to tradi-
tional cancer research. Models provide an opportunity to study biological phenomena
in silico that may not be empirically observable and, moreover, in silico experiments are
fast and cheap to run, easy to reproduce and not directly associated with any ethical
concerns. Previous mathematical studies have already contributed to the overall under-
standing of HAPs, quantied key mechanisms associated to them and illustrated their
clinical feasibility. Foehrenbacher et al. [183] have deployed a Green's function method,
in customised form, and pharmacokinetic/pharmacodynamic (PK/PD) modelling to
quantify anticancer bystander eects elicited by the HAP PR-104 in a simulated, three-
dimensional tumour comprising a microvascular network. Another concurrent article
used similar mathematical concepts to compare Class I HAPs to Class II HAPs and,
furthermore, to determine optimal properties for Class II HAPs [177]. Lindsay et al.
[184] developed a stochastic model to study monotherapies and combination thera-
pies involving HAPs, specically TH-302, and erlotinib. Amongst other ndings, they
74
4.3 Model
concluded that a combination therapy of the two drugs impedes the uprising of drug
resistance. Since HAPs bioreduce to activated form under hypoxic conditions it follows
that AHAP activity increases with intratumoural hypoxia. Accordingly, a previous
study by Wojtkowiak et al. [185] conceptually validated the strategy of amplifying
TH-302 activity by deliberately exacerbating intratumoural hypoxia using exogenous
pyruvate. Their study combined mathematical modelling with metabolic proling and
EPR (electron paramagnetic resonance) imaging. HAP dynamics were modelled using
reaction-diusion/convection equations coupled with uid-structure interactions. In line
with these previous mathematical studies, the aim of this in silico study is to contribute
HAP-related insights gained by mathematical modelling, according to a Blackboard-to-
Bedside [186] approach.
In clinical settings, the intratumoural oxygenation status can be assessed in multiple
ways. By inserting oxygen electrodes into tumours, pO2 values can directly be measured,
but this measuring technique is invasive and does not distinguish between hypoxic and
necrotic tumour regions [162]. Alternatively, less invasive imaging techniques, such as
positron emission (PET-scans) and oxygen-enhanced magnetic resonance (MRIs), can
be used to evaluate oxygen levels in tumours [85, 162]. Consequently, it is indeed feasible
to invoke stricter selection regimes when deciding whether or not to pair tumours with
HAP treatments in clinical trials [162]. A recent publication, by Spielberg et al. [162],
claims that the (lack of) clinical progress with HAP-treatments can, in great part,
be attributed to the omission of hypoxia-based patient selection in phase III trials.
In this study, we demonstrate that the ecacy of HAP monotherapies and HAP-IR
combination therapies in silico is, indeed, highly dependent on tumour-specic oxygen
features.
4.3 Model
The on-lattice, hybrid, multiscale cellular automaton (CA) presented in Chapter 2 is
used in this chapter to model solid tumours subjected to HAP and IR monotherapies,
as well as HAP-IR combination therapies. Tumour growth and HAP responses are pa-
rameterised by published data from an in vitro study performed by Voissiere et al. [3],
in which MCTSs where grown and exposed to HAPs. Specically, we use their data for
human chondrosarcoma HEMC-SS cells exposed to the hypoxia activated prodrug TH-
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302. Our mathematical model is thereafter extended to simulate in vivo drug dynamics
in order to investigate scheduling aspects of HAP-IR combination therapies. The pa-
rameters used in this chapter can be modied in order to simulate specic cell-lines
and drugs, and model rules can be altered in order to simulate both in vitro and in
vivo tumours. Thus, with the availability of appropriate data, various tumour scenarios
and treatment schedules and doses can be investigated in silico. Hence, the mathe-
matical model presented here constitutes a valuable and versatile complement to both
in vitro and in vivo experiments. The model used in this study is an extension of a
previous, well-established model presented by Powathil et al. [6]. All parameters used
in the model are motivated from experiments and literature, as described throughout
this section, and are summarised in Section 4.3.7, Table 4.1.
4.3.1 Mathematical Framework
The CA used in this model allows for spatio-temporal dynamics and intratumoural
heterogeneity including variations in cell-cycle progression, oxygen levels, drug con-
centrations and treatment responses amongst cancer cells [6, 186, 187]. The model is
multiscale and integrates both intracellular and extracellular regulations. In vitro exper-
iments have demonstrated that MCTSs are more HAP-sensitive than are monolayers.
This increase in sensitivity has been attributed to the microenvironment correlated to
multilayer cultures [175]. Aspiring to achieve an in silico model that is as clinically
relevant as possible, we here let the CA lattice extend in three spatial dimensions. The
lattice is specically a square lattice containing 1003 lattice points, simulating a physi-
cal environment of (2mm)3. Thus each voxel in the lattice spans a volume of (20µm)3
and each lattice point may be occupied by either one cancer cell or extracellular matrix
only. These dimensions agree with previous mathematical studies [6], and cell popu-
lation density in the MCTSs that are used to calibrate the model [3]. The time step
used to model the temporal progression of the CA is ∆t = 10−3 hours, by appropriate
non-dimensionalisation of oxygen dynamics [6].
4.3.2 Cell Cycle Progression
On an intracellular scale, sub-cellular mechanisms are modelled individually for each cell
in order to allow for variations amongst cancer cells. Cell-cycle progression is one such
intracellular process, it is governed by an intrinsic cell-cycle clock attributed to each
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Figure 4.1: Cell count over time for tumour spheroids. The in silico data is based on 10
simulations runs, the mean (black line) shows the average value and the gray ribbon shows
standard deviation. In vitro data (red error bars) are extracted from plots produced by
Voissiere et al. [3] using a Java program [4].
individual cell. In order to account for cell-cycle asynchronicity amongst cells, each cell
i is assigned an individual, stochastic doubling-time τi which corresponds to the time it
takes for a cell to complete one cell-cycle, and double by producing a daughter cell, in
well-oxygenated conditions. τi is picked from a normal distribution with a mean value
µ and a standard deviation σ, which are picked to match cell population growth-rates
reported from Voissiere et al. [3]. as demonstrated in Figure 4.1.
Each cell in the model follows a cell-cycle typical to that of eukaryotic cells. In
particular, a cell is dened to be in the gap 1 (G1), synthesis (S), gap 2 (G2) or mitoses
(M) phase of the cell-cycle. As sensitivity to radiotherapy is cell-cycle dependent [79], it
is important to track cell-cycle phase progression in the model. Each cell that is placed
on the lattice commences its rst cell-cycle in the G1 phase. Under well-oxygenated
conditions, the fraction of time spent in each of the four distinct cell-cycle phases are
ΘG1, ΘS , ΘG2 and ΘM for the cell-cycle phases G1, S, G2, M respectively, where the
Θ-fractions sum up to, as described in Chapter 2.2.2, and the four theta values, listed
in Table 4.1, are picked from literature in order to match typical lengths of cell-cycle
phases for human cells with a doubling time of roughly 24 hours [63]. Thus, the time
spent in each of the four distinct cell-cycles, for a well-oxygenated cell i with a cell-cycle
length τi, is ΘG1τi, ΘSτi, ΘG2τi and ΘMτi for the cell-cycle phases G1, S, G2 and M
respectively. However, low cellular oxygen levels have been shown to delay cell-cycle
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progression by inducing arrest in particularly the G1 phase of the cell cycle [1] and thus,
in accordance with the cell cycle clock model described in Chapter 2.2.2, the G1 phase
is elongated under hypoxic circumstances according to Equation 2.3 and Figure 2.2.
4.3.3 Tumour Growth
In the model, a tumour is grown from one seeding cancer cell which divides and gives
rise to a heterogeneous MCTS. Once a viable, i.e. undamaged, cell has completed
the mitoses (M) phase of the cell-cycle, a secondary cell, namely a daughter cell, is
produced and placed in the neighbourhood its mother cell. This cell-division occurs
provided that free space is available on the lattice in the neighbourhood of the mother
cell. If this is not the case, no daughter cell is produced and instead the mother cell exits
the cell-cycle to enter the quiescent phase, G0. Should neighbourhood space be made
available again, as a result of cells getting removed from the lattice due to anticancer
treatments, quiescent cells may re-enter the cell-cycle. Each daughter cell is placed on
a random lattice point in the neighbourhood of the mother cell, where up to ν spherical
neighbourhoods are regarded. In order to agree with the MCTS data [3] used to calibrate
the model, ν = 3, as illustrated in Figure 4.2, and thus a daughter cell may be placed
up to three neighbourhoods away from its mother cell. To accomplish spherical-like
tumour growth the model stochastically alternates between deploying Moore and von
Neumann neighbourhoods [6].
4.3.4 Oxygen Distribution and Hypoxia
Oxygen is assumed to be readily available in the extracellular space and, accordingly,
extracellular lattice points are oxygen source points. On the other hand, viable (i.e.
non-damaged) cells are modelled as oxygen sinks as they consume oxygen in order to
function. As is previously discussed in this thesis, the distribution of oxygen across the
lattice is modelled by a mechanistic partial dierential equation (PDE), such that
∂K(x, t)
∂t
= ∇ · (DK(x, t)∇K(x, t)) + rKm(x, t)− φKK(x, t)cell(x, t), (4.1)
coupled with no-ux boundary conditions. Here K(x, t) denotes the oxygen level in
lattice point x at time t. DK(x, t) is the diusion coecient, which is higher in lattice
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Figure 4.2: Top: Images from in vitro experiments performed by Voissiere et al. [3],
in which cell nuclei are stained blue and furthermore proliferative cells are stained green
by the proliferation marker Ki-67. Bottom: Images from in silico experiments performed




points occupied by cells compared to unoccupied lattice points, so that oxygen diuses
slower over cancer cells than in extracellular material in the model [6]. The binary
function cell(x, t) is equal to one if the lattice point is occupied by a cancer cell, and
zero otherwise. Similarly, the binary functionm(x, t) is one if the lattice point is outside
the tumour, and zero otherwise. The oxygen production rate is denoted by rK and the
cellular oxygen consumption rate is φK . In this study, the diusion coecient for oxygen
is gathered from literature but the production and consumption rates are calibrated in
silico to match in vitro data from Voissiere et al. [3], specically to achieve appropriate
oxygen gradients. Note that the no-ux boundary condition causes the total amount of
oxygen on the lattice to increase over time. To express oxygenation levels on the lattice





where maxnK(n, t) denotes the maximal K(x, t)-value (of all n lattice points) at
time t [67]. The scaling-factor, h, (with unit mmHg), is incorporated in order to calibrate
the model to t the MCTS data, as illustrated in Figure 4.3. A cell is dened to be
hypoxic if it has a scaled oxygen value such that K̂(x, t) ≤ 10 mmHg [6]. In the model,
the K̂(x, t)-value inuences G1-arrest (Figure 2.2), radio-sensitivity (Figure 2.6) and
HAP-AHAP bioreduction rates (Figure 4.4).
4.3.5 Hypoxia Activated Prodrugs
Anticancer prodrugs constitute relatively harmless compounds in their inactivated form
with the potential to bioreduce, or transform, into cytotoxic species [103]. Specically
for HAPs, this bioreduction occurs in hypoxic conditions and thus HAPs are able to
selectively target hypoxic tumour regions [103]. The oxygen dependent bioreduction is
here modelled by the function fHAP→AHAP (K̂(x, t)), where
fHAP→AHAP (x, t) = b ·BRF (K̂(x, t)), (4.3)
where b is a time-scaling factor with and BRF is a bioreduction factor as illustrated
in Figure 4.4 and
BRF (K̂(x, t)) =
[pO2]50




Figure 4.3: Top: Images from in vitro experiments performed by Voissiere et al. [3], in
which hypoxic cells are stained green by pimonidazole and normoxic cells are stained blue.
Bottom: Images from in silico experiments performed in this study, where hypoxic cells

















HAP to AHAP Bioreduction Factor (BRF)
Figure 4.4: The bioreduction factor, BRF , expresses the fraction of HAP compound that
reduces to AHAP compound within one hour as a function of oxygenation (measured in
mmHg)
Here [pO2]50 denotes the oxygen value yielding 50% bioreduction (in one hour), cho-
sen to be 0.2 mmHg as is done in a previous mathematical model by Hong et al. [188].
As illustrated in Figure 4.4, the BRF value rapidly decreases for pO2 values (i.e. K̂(x, t)
values) between 0 and 10 mmHg.
The mechanistic reaction-diusion equations governing the distribution of HAPs
and AHAPs across the lattice are respectively given by [189]
∂[HAP ](x, t)
∂t
= ∇ · (D[HAP ](x, t)∇[HAP ](x, t)) + r[HAP ](x, t)m(x, t)






= ∇ · (D[AHAP ](x, t)∇[AHAP ](x, t))
+ fHAP→AHAP (x, t)[HAP ](x, t)− η[AHAP ][AHAP ](x, t),
(4.6)
where [HAP ](x, t) denotes the concentration of HAPs and [AHAP ](x, t) denotes the
concentration of AHAPs in point x at time t. D[HAP ](x, t) and D[AHAP ](x, t) denote the
respective diusion coecients, r[HAP ](x, t) denotes the HAP production rate, η[HAP ]
and η[AHAP ] denote the corresponding decay rates. AHAPs are harmful agents which
are here assumed to inict damage that is cell-cycle non-specic. Consequently, cells
that are in any cell-cycle phase (G1, S, G2, M) or in the quiescent phase (G0) are
susceptible to AHAP-inicted damage. A cell in point x at time t is damaged by the
cytotoxic AHAPs if [AHAP ](x, t) ≥ Ψ, where Ψ is the lethal AHAP concentration
threshold. Ψ and the production coecient in Equation 4.5 are calibrated in silico to
make it so that HAPs and IR yield the same eect (in terms of number of cells killed)
for a large tumour (see the Large Tumour in Figure 4.5). When a cell dies, it reduces
to a membrane-enclosed cell-corpse which is (in vivo) digested by macrophages [7]. In
the model, the time it takes for a cell to receive lethal damage until it is removed from
the lattice, to give space to other cells, is denoted TL→R (L for lethal, R for removal).
Three cases for this time TL→R are investigated in this study: (i) the rst extreme
case in which a dead cell in never removed from the lattice (simulating an in vitro
environment), (ii) the other extreme case in which a cell is instantaneously removed
from the lattice upon receiving lethal damage, and (iii) a mid-way case in which a cell
is removed from the lattice after a time-period corresponding to its doubling time has
passed, i.e. TL→R,i = τ. Results using the rst case are included in the main text,
results for cases (ii) and (iii) are provided in Appendix A2 in which we demonstrate
that, within the scope of the performed in silico experiments, this choice of TL→R value
does not aect our qualitative ndings.
4.3.5.1 Drug Parameters
In our mathematical model, HAPs are produced on the source points (i.e. extracellular
lattice points outside the tumour) and are quickly distributed across the lattice. Drug
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transportation of HAPs from source points to cells is mediated only by the diusion
terms in Equation 4.5 and and similarly AHAP transportation is mediated only by the
diusion term in Equation 4.6. Consequently, the drug diusion coecients D[HAP ]
and D[AHAP ] represent all biophysical drug transportation across the lattice in silico.
HAPs must possess certain appropriate attributes in order to produce desired eects
[175]. Specically, HAPs should be able to travel relatively long distances without being
metabolised, specically distances longer than that of which oxygen travels, in order to
reach hypoxic tumour regions. It has, indeed, been demonstrated in vivo that TH-302
has the ability to reach hypoxic regions, where it is activated [190]. Conversely, AHAPs
should travel relatively short distances in order to localise AHAP activity to tumour
regions only, and thus to minimise unwanted extratumoural toxicity. The diusion
length of oxygen is reported in literature to be approximately 100 µm [6] however, to
our knowledge, no diusion length of neither TH-302 nor Br-IPM has been explicitly
reported. However, the diusion length of the HAP/AHAP pair AQ4N/AQ4 has been
shown to be reach roughly 1.5 times that of oxygen (or 150µm) in xenografts [191].
With this motivation, we here approximate the diusion coecient of TH-302 to be
twice that of oxygen. ( According to the relationship L =
√
D/Φ, where L is the dif-
fusion length scale and Φ is the compound uptake, the diusion coecient of a certain
compound, D, is proportional to L2, neglecting details of compound uptake. Thus here
we make the simplied approximation that L[HAP ](x, t) =
√
2 ·DK(x, t). ) Similar to
previous procedure, the diusion length of AHAPs is approximated to be half that of
oxygen so that D[AHAP ](x, t) = (1/4) · DK(x, t). These parameter estimations suce
to conceptually, and qualitatively, describe the nature of HAPs and AHAPs, but can
be amended upon the availability of new data. By adjusting the diusion coecients
D[HAP ] and D[AHAP ], the inuence of bystander eects are allowed to range from neg-
ligible to highly inuential.
The half-life times of TH-302 and Br-IPM have been reported to be 0.81h and
0.70h respectively in a clinical trial [170], these values are used to determine the decay
rates η[HAP ] and η[AHAP ]. This half-life time of TH-302 is in accordance with preclinical
predictions obtained from allometric scaling [180]. Note that the drug decay coecients,
η[HAP ] and η[AHAP ] in Equation 4.5 and Equation 4.6 respectively, simulate all drug




Cellular responses to radiotherapy are dependent on oxygenation status [88], cell-cycle
phase [89, 90], and cell-line characteristics. Cellular radiotherapy responses are here
modelled using Equation 2.23, an appropriate CA adaptation of the widely accepted
Linear-Quadratic (LQ) model discussed in Chapter 2.6.3. Equation 2.23 reads,
S(x, t) = e−d([OMF ]α(x,t)+d[OMF ]
2β(x,t)),
where details are provided in 2.6.3. To include cell cycle sensitivity, α and β are here
cell cycle dependent and the oxygen modication factor (OMF), expressed in Equation
2.24, is incorporated to include oxygen sensitivity. The survival probability of a cell in
point x at time t, exposed to a radiation dose of 2 Gy, is illustrated in Figure 2.6 in
Chapter 2.8, where the survival probability depends on both oxygenation and cell-cycle
phase details.
4.3.7 Parameters
In this study we attempt to replicate the nature of generic eukaryotic cell-lines, the
HAP evofosfamide (TH-302) and its corresponding AHAP, Br-IPM. The parameters,
which are listed in Table 4.1, are chosen accordingly but can be adapted to represent
other specic cell-lines or drugs upon data becoming readily available.
4.3.8 Implementation and in silico Framework
The mathematical model is implemented in an in-house computational framework writ-
ten in C++. A owchart of the programming code is available in Appendix A2. The
PDEs describing oxygen and drug distribution across the lattice are solved using ex-
plicit nite dierence methods with no-ux boundary conditions. Maps of cancer cells
and the microenvironment are visualised in ParaView [161]. Using this computational
framework, various experimental in vitro and in vivo scenarios are formulated and sim-
ulated in silico. In order to grow an in silico MCTS, one seeding cancer cell is placed
on the lattice and this cell divides and gives rise to a heterogeneous MCTS. Such vir-
tual spheroids are thereafter subjected to various treatment combinations comprising
HAPs and IR. Treatment commence when MCTSs consist of, in the order of, 100,000
cancer cells or `agents' in out agent-based model. Due to the high number of agents,
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Section, Equation Parameter Value
Cellular Automaton
4.3.1, N/A ∆x1 = ∆x2 = ∆x3 (spacing) 20 µm
∆t 0.001 hours
Cell-cycle and proliferation
4.3.2, N/A µ, σ 40 hours, 4 hours









4.3.2, 2.3 a1, a2, a3 0.9209, 0.8200, -0.2389
4.3.3, N/A ν 3
Oxygen
4.3.4, 5.1 DK(x, t) =
{
DK/1.5 if cell in (x, t)
DK otherwise
DK = 2.5 × 10−5 cm2s−1
cell(x, t) =
{




1 if (x, t) outside MCTS
0 otherwise
4.3.4, 5.2 h 0.5 mmHg
4.3.6, 2.24 OERm 3
4.3.6, 2.24 Km 3 mmHg
Drugs
4.3.5, 4.3 b (hour)−1
4.3.5, 4.4 [pO2]50 0.2 mmHg
4.3.5, 4.5 and 4.6 DHAP , DAHAP 2 ×DK(x, t), 14 ×DK(x, t)
ηHAP , ηAHAP picked from half-life times:
t1/2,HAP=0.81 hours,
t1/2,AHAP=0.70 hours
4.3.5, 4.5 TL→R (for the no removal in vitro case) Innity
Radiotherapy
4.3.6, 2.23 α(G1), β(G1) 0.351, 0.04
α(S), β(S) 0.1235, 0.04
α(G2), β(G2) 0.793, 0
α(M), β(M) 0.793, 0
α(G0), β(G0) α(G1)/1.5, β(G1)/(1.52 )
Table 4.1: A summary of model parameters used in the mathematical framework.
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and the fact that the intrinsic model stochasticity only involves a few events during the
simulated treatment time (specically 0-3 cell divisions and potentially one response to
radiotherapy) the quantitative results do not dier much between in silico runs. Per-
forming the same in silico experiment 10 times yields a standard deviation that can be
regarded as negligible (less than 0.5%), and thus we argue that basing our results from
means from 10 simulation runs per experiment is enough to mitigate intrinsic model
stochasticity to a level that is sucient for this qualitative study.
4.4 Results and Discussion
In Sections 4.4.1 through to 4.4.3, we compare treatment responses in two dierent in
silico tumour spheroids, specically a `Large' and more hypoxic MCTS and a `Small',
less hypoxic MCTS. The `Small' tumour corresponds to the 20 day-old MCTS in Figures
4.2 and 4.3, that is calibrated by in vitro data from Voissiere et al. [3]. The `Large'
MCTS is extrapolated by letting the `Small' MCTS grow for yet another 10 days in
silico, until it reaches an age of 30 days. The `Small' and `Large' MCTSs are illustrated
in Figure 4.5.
The simulated IR dose is chosen to be 2 Gy, a dose commonly used in clinical set-
tings [79]. To allow for intuitive comparisons between the two dierent monotherapies,
the HAP dose (DoseHAP ) is here qualitatively chosen, and calibrated to yield the a
similar response as the 2 Gy IR dose (in terms of cell survival) in the `Large' MCTS.
Quantitative doses can be specied and implemented upon the availability of data.
4.4.1 HAP and IR Monotherapies Attack Tumours in Dierent Ways
In this initial in silico experiment, a MCTS is subjected to a monotherapy of either one
dose of HAPs or one dose of IR. Our in silico results demonstrate that HAP and IR
monotherapies attack the MCTS in dierent ways. This can be understood by regarding
the treatment responses in Figure 4.6 and Figure 4.7. Figure 4.6 shows cell-cycle phase
specic survival data, in terms of cell count over time, when the `Small' or `Large' MCTS
is subjected to a HAP or IR monotherapy. Similarly, Figure 4.7 shows the composition
of cells, in terms of their cell-cycle phase, in response to a HAP or IR monotherapy
dose. Our results demonstrate that for the `Small', well-oxygenated MCTS, HAPs have
negligible eect on the cell count (see Figure 4.6) and, by extension, on the cell-cycle
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Figure 4.5: The `Small' (20 day old) MCTS and the `Large' (30 day old) MCTS are
used in Sections 4.4.1, 4.4.2, 4.4.3 to allow for comparisons in treatment responses between
tumours with dierent oxygenation levels. Top: Simulation snapshots of the MCTSs at
the time point T0 when treatments commence (A1: Small MCTS, B1: Large MCTS).
Hypoxic cells (pO2 ≤ 10 mmHg) are green whilst normoxic cells are blue. Middle: Oxygen
histograms at time T0, in which hypoxic cell counts are shown in green and normoxic cell
counts are shown in blue (A2: Small MCTS, B2: Large MCTS). Bottom: Cell-cycle phase
histograms at time T0 (A3: Small MCTS, B3: Large MCTS).
phase composition (see Figure 4.7). This shows that, by design, HAP treatments have
little eect on tumours that are not hypoxic enough to cause signicant HAP-to-AHAP
bioreduction. For the `Large' MCTS, however, HAPs successfully eliminate cells, par-
ticularly G0 cells (see Figure 4.6). This causes an alteration in the cell-cycle phase
composition in favour of proliferative (i.e. non-G0) cells (see Figure 4.7). Our results
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further show that, for both the `Small' and the `Large' MCTSs, IR eliminates cells of all
cell-cycle phases (see Figure 4.6), but alters the cell-cycle phase composition in favour
of G0 cells (see Figure 4.7). These opposing eects on the cell-cycle phase composition
achieved by HAPs and IR in the `Large' MCTS indicate that, for tumours that are
hypoxic enough for HAPs to have an eect, HAP-IR combination treatments have the
potential of producing multifaceted attacks on tumours.
Since radiation responses are enhanced by the presence of molecular oxygen, we
investigated which monotherapy (i.e. HAP or IR) best eliminates hypoxic cells and
reoxygenates MCTSs. To demonstrate the overall alteration of oxygenation levels in
the MCTSs as a result of the monotherapies, Figure 4.8 provides histograms for cellular
oxygenation levels at time T0 (the time of therapy administration) and at time T0 + 4
hours. From this gure we can see that for the `Small' MCTS, HAPs do not alter the
overall intra-tumoural oxygenation but IR does. For the `Large' MCTS, on the other
hand, both HAPs and IR alter the overall intra-tumoural oxygenation but only HAPs
manage to shift the oxygen histogram away from the most severe levels of hypoxia. This
indicates that administering HAPs as a neoadjuvant therapy prior to radiotherapy may
enhance the eect of radiotherapy in tumours that are suciently hypoxic for HAPs to
be eective.
4.4.2 HAP-IR Treatment Scheduling Impacts HAP Ecacy in Su-
ciently Hypoxic Tumours
In order to study the optimal treatment scheduling of HAP-IR combination therapies,
simulated MCTSs are here given one dose of HAPs and one dose of IR. Figure 4.9 shows
the cell count over time when one dose of HAPs and one dose of IR are administered with
various schedules. The results in Figure 4.9 demonstrate that for the `Small' tumour,
scheduling does not impact the overall treatment outcome, as HAPs are not eective.
For the `Large' tumour however, it is more eective to give HAPs before IR than to give
IR before HAPs. This indicates that, in tumours that are hypoxic enough for HAPs to




Figure 4.6: Treatment responses for HAPs (left) and IR (right) monotherapies for the
`Small' (top) and `Large' (bottom) MCTS. The monotherapy is given at 0 hours. Graphs
demonstrate cell-cycle specic cell count (i.e. number of viable, undamaged cells) over
time. Solid lines show mean values, and `+' markers show standard deviations for 10 in
silico runs.
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Figure 4.7: Treatment responses for HAPs (left) and IR (right) monotherapies for the
`Small' (top) and `Large' (bottom) MCTS. The monotherapy is given at 0 hours. Graphs
demonstrate cell-cycle specic composition (of viable, undamaged cells) over time.




Figure 4.8: Treatment responses for HAPs (left) and IR (right) monotherapies for the
`Small' (top) and `Large' (bottom) MCTS. Histograms over cellular oxygenation levels at
time T0 (monotherappy administration time) and 4 hours later are shown. Results are
based on mean values from 10 in silico runs.
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Figure 4.9: Treatment responses (in terms of cell count) for HAP-IR combination ther-
apies in the `Small' MCTS (left) and the `Large' MCTS (right). One dose of HAPs and
one dose of IR are administered at various schedules. Solid and dashed lines show mean
values, and `+' markers show standard deviations for 10 in silico runs.
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4.4.3 HAPs Enhance Radiotherapy Eects in Suciently Hypoxic
Tumours
To investigate if and when HAPs enhance the eect of radiotherapy, simulated MCTSs
are subjected to either IR monotherapies or HAP-IR combination therapies. In the
combination therapy case, HAPs are administered at time T0 and IR is administered
at time T0 + 48 hours. In the monotherapy case, radiotherapy is administered at time
T0 +48 hours. For a thorough investigation, the oxygen-levels of the `Large' and `Small'
tumours are further scaled by multiplication with a factor 1, 1/2 or 1/4 so that we
have 6 dierent tumours on which to test if neoadjuvant HAPs enhances radiotherapy
ecacy. Figure 4.10 shows IR treatment responses in form of survival data (both in
terms of number of surviving cells and fraction of surviving cells). From these plots
we see that for very hypoxic MCTSs, the administration of neoadjuvant HAPs does
increase the eect of radiotherapy. However, for well-oxygenated MCTS, neoadjuvant
HAPs do not increase the eect of radiotherapy.
4.4.4 The Intratumoural Oxygen Landscape Impacts HAP Ecacy
In Sections 4.4.1, 4.4.2, 4.4.3 we have demonstrated various ways that the intra-tumoural
oxygenation level impacts HAP and IR monotherapies and combination therapies. Fur-
ther, in order to investigate if the spatio-temporal intumoural oxygen landscape impacts
HAP ecacy, two MCTSs with dierent oxygen landscapes are here compared. Omit-
ting details of oxygen dynamics and vessel structure, hypoxic regions are here manually
assigned in the MCTSs so that every cancer cell is set to be either severely hypoxic
(pO2 = 0 mmHg) or very well-oxygenated (pO2 = 100 mmHg). Both MCTSs, named
MCTS A and MCTS B, are assigned the same number of severely hypoxic and well-
oxygenated cancer cells at the time-point when treatment commences. In MCTS A,
the hypoxic region is made up of one concentric sphere in the core of the MCTS, whilst
in MCTS B, the hypoxic regions consist of multiple spheres, evenly spread out across
the MCTS. MCTS A and MCTS B are illustrated in Figure 4.11. The severely hypoxic
cancer cells are here called activator cells, as the prodrug bioreduction (or activation) is
maximal in severly hypoxic environments. The well-oxygenated cells are here referred
to as bystander cells, as the bioreduction is minimal in well-oxygenated environments.
Thus any lethal AHAP concentration occurring in a bystander cell is a result of HAP-
to-AHAP bioreduction occurring outside the bystander cells.
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Figure 4.10: Treatment responses of radiotherapy in various MCTSs when either (1)
an IR monotherapy dose is administered at T0+48 hours or (2) IR is given at T0+48
hours following a prior HAP dose at time T0. Note that only explicit IR responses (not
HAP responses) are shown. The oxygen-levels of the `Large' (left) and `Small' (right)
tumours are scaled by a factor of 1 (least hypoxic), 1/2 or 1/4 (most hypoxic). The value
calibrated from in vitro experiments [3] correspond to the scaling with factor 1. Yellow
bars show number of viable cells (instantaneously) before IR administration, blue bars
show the number of viable cells (instantaneously) post IR. Red bars show how many cells
(as a fraction) survived the IR attack.
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Figure 4.11: Top: MCTS A and B prior to treatment commencing. The MCTSs are
visualised in both opaque and transparent formats. Bottom: Oxygen histograms for MCTS
A and B prior to treatment commencing, hypoxic (pO2 ≤ 10 mmHg) cell counts are shown
in green and normoxic cell counts are shown in blue.
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Figure 4.12: Treatment responses in MCTS A and MCTS B when HAPs are administered
at 0 hours. The number of viable (undamaged) cells are plotted over time for MCTS A
and MCTS B tumour. Activator cells (pO2 = 0 mmHg) are shown in dashed lines and
bystander (pO2 = 100 mmHg) cells shown in solid lines. Results show mean values for 10
in silico runs and `+' markers show standard deviations.
From Figure 4.12 it is clear that the bystander eects are higher in MCTS B than in
MCTS A, although all activator cells are eliminated in both MCTSs. When the activator
cells are spread out across the spheroid, as in MCTS B, there are more interfaces in which
bystander cells experience signicant bystander eects. Even if the oxygen landscape
in MCTS B is highly synthetic, this in silico experiment shows that the intratumoural
oxygen landscape impacts the ecacy of HAPs.
4.5 Conclusion
Previous in vitro and in vivo studies have validated the successfulness of HAPs in lab-
oratory settings, however, this preclinical success has not yet been reected in clinical
trials. In an attempt to elucidate the unsatisfactory results from clinical HAP trials,
we in this study investigate how oxygen-related tumour features and treatment admin-
istration plans impact the ecacy of HAP monotherapies and HAP-IR combination
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therapies in silico. To this end we have developed a mathematical model capturing the
spatio-temporal dynamics of tumours subjected to multimodality treatments compris-
ing HAPs and IR. A set of results (i to iv) relating to HAP ecacy in silico have here
been demonstrated.
i HAPs and IR attack tumours in dierent, complementary, fashions. Whilst IR
provides a highly eective way to kill cancer cells in tumours, hypoxic and resting
cells are signicantly more resistant to IR than are well-oxygenated and actively
cycling cells. HAPs, however, are alkylating agents which bioreduce in (primarily)
hypoxic areas, hence HAPs primarily inict damage in hypoxic tumour regions,
which are often conferred with a high density of quiescent cells, which are suscep-
tible to HAP damage. Consequently, HAP-IR combination treatments have the
potential of produce a multifaceted attack on tumours.
ii In suciently hypoxic tumours, the HAP-IR treatment schedule inuences treat-
ment ecacy. However, in well oxygenated tumours the schedule is not important.
iii In suciently hypoxic tumours, HAP functions as a radiosensitiser and treatment
intensier, however, in well oxygenated tumours it does not.
iv Not only the overall intra-tumoural oxygenation levels, but also the intratumoural
oxygen landscape, impacts HAP ecacy.
In a recent publication, Spielberg et al. [162], claim that the (lack of) clinical
progress with HAP-treatments can, in great part, be attributed to the omission of
hypoxia-based patient selection. This in silico demonstrates that whilst HAPs are ef-
fective treatment intensiers for suciently hypoxic tumours, they have negligible eect
on more well-oxygenated tumours. In simple terms: some tumours are suitable to be
paired with treatment plans involving HAPs whilst others are not. In line with Spiel-
bergs claims [162], our in silico results indicate that a personalised medicine approach is
preferable if treatments involving HAPs (that are similar to TH-302) are to achieve their
maximum potential in clinical settings. In this study, we qualitatively studies various
aspects of HAP-IR treatment schedules using a multiscale mathematical framework.
Upon the availability of in vitro and in vivo data, this mathematical framework can
be calibrated in order to serve as an in silico testbed for predicting HAP-IR treatment
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scenarios. As a result of interdisciplinary collaborations, the mathematical framework
used in this study has previously been validated in vitro and in vivo for applications
other than HAP-IR combination treatments [31, 192]. The multiscale nature of the
framework enables integration of data from various scales, be it from the subcellular
scale, the cellular scale or the tissue scale. As an example of useful data, the multi
cellular tumour spheroid data previously produced by Voissier et al. [3] provided our
framework with calibration data for tumour growth and spatio-temporal oxygen evolu-
tion. Using existing experimental data to create data-driven mathematical models is a





Bridging in vitro and in vivo
research via agent-based modelling
The micro-environment in an in vitro cell culture is signicantly dierent from the
micro-environment in a solid tumour in vivo. In this chapter, we use an in
vitro-calibrated mathematical model to predict in vivo treatment responses to a drug
that inhibits DNA damage repair.
5.1 Chapter Summary
Translating quantitative information between in vitro and in vivo research remains a
scientically and nancially challenging step in preclinical drug development processes.
However, well-developed in silico tools can be used to facilitate this in vitro to in vivo
translation, and we here propose using an agent-based model to bridge the gap between
in vitro and in vivo research. The agent-based model used in this chapter is governed
by a set of empirically observable rules, and by adjusting only the rules when moving
between in vitro and in vivo simulations, whilst keeping the fundamental mathematical
model and parameters intact, the agent-based model can rst be parameterised by in
vitro data and thereafter be used to predict in vivo treatment responses.
As a proof-of-concept, this modelling approach is here validated against data pertain-
ing to LoVo cells subjected to the ATR (ataxia telangiectasia mutated and rad3-related
kinase) inhibiting drug AZD6738, but the modelling approach has the potential to be
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expanded to numerous applications. In this chapter we also highlight how agent-based
models, that are currently underutilised in pharmaceutical contexts, can be used in
preclinical drug development.
5.2 Introduction
5.2.1 Bridging in vitro and in vivo research
Mathematical models, and corresponding in silico tools, can be used to simulate both
in vitro and in vivo scenarios that involve cancer cell populations, or tumours, and their
responses to anti-cancer treatments. However, cancer cells in an in vitro cell culture
experience a microenvironment that is signicantly dierent from the microenvironment
experienced by cancer cells in a solid tumour in vivo. As these microenvironments
inuence cell proliferation and the delivery of oxygen, drug and nutrient molecules to
cells, it follows that the dynamics of a cancer cell population in vitro diers from the
dynamics of a solid tumour in vivo. Consequently, translating data obtained by in vitro
experiments into quantitative information that can guide or predict in vivo experiments
remains a challenging, but important, step in drug development processes.
Agent-based models (ABMs) are used in many applications in mathematical biol-
ogy but are underutilised in the context of pharmaceutical drug development [193]. An
ABM consists of multiple, distinct agents that may interact with each other and with
their microenvironment. In this study, we introduce a novel modelling approach that
uses an agent-based mathematical model to bridge the gap between in vitro and in
vivo research, as is conceptually illustrated in Figure 5.1. In the ABM at the core of
this modelling approach, an agent consists of one cancer cell or a group of cancer cells,
and the behaviour and fate of each agent is governed by a set of empirically observable
and well-established modelling rules that incorporate both intracellular and microen-
vironmental dynamic variables, as is thoroughly described throughout Section 5.3. To
account for dierences between in vitro and in vivo scenarios, the modelling rules are
appropriately adjusted when moving between in vitro and in vivo simulations. By only
adjusting the rules, whilst keeping the fundamental mathematical model and parame-
ters intact, when moving between in vitro and in vivo simulations, the mathematical
framework can rst be parameterised by in vitro data and thereafter be used to predict
in vivo treatment responses.
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Figure 5.1: A schematic of the mathematical modelling approach used in this study. An
agent-based mathematical model, that distinguishes between in vitro and in vivo modelling
rules, is used to bridge the gap between in vitro and in vivo research. In this study, the
mathematical model is rst parameterised by in vitro data and is thereafter used to predict
in vivo outcomes.
As a proof-of-concept of this modelling approach, we here simulate LoVo (human
colon carcinoma) cells subjected to the anti-cancer drug AZD6738. The in vitro and
in vivo data used in this work are gathered from previous work by Checkley et al. [5].
The ABM used in this study is an based on the cellular automaton (CA) introduced in
Chapter 2.
5.2.2 DNA damage response inhibiting drugs
The deoxyribonucleic acid (DNA) in human cells is perpetually exposed to, potentially
harmful, inuences that can be derived from both exogenous and endogenous sources
and events [194, 195]. Exogenous sources include ultraviolet radiation, ionising radia-
tion and chemotherapeutic drugs, whilst erroneous DNA replication is an example an
endogenous event yielding DNA damage [194]. Regardless of the source, a multitude
of intracellular events are triggered when the DNA in a cell becomes damaged. Cells
may, for example, respond to DNA damage by activating DNA repair mechanisms,
cell cycle arrest or, in cases of severe DNA damage, apoptosis [196]. Such cellular re-
sponses to DNA damage are mainly governed by the DNA damage response (DDR),
which comprises a complex network of signalling pathways [196]. The DDR has many
functionalities and, amongst other things, it monitors DNA integrity and repairs DNA
damage in order to maintain genomic stability in cells. The DDR also governs DNA
replication, cell cycle progression, and apoptosis [194, 197].
When DNA repair in a cell is needed, the DDR activates relevant eector proteins
[194]. Included in the group of DDR-associated eector proteins are approximately
450 proteins [197], out of which the two main regulators for cell cycle checkpoints
are ataxia telangiectasia mutated kinase (ATM) and ataxia telangiectasia mutated
and rad3-related kinase (ATR) [195]. ATM and ATR belong to the enzyme family
103
5. BRIDGING IN VITRO AND IN VIVO RESEARCH VIA
AGENT-BASED MODELLING
phosphatidyilinositol-3-OH-kinases (PI3K), and they both play central roles when cells
respond to DNA damage [196]. In this work, we study the eects of an anti-cancer
drug, namely AZD6738, that works by inhibiting ATR activity.
DNA lesions in form of single-strand breaks are a common result of replication
stress, and the repair of single-strand DNA breaks is mainly attributed to ATR activity.
A drug that inhibits ATR activity consequently inhibits the repair of single-strand
DNA breaks post replication stress. Cancer cells are associated with high replication
stress and consequently ATR inhibitors have, during the last decade, been explored
as anti-cancer agents [194, 196, 198]. With the premise that inhibiting DNA damage
responses should increase the eect of some other main therapy, DDR inhibitors have
been explored as both radiotherapy and chemotherapy treatment intensiers [196, 198].
Two well-studied ATR inhibitors are AZD6738 and VX-970. AZD6738 is an oral ATR
inhibitor, and its anti-tumour potential has been demonstrated in preclinical vitro and
in vivo xenograft studies for various ATM decient cell lines, including ATM decient
lung cancer, chronic lymphocytic leukemia and metastatic adenocarcinoma of the colon
[5, 195, 199]. Combination treatments that combine AZD6738 with either radiotherapy
or chemotherapy have produced synergistic results in preclinical settings [195], and
AZD6738 is currently being evaluated in clinical phase I/II trials [194, 198]. VX-970 is
an intravenous ATR inhibitor [200] that has demonstrated tumour controlling eects in a
phase I clinical trial, both as a monotherapy and in combination with the chemotherapy
drug carboplatin [194]. A summarising table of clinical trials involving ATR-inhibitors
can be found in an article by Mei et al. [198].
5.3 Model and Method
An ABM, specically a CA, is used to model a population of cancer cells (in vitro), or
a solid tumour (in vivo), that evolves in time and two spatial dimensions. The model
describes the behaviour of cancer cells using a set of modelling rules. In order to ac-
count for dierences between in vitro and in vivo scenarios, these rules are appropriately
adjusted when moving between in vitro and in vivo simulations, as is described through-
out Section 5.3. Taking a minimal parameter approach, we aim to use as few rules and
parameters as possible to capture the nature of the regarded system. We here chose
to include model rules and parameters that pertain to the doubling time and cell cycle
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state of a cell (see Section 5.3.2), cell proliferation on the lattice (see Section 5.3.3),
the distribution of oxygen and drugs across the lattice (see Sections 5.3.4 and 5.3.5 re-
spectively) and cellular responses to local oxygen and drug concentrations (see Sections
5.3.4 and 5.3.6 respectively). In this work, details concerning nutrient distribution and
its eect on tumour growth are not included. Instead, under a simplifying modelling
assumption, the diusion of oxygen forms a surrogate for distribution of nutrients. Dif-
ferences between the in vitro and the in vivo modelling rules are pictorially summarised
in Section 5.3.8, and in vitro-calibrated model parameters are listed in Table 5.1.
The in vitro and in vivo data used in this study are gathered from previous work by
Checkley et al. [5]. In the in vitro experiments, populations of LoVo cells were plated
and subjected to AZD6738, where population sizes of up to roughly 4000 cells were
reported [5]. In the in vivo experiments, LoVo cells were subcutaneously injected in
anks of female Swiss nude mice in order to produce human tumour xenografts, and
AZD6738 treatments started when the tumours had reached a volume of 0.2-0.3 cm3
[5]. Here, we regard treatment responses in terms two dynamic variables: population or
tumour size and percentage of DNA-damaged (i.e. γH2AX-positive) cells. The in vitro
and in vivo data used in our current study are available in the Section 5.6.
5.3.1 Cellular automaton lattice
In the model, one agent corresponds to one cancer cell (in vitro) or, due to computa-
tional costs, one group of cancer cells (in vivo). The behaviour and fate of each agent
is governed by a set of rules that incorporate both intracellular and environmental dy-
namic variables using multiscale modelling techniques [50]. At the start of an in silico
experiment, one initial agent is placed in the centre of the lattice. This initial agent
produces daughter agents and ultimately gives rise to a heterogeneous population of
agents. When the population has reached an appropriate size (chosen to match the in
vitro and in vivo data), AZD6738 anticancer treatments commence. The CA lattice
is a square lattice, and every lattice point is either empty or occupied by one agent.
If a lattice point is empty, it only consists of extracellular solution (in vitro) or extra-
cellular matrix (ECM) (in vivo). The ECM comprises multiple components such as
collagen, elastin and bronectin but we do not distinguish between these components
in the model [58]. In the in vitro simulations, the dispersion of any molecules across the
lattice is modelled as instantaneous, and thus the extracellular solution is considered
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to render the entire lattice homogeneous in terms drug and oxygen concentrations at
all times. In the in vivo simulations, however, drug and oxygen molecules are modelled
as gradually diusing over the ECM and tumour cells on the lattice, and consequently
the in vivo lattice will be heterogeneous in terms of drug and oxygen concentrations.
Oxygen and drug distribution across the lattice are further discussed in Sections 5.3.4
and 5.3.5 respectively. Dierences between the simulated in vitro an in vivo lattices are
described below.
In vitro lattice: Cell populations evolve on a two-dimensional square lattice with
100× 100 lattice points, where the spacing in both spatial directions, x1 and x2, corre-
sponds to one cell diameter.
In vivo lattice: Approximating the tumour as spherical, we simulate (only) a cen-
tral cross section of the tumour as an, approximately circular, disk of cells living on
a two-dimensional square lattice. This lattice is specically an L̃ × L̃ = 500 × 500
square lattice, with a spacing in both spatial directions x̃1 and x̃2 equal to 40µm. The
dimensions are chosen in order to allow our agent-based model to simulate the required
physical dimensions, whilst keeping computational costs low. Post simulation time, the
two-dimensional cross section of cells is extrapolated to represent a three-dimensional
tumour-spheroid. This disk-to-spheroid extrapolation process is outlined in Section 5.5.
5.3.2 Cell cycle model
In order to capture the inuence of ATR and the ATR inhibitor AZD6738 on the
cell cycle, we use a probabilistic, rule-based cell cycle model adapted from previous
mathematical (non-agent-based) work by Checkley et al. [5]. In this model, a cancer
cell progresses through various states in the cell cycle, where the states correspond to
dierent cell cycle phases. As illustrated in Figure 5.2, a cell can be in an undamaged
state (G1, S or G2/M), a replication stress-induced DNA damaged state (D-S) or a
dead state. The cause of cell death is here unrepaired replication stress. As ATR is
active in the checkpoint in the intra-S phase of the cell cycle, both under undamaged
circumstances and in response to DNA damage [196], ATR inhibition will inhibit the
cell from progressing to the G2/M state in the mathematical cell cycle model. A cell
can take dierent possible paths through the cell cycle, and every time the cell cycle
path forks, random number generation from a uniform distribution determines which
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Figure 5.2: Cell cycle model: An agent, i.e a cell (in vitro) or a group of cells (in vivo),
progresses through various states of the cell cycle, where the states correspond to cell cycle
phases and are shown as nodes in the graph. Viable (undamaged or damaged) states are
shown in circles, whilst the dead state is shown as a cross. Paths illustrate transitions
between states, and symbols next to the paths denote the probabilities that the paths will
be taken. The dashed path can be inhibited by an ATR inhibiting drug, such as AZD6738.
path will be taken. Every cell commences its life in the G1 state, but thereafter a cell
can enter either the S state or the damaged S (D-S) state. The probability that a cell
enters the D-S state is denoted ΠD−S and is calibrated by in vitro data [5]. If a cell
enters the D-S state, it has a chance to repair itself and enter the S state. If there
is no drug in the system, this repair is always achieved, however the repair path is
inhibited by the presence of the drug AZD6738. The higher the drug-concentration is,
the more unlikely it is that a cell in the D-S state will successfully repair itself to the S
state. If a cell in the D-S state can not repair, it is sentenced to die. Whether a cell in
state D-S repairs or dies is decided by comparing a random number, generated from a
uniform distribution, to the cell's survival probability, which is inuenced by the local
drug concentration C(x̄, t), as described in Section 5.3.6. A cell that has successfully
reached the S state continues to the G2/M state after which it duplicates and starts
over in the G1 state again, ready to perform another cell cycle.
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Each agent i on the lattice is assigned an individual doubling time τi, where τi is a
random number generated from a normal distribution with mean value µ and standard
deviation σ. Each agent is attributed an individual cell cycle clock, that determines
when the agent should progress to a subsequent state in the cell cycle model. Pro-
gression to a subsequent state occurs once an agent has spent a certain fraction of its
doubling time in its current state. The fraction of the doubling time spent in the G1, S
(including D-S) and G2/M states are respectively denoted ΘG1, ΘS and ΘG2/M , where
these values are approximate and chosen from literature to match values for typical
human cells with a rapid doubling time of 24 hours so that ΘG1 = 11/24, ΘS = 8/24
and ΘG2/M = 5/24 [63]. The fraction of an agent's doubling-time spent in the D-S
state, ΘD−S , is on the other hand tted by in vitro data produced by Checkley et al.
[5]. In vitro and in vivo cell cycle modelling rules are described below.
In vitro cell cycle model rules: One agent corresponds to one cancer cell that is
assigned an individual doubling time τi. The cell cycle path taken by cell i is governed
by random number generations specic to that cell.
In vivo cell cycle model rules: One agent comprises a group of identical cancer
cells. Each agent is assigned an individual doubling time, τi, and thus all cells belonging
to agent i progress simultaneously uniformly through the cell cycle model. Random
number generations specic to agent i determine which path the agent takes through
the cell cycle.
5.3.3 Cell proliferation
When an agent has completed the mitosis state in the cell cycle model, a secondary
agent, namely a daughter agent, is produced. Each daughter agent is placed on a ran-
dom lattice point in the (approximately circular) neighbourhood of its parental agent.
To accomplish circular-like growth, the model stochastically alternates between placing
daughter agents on Moore and von Neumann neighbourhoods of parental agents, as is
pictorially described in Chapter 2.3. A daughter agent is allowed to be placed on, up
to, a νth order neighbourhood of its parental agent, but lower order neighbourhoods
(i.e. neighbourhoods closer to the parent) are prioritised and lled up rst. Modelling
rules concerning in vitro and in vivo cell proliferation are outlined below.
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In vitro proliferation rules: In the experimental in vitro setup, there is no spatial
constraint or nutrient deciency that is inhibiting cell division within the time-course
of the experiment. Consequently cells are allowed to divide freely in the in vitro model
and we set ν to be equal to innity in the in vitro case (with the restriction that agents
can not be placed outside the lattice in the in silico implementation).
In vivo proliferation rules: In vivo tumours typically consist of a core with
quiescent cells and a shell of proliferating cells. To accommodate for this, a daughter
agent (representing a group of daughter cells) is allowed to be placed on up to a third
order (approximately circular) neighbourhood of its parental agent, so that ν̃ = 3, in
accordance with previous mathematical models [6]. For the in vivo experiment regarded
in our current study, ν̃ = 3 matches the experimental data. However, for other experi-
ments the value of ν̃ may be adjusted to t the specic cell-line and modelling scenario
at hand. When an agent is in the G1 phase of the cell cycle, it scans its environment to
see if it has enough resources, in terms of space and nutrients, to commence the process
of producing a daughter cell. If not, the cell enters the quiescent phase [1]. Thus in
the model, when an agent is in the G1 phase, it continues to progress through the cell
cycle model, provided that some free space is available on the lattice within in its ν̃th
neighbourhood. If this is not the case, the agent exits the cell cycle to enter a quiescent
state G0. Should neighbourhood space be made available again, here as a result of
anticancer targeting, quiescent agents may re-enter the cell cycle.
5.3.4 Oxygen distribution and inuence on cells
Tumour growth and treatment responses are highly inuenced by intratumoural oxy-
gen levels [165, 168, 171] and severely hypoxic (cancer) cells proliferate slower than do
well-oxygenated cells [1].
In vitro oxygen distribution and responses: In the mathematical in vitro
model, all cells are assumed to be well-oxygenated in accordance with the experimental
in vitro setup performed by Checkley et al. [5]. Consequently, neither oxygen dynamics
nor cellular responses to low oxygen levels are incorporated in the in vitro model.
In vivo oxygen distribution and responses: Within solid tumours, oxygen
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concentrations typically vary and hypoxic regions are common tumour features [168,
169, 201]. Avoiding complicated details of vasculature in the model, we here approximate
oxygen as diusing in from `outside the boundary of the tumour'. Oxygen dynamics
across the CA lattice is here described using a mechanistic diusion equation, where
the oxygen concentration in location x̄ at time t is denoted by K(x̄, t) where
∂K(x̄, t)
∂t
= ∇ · (DK(x̄, t)∇K(x̄, t)) + rKm(x̄, t)− φKK(x̄, t)cell(x̄, t). (5.1)
The rst term in Equation 5.1 describes oxygen diusion across the CA lattice, the
second term is an oxygen supply term and the third term describes oxygen uptake by
cells. Accordingly, DK(x̄, t) denotes the oxygen diusion coecient, and rK and φK are
supply and consumption coecients respectively. The diusion coecient for oxygen
is known from literature to be 2.5 × 10−5 cm2s−1 [6]. Assuming that oxygen diuses
slower over cells than in the ECM, the oxygen diusion coecient is divided by a factor
1.5 if there is a cell in location x̄ at time t. The binary factor m(x̄, t) is 1 if the regarded
location x̄ is outside the tumour boundary at time t and 0 otherwise, i.e. m(x̄, t) is 1
if the regarded lattice point is not occupied by an agent nor completely surrounded by
agents. Similarly, the binary factor cell(x̄, t) is 1 if there is a viable cell in location x̄ at
time t, and 0 otherwise [6]. Equation 5.1 is coupled with no-ux boundary conditions,
thus the total amount of oxygen in the system uctuates over time [67]. A scaled oxygen
variable K̂(x̄, t) is introduced in order to express oxygenation levels in percentages (%)






where maxx̄,tuK(x̄, tu) denotes the maximum occurring K(x̄, tu)-value at the time
point tu [67] and h is a scaling factor [6]. Low cellular oxygen levels have been shown
to delay cell cycle progression by inducing arrest in, particularly, the G1 phase of the
cell cycle [1] and in our model, hypoxic cells with an oxygen concentration of 10%
or less display arrest (i.e. delay) in the G1 phase of the cell cycle. In mechanistic
Tyson-Novak type cell cycle models [6062], the cell cycle is governed by a system of
ordinary dierential equations (ODEs) in which the G1 phase is inherently elongated
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under hypoxic conditions by incorporating hypoxia-induced factors into the ODEs [6].
In this model, we use a clock to model cell cycle progression and thus we introduce a
G1 delay factor (G1DF) in order to achieve a longer G1-phase under hypoxic conditions
where
G1DF (K̂(x, t)) =





if 1% ≤ K̂(x, t) ≤ 10.5%,
1 otherwise.
(5.3)
The G1DF is an approximation for how much the G1 phase is expanded in time as
a function of oxygen concentration. It is matched to t data points extracted from a
previous mathematical study by Alarcon et al. [1], in which a Tyson-Novak cell cycle
model is extended to incorporate the action of p27, a protein that is up-regulated under
hypoxia and delays cell cycle progression. Data-tting yields the parameter values
a1 = 0.9209, a2 = 0.8200, a3 = −0.2389 [201]. Thus the fraction of an agent's doubling
time spent in the G1 state is G1DF (K̂(x̄, t)) · ΘG1, where G1DF (K̂(x̄, t)) = 1 for
normoxic cells.
5.3.5 Drug distribution across the lattice
Drug distribution signicantly varies between in vitro and in vivo settings. In the re-
garded in vitro setup, the drug concentration can be regarded as homogeneous, whilst
heterogeneous drug concentrations must be accounted for in vivo.
In vitro drug distribution: In the in vitro experiments performed by Checkley
et al. [5], plated cell populations of roughly 1000 cells were treated with AZD6738 in
the solvent dimethylsulfoxide (DMSO). In the mathematical model, we approximate
the drug distribution across the CA lattice to be instantaneous (occurring at treatment
time T0) and homogeneous. We furthermore assume that the drug has a half-life time
that exceeds the time course of the experiment, and note that there is no other drug
elimination from the in vitro system. In our mathematical model, this is equivalent
to there being no drug decay or elimination, hence the drug concentration C(x̄, t), in
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location x̄ at time t is simply given by
C(x̄, t) =
0 everywhere if t < T0,C everywhere if t ≥ T0, (5.4)
where C denotes the applied drug concentration (in units of molarity).
In vivo drug distribution: In the in vivo experiments performed by Checkley et
al. [5], AZD6738, or vehicle in the control case, were administered via oral gavage once
per day to female Swiss nude mice. In the mathematical in vivo model, we consider
the drug to diuse through the tumour from its surrounding, creating a drug gradient
within the tumour. In the mathematical model, this drug dynamics is modelled using
a partial dierential equation (PDE), where the concentration of AZD6738 at location







+ p(x̄, t)− ηAZDC(x̄, t), (5.5)
where DAZD is the diusion coecient of the drug AZD6738, and the supply coef-
cient p(x̄, t) is greater than zero at drug administration times only for lattice points
outside the tumour. Assuming rst order kinetics for drug elimination, the drug decay
constant ηAZD is matched to the reported half-life time of 6 hours for AZD6738 in vivo
[7, 202]. Note that the drug decay term here represents all drug elimination from the
system, both metabolic and that caused by excretion.
The diusion rate of a drug is predominantly aected by the molecular size of the
drug. More specically, the diusion coecient of a drug is inversely proportional to
the square root of the molecular weight of the drug, so that large molecules diuse
more slowly than do small molecules [7]. Using this assumption, the drug diusion
coecient is set in relation to the oxygen diusion coecient, as is done in previous
mathematical studies [6]. Thus the relationship between the diusion coecients for
the drug (AZD) and oxygen (O2) corresponds to the square of the inverse relationship
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where the molecular weights are collected from the PubChem database [8]. Details
regarding pharmacokinetics are outside the scope of this study, bioavailability is instead
calibrated using the extreme case drug scenario, as described in Section 5.4.
5.3.6 Drug responses
AZD6738 inhibits the repair from the D-S state to the S state in the cell cycle, as illus-
trated in Figure 5.2, and maximal drug eect corresponds to complete repair inhibition.
The drug eect is modelled using an agent-based adaptation of the sigmoid Emax model
[70], in which the drug eect on a cell in position x̄ at time t is given by
E(x̄, t) = Emax
C(x̄, t)γ
ECγ50 + C(x̄, t)
γ
. (5.7)
Emax denotes the maximal drug eect, here corresponding to complete repair inhi-
bition (Emax = 1), EC50 denotes the drug concentration required to achieve half of the
maximal drug eect, 0.5 · Emax and γ is the Hill-exponent [70]. EC50 and γ are tted
from the in vitro data. When an agent is scheduled to progress from the D-S state in
the cell cycle, it has a probability Πrep ∈ [0,1] to repair which is determined by the local
drug concentration such that
Πrep(x̄, t) = 1− E(x̄, t). (5.8)
Note that in the absence of drugs, the repair probability is 1. When a cell dies, it
is transformed into a membrane-enclosed `cell-corpse' [7]. In the in vivo setting, this
cellular debris is digested by macrophages but in the in vitro setting such `cell-corpses'
linger on the lattice during the course of the experiment. Post the lethal event (i.e. the
D-S to S repair failure) a cell is declared `dead' in the model after a time TL→D has
passed (where L stands for `lethal event' and D stands for `death'). The parameter
TL→D is calibrated by in vitro experiments. The dierences between modelling rules
for in vitro and in vivo drug responses are described below.
In vitro drug responses: After failure to repair from the D-S state, a cell (i.e.
and agent) is considered to be dead after a time TL→D has passed. However, a dead
cell is never physically removed from the lattice.
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Section Parameter Calibrated Value
5.3.2 µ, σ 24 h, 0.5 h
ΠD−S , θD−S 0.75, 0.03
5.3.6 EC50, γ 1 µM, 2
TL→D τi
Table 5.1: In vitro calibrated parameters.
In vivo drug responses: An agent (i.e. a group of cells) is declared to be
dead and removed from the lattice after an amount of time TL→D post the lethal event
(failure to repair).
5.3.7 Parameters
The parameters used in the mathematical model are calibrated by in vitro data, this
calibration process is described in Section 5.4. In the context of quantitative pharmacol-
ogy, knowledge about a model's robustness is crucial [203], therefore we have provided
results from the uncertainty and sensitivity analysis, as a worked example, in Chapter 6.
We performed three dierent uncertainty and sensitivity analyses techniques, suitable
for agent-based models with stochastic elements, namely (i) consistency analysis, (ii)
robustness analysis and (iii) Latin hypercube analysis [64, 204]. Detailed descriptions of
how to perform and interpret these techniques are available in Chapter 6. In accordance
with the performed consistency analysis, we run 100 simulations per in silico experiment
in order to formulate results (in terms of mean values and standard deviations) that
mitigate uncertainty originating from intrinsic model stochasticity.
5.3.8 Dierences between in vitro and in vivo modelling rules
Dierences between the in vitro and in vivo modelling rules in the ABM are pictorially
summarised in Figure 5.3.
A note on simplifying modelling assumptions Note that an agent in the in
vivo setting can, in general, be chosen to comprise either one cancer cell or a group
of cancer cells. Note also that modelling the in vivo tumour as a (spatially) two-
dimensional disk means that the distribution of nutrients and drugs is modelled across
a two-dimensional (rather than a three-dimensional) space. Likewise, the parameter
ν̃, that governs the allowed distance between a parental agent and its daughter agents,
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only concerns proliferation on a two-dimensional plane. By increasing ν̃, the tumour will
grow quicker and comprise a higher fraction of cycling (to quiescent) agents. Thus both
the parameters ν̃ and µ inuence the rate of tumour growth in the in vivo simulation,
and should ideally be tted to match detailed in vivo data. In the current study, we
choose to keep µ at the in vitro-calibrated value and thereafter t ν̃ to match the in
vivo data. A modeller can chose to use a three dimensional spatial domain, and thus
explicitly model a tumour spheroid instead of a tumour cross-section. Computational
costs, neness of available data, and the desired level of simulation details should be
used to guide the choice of agents and spatial domain.
5.3.9 Implementation
The mathematical model is implemented in an in-house C/C++ framework. PDEs are
solved using explicit nite dierence methods. A owchart of the programming code
is available in Appendix A3. Simulation cell-maps are visualised using ParaView [161].
Uncertainty and sensitivity analyses are performed using MATLAB [205].
5.4 Model Parameterisation
Using a minimal-parameter approach, seven model parameters are calibrated using the
in vitro data previously produced by Checkley et al. [5], as listed in Table 5.1. Parameter
sensitivity is explored in the sensitivity analysis in Chapter 6. The calibration process
is outlined in Sections 5.4.1 through to 5.4.4. The in vivo calibration is described in
Section 5.4.5.
5.4.1 Cell doubling
In the model, the doubling time of a cell i is denoted τi, where τi is stochastically picked
from a normal distribution with mean value µ and standard deviation σ. Thus µ cor-
responds to the average cell doubling time and σ corresponds to how synchronised the
cells are. If σ is zero, then all cells have perfectly synchronised cell cycles and duplicate
at the same time. Higher σ values achieve less synchronised cell cycles amongst cells
and smoother cell count growth curves over time. The control case (i.e. no drug) cell
count data is used to estimate µ and σ.
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By observing the control case cell count data in Table 5.2, we note that the cell
population roughly doubles between 2 and 24 hours (indicating an average cell doubling
time, or µ, of approximately 22 hours, which is less than 24 hours). Furthermore, the
cell population also roughly doubles between 24 and 48 hours (indicating that µ is
approximately 24 hours). However, in the last 24-hour interval, between 48 and 72
hours, the control population increases by less than 5% (indicating that µ is more than
24 hours). From these three observations, we choose to make the modelling assumption
that the average doubling time for cells should be around 24 hours, and σ-values in the
parameter range [22,26] hours are investigated in silico. Due to the synchronised nature
of the cell count data, σ-values between 0 and 2.5 hours were investigated in silico,
where σ = 0 h corresponds to completely synchronised cells and σ = 2.5 h achieves a
smooth cell count growth curve. After an iterative process of tuning parameters and
running in silico experiments, the calibrated values are set to be µ = 24 hours and
σ = 0.5 hours. As is previously discussed, the ABM can be improved to better t wet
lab data by including variable parameter values or rules, that are updated over time.
However, in the current stage of our work, we decided to x µ and σ.
5.4.2 Cell cycle progression
The in vitro data provides information on how many cells are in the damaged S state via
the biomarker γH2AX. For the control case, the number of γH2AX positive cells in our
mathematical model depends on two variables: (1) the probability (ΠD−S) that a cell
enters the D-S state and (2) the amount of time (ΘD−S · τi) spent in the D-S state prior
to repairing. Recall that ΘD−S is the fraction of a cell's doubling time (τi) spent in the
D-S state. As a rst step, in silico experiments are performed in which we nd various
parameter pairs (ΠD−S , ΘD−S) that agree with the control data. We thereafter note
that the in vitro drug eect saturates for concentrations 3, 10 and 30 µM and assume
that the maximal dose (30 µM) yields 100% D-S to S repair inhibition. Thus a second
step we test the variable pairs (ΠD−S , ΘD−S) for this `maximal drug and no repair'
scenario in silico, and we match these in silico results to the 30 M in vitro data. Here,
we only use data from early time points (time < 12 hours) in order to avoid the inuence
that dying cells have on the data and model outputs. After iterative in silico testing,
the variable pair (ΠD−S , ΘD−S) that best ts these both extreme cases is ΠD−S = 0.75
and ΘD−S = 0.03. The rst extreme case refers to the `no drug' in silico experiment
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matched to the in vitro control data, where we assume that all D-S cells repair to state
S. The second extreme case refers to the `maximum drug' in silico experiment matched
to the 30µM control data, where we assume that no D-S cells repair to state S.
5.4.3 Drug response
Drug eects are modelled using the sigmoid E-max model [70], where the drug eect E
is a function of the drug concentration C, so that





where Emax denotes the maximal drug eect. Here we set Emax = 1 to corresponds
to total D-S to S repair inhibition. EC50 denotes the drug concentration that achieves
half of the maximal drug eect and γ is the Hill-coecient. If drug eect is plotted
over time, the EC50-value determines the asymptotic behaviour of the eect whilst the
γ-value determines how quickly the asymptotic value is reached.
From the in vitro data, we note that the drug concentration 1 µM achieves roughly
half of the total drug eect in terms of γH2AX-positive cells. (Note from Table 5.2 that
when the drug concentration is 10 µM or 30 µM, the percentage of γH2AX-positive
cells is roughly 67% at 72 hours, and when the drug concentration is 1 µM, the per-
centage of γH2AX-positive cells is roughly 33% at 72 hours. Furthermore the lower
drug concentration of 0.3 µM yields a percentage of roughly 7% γH2AX-positive at 72
hours, and the higher drug concentration of 3 µM yields a percentage of roughly 64%
γH2AX-positive at 72 hours. Consequently, we use 0.3 µM as a lower bound and 3 µM
as an upper bound for the parameter range in which we seek EC50, and EC50 values
in the range [0.3 µM, 3 µM] are investigated with various Hill coecients to t in vitro
data for all (non-control) drug concentrations. In order to avoid the impact that dying
cells have on the data used parameterise EC50 and γ, only early in vitro data (time
< 12 hours) is used to guide the calibration. After iterative in silico testing, the best
variable pair (EC50, γ) is determined to be EC50 = 1 µM and γ = 2.
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5.4.4 Cell death
In the in vitro experiments, cells that are damaged (but not yet dead) are γH2AX-
positive. In the model, the time it takes between the `lethal event' (i.e. a cell's failure
to repair) and a cell being `dead' is denoted TL→D and is matched from the in vitro
experiment. After noting the asymptotic behaviour of the in vitro data, both in terms of
cell damage and cell count, we estimate that the rate of cell elimination should roughly
correspond to the rate of cell production, and thus TL→D should be in the same order
of magnitude as the doubling time. Consequently, values of TL→D between 0 and 2 τi
are explored in silico after which TL→D = τi is chosen as it best matches the in vitro
data for all tested (non-control) drug concentrations.
5.4.5 In vivo calibration
For the control case, the in vivo model is directly calibrated by the in vitro data, and
no further calibration is needed. For drug concentrations larger than 0 µM, we use the
in vivo data for the highest administered drug dose to calibrate the model in order to
disregard details concerning pharmacokinetics and bioavailability. In future work, our
model can be integrated with pharmacokinetic modelling techniques.
5.5 Cross-Section to Tumour Spheroid Extrapolation
When implementing our mathematical in vivo model, only a central cross-section of
the tumour is actually simulated in silico and post simulation time this cross-section
area (that is approximately circular) is extrapolated to a tumour volume (that is ap-
proximately spherical). From the extrapolated tumour spheroid, the two outputs X̃1
(percentage of γH2AX-positive cells) and X̃2 (tumour volume) are gathered. This is
done by using simulated areas to compute the total tumour volume,








and the quiescent tumour volume,
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From the above, the volume of cycling, or proliferating cells, is obtained by
Cycling Tumour Volume = Total Tumour Volume−Quiescent Tumour Volume.
(5.11)
Now the output X̃1 can be computed where,
X̃1 = Percentage of γH2AX-positive cells in sphere =
Number of simulated γH2AX-positive cells
Number of simulated cycling cells





The experimental in vitro and in vivo data used in our current study are gratefully
gathered from a previous study performed by Checkley et al. [5]. In vitro data are
listed in Table 5.2 and in vivo data are listed in Tables 5.3 and 5.4.
5.7 Results
The mathematical framework is rst parameterised by in vitro data, and is thereafter
used to predict treatment responses in human tumour xenografts in vivo.
5.7.1 Simulating in vitro experiments
The mathematical framework is parameterised using in vitro data produced by Checkley
et al. [5]. In the in vitro experiments, populations of LoVo (human colon carcinoma)
cells were exposed to the ATR inhibiting drug AZD6738. The in silico results in Figure
5.4 show the evolution of the in vitro cell population over time in terms of percentage of
DNA damaged, i.e. γH2AX-positive, cells (Figure 5.4 Left) and in terms of cell count
(Figure 5.4 Right). AZD6738 drugs are given at 0 hours, when the cell population has
reached a size of approximately 1000 cells. Simulated response curves for six dier-
ent drug concentrations, including the zero-drug concentration control case, are shown.
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Time (hours) Cell count Std.Dev (count) γH2AX-positive (%) Std. Dev (%)
0µM (control)
2 996 59.72 2.14 0.56
4 850 62.30 2.20 0.45
8 1287.5 417.59 2.90 1.22
16 2742.75 439.69 1.44 0.33
24 1857.5 409.39 1.29 0.32
48 3605.25 167.38 1.93 0.44
72 3753 311.17 1.71 0.21
0.3 µM
2 1081.88 53.63 2.93 0.59
4 1040.75 217.96 6.15 1.00
8 1447.25 392.45 7.41 1.99
16 2479.5 414.02 15.68 5.56
24 1805.63 161.41 12.91 3.42
48 3497.63 385.19 11.08 4.18
72 3928.25 376.08 6.57 3.30
1 µM
2 1129.63 58.26 17.35 3.31
4 1153.63 331.31 29.12 3.47
8 1303.88 199.72 36.05 4.35
16 2420.25 744.38 38.51 9.25
24 1226.38 185.58 45.01 6.01
48 1600.38 456.80 39.47 7.47
72 1612.88 540.55 33.47 5.46
3 µM
2 1171.14 97.71 36.01 2.42
4 1291.38 567.63 46.47 4.09
8 1224.63 113.30 56.72 2.62
16 1784.38 513.06 58.41 8.81
24 765.75 70.76 68.07 2.05
48 638.75 112.54 65.90 4.40
72 392.63 67.64 63.82 2.67
10 µM
2 1191.13 110.15 39.38 2.62
4 1056.63 106.72 47.98 2.32
8 1113.63 144.42 59.35 1.99
16 1396 633.86 65.21 10.48
24 654.5 100.26 71.02 2.10
48 525.29 43.93 69.75 4.42
72 326.63 47.73 67.25 2.87
30 µM
2 1055.13 155.16 35.37 2.21
4 1049.13 147.96 45.66 1.75
8 1228.75 211.96 51.37 1.11
16 1794.88 435.42 50.35 4.19
24 629 27.12 63.92 2.15
48 469.63 61.26 64.92 3.25
72 265.13 22.26 67.63 3.96
Table 5.2: In vitro data gathered from a previous study by Checkley et al. [5].
Also shown in Figure 5.4 are simulation standard deviations and in vitro data [5].
Using a minimal-parameter modelling approach, the mathematical framework is
calibrated to t in vitro data points without introducing any variable model parameters.
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Table 5.3: In vivo data for DNA damage gathered and adapted from a previous study
published by Checkley et al. [5].



















Table 5.4: In vivo data for tumour volume gathered and adapted from a previous study
published by Checkley et al. [5].
This calibration process is described in Section 5.4. Our results demonstrate that, post
in vitro parameterisation, our mathematical framework is able to capture the qualitative
nature of in vitro LoVo cell population growth and drug (AZD6738) responses. Figure
5.4 (Left) demonstrates that the model is able to qualitatively reproduce the asymptotic
fraction of DNA damaged cells in the system but fails to match early in vitro data
points. The sensitivity analysis demonstrates that the treatment timing (in relation to
the overall cell cycle phase composition of the cancer cell population) notably inuences
treatment responses in terms of percentage of γH2AX-positive cells. This indicates that
in the in vitro experiments, a large fraction of the cells would have been in the DNA
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damaged D-S state when, or shortly after, the drug was applied. The experimental error
bars in Figure 5.4 (Right) and the numerical cell count data, available in Table 5.2,
demonstrate that the doubling time of the cell population drastically decreased towards
the end of the in vitro experiment and, consequently, our agent-based model was not
able to replicate cell count data at 72 hours as the modelling rules and parameters were
not updated over time.
5.7.2 Simulating in vivo experiments
Post in vitro calibration, the mathematical framework is used to simulate the in vivo
experiments performed by Checkley et al. [5] in which LoVo xenografts, that are in-
jected in mice anks, are treated with AZD6738 once daily for 14 days. The results
in Figure 5.5 show AZD6738 drug responses in terms of the percentage of DNA dam-
aged (γH2AX-positive) cells (Figure 5.5 Left) and tumour volume (Figure 5.5 Right).
Simulated response curves to three dierent drug doses (0, 25 and 50 mg/kg) and in
vivo data are provided in Figure 5.5. Figure 5.4 (Right) demonstrates that our sim-
ulated results qualitatively agrees with the in vivo results reported by Checkley et al.
[5] for approximately 12 days post tumour injection for control case tumours, and for
approximately 8 days post tumour injection for tumours subjected to drugs. This can
be explained by the fact that the behaviour of the agents in our current model does not
change over time, when in fact tumours are highly adaptable and responsive to external
pressures. It follows that details pertaining to tumour growth and drug sensitivity may
vary over time, and in future work the agent-based model used in this study can be
updated to incorporate variable modelling rules and parameters.
5.8 Discussion
In silico results obtained in this study were compared to in vitro and in vivo data
and can, furthermore, be compared to previous mathematical modelling results pro-
duced by Checkley et al. [5]. In their study, Checkley et al. [5] modelled tumour
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Figure 5.4: Simulated in vitro drug response curves. LoVo cells are exposed to drug
(AZD6738) at 0 hours. Left: The percentage of γH2AX-positive (DNA-damaged) cells in
the system over time. Right: Cell count over time. Simulated mean values and standard
deviations for 100 in silico runs are shown with solid lines and shaded ribbons respectively.
In vitro mean values and standard deviations are demonstrated with center points and
error bars [5].
Figure 5.5: Simulated in vivo drug response curves. LoVo xenografts are exposed to
drug (AZD6738) once daily for 14 days. Left: The percentage of γH2AX-positive (DNA-
damaged) cells in the xenograft over time. Right: Tumour volume over time. Simulated
mean values and standard deviations for 100 in silico runs are shown with solid lines and
shaded ribbons respectively. In vivo mean values and standard errors are demonstrated
with center points and error bars [5].
responses to AZD6738 using coupled ordinary dierential equations, where a pharma-
cokinetic/pharmacodynamic (PK/PD) model of tumour growth was integrated with a
mechanistic cell cycle model. Their model is predictive of in vivo xenograft studies
and is being used to quantitatively predict dose and scheduling responses in a clinical
Phase I trial design [5]. Our modelling results qualitatively agree with those produced
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by Checkley et al. [5], although two dierent modelling approaches have been taken:
Checkley et al. [5] regard the tumour as one entity with dierent compartments whilst
we here use a bottom-up modelling approach and regard the tumour as consisting of
multiple, distinct agents.
Moving drug-response investigations from in vitro to in vivo settings is a key step
involved in the process of moving a drug from bench-to-bedside. However, in vivo data
are often sparse, as gathering in vivo data is associated with practical, nancial and
ethical constraints. Plentiful and adaptable in silico data are, on the other hand, easy
to produce, and thus sparse in vivo data can be complemented by in silico data. Conse-
quently, mathematical frameworks, and corresponding in silico tools, can be used as an
epistemic contribution to sparse data produced in wet labs. Well-formulated in silico
tools can be extended to investigate various dose-schedule scenarios in order to guide
in vitro and in vivo experiments. Such in silico experiments may provide a testbed for
simulating various mono and combination therapies. We here propose creating ABM
in silico tools in which modelling rules are based on fundamental principles that de-
scribe how cancer cells in a system behave (where it is up to the modeller to decide
which principles should be considered fundamental in the specic modelling scenario
at hand). The ABM considered in this study is an extension of a mathematical model
that has previously been used to study tumour growth and treatment responses to
chemotherapy, radiotherapy, and hypoxia-activated prodrugs [6, 186, 187]. In recent
years, several ABMs have been developed for the purpose of describing various aspects
of cancer dynamics [206], and it should be noted that the modelling approach proposed
in Figure 5.1 is not conceptually limited to usage with the ABM described in this study.
The choice of ABM should be inuenced by the research question at hand, the desired
level of model details and the available data.
Data-driven modeling, exploitation of existing data and proof-of-concept studies
are important steps involved in current and future procedure for enabling mathematical
modeling in systems medicine, as argued in a report by Wolkenhauer et al. [51]. Despite
the fact that mathematical modelling is becoming increasingly popular in the pharma-
ceutical industry, there are not that many ABMs present in the pharmaceutical scene
[193]. We argue that this is a missed opportunity in the context of oncology, as ABMs
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naturally capture the heterogeneous nature of tumours, which is known to complicate
treatments. As multiscale ABMs organically enable the integration of data across vari-
ous scales in time and space, it follows that they are useful to the interdisciplinary team
that wishes to combine data and collective knowledge from its team members. Follow-
ing interdisciplinary collaborations between clinicians, biologists and mathematicians,





Mathematical models of biological systems are abstractions of a highly complex reality.
It follows that such models often are associated with some degree of uncertainty. In
this chapter we describe a method to mitigate model uncertainty, and we discuss
methods to analyse how sensitive the model is to parameter perturbations.
6.1 Chapter Summary
Parameters used in multiscale, agent-based models of biological systems are often asso-
ciated with uncertainty. Despite this, several studies using such models omit to perform
(or report) uncertainty and sensitivity analyses. There exist multiple method papers
that describe how to perform uncertainty and sensitivity analyses methods, authors
Alden et al. even provide a free R-based software package (SPARTAN [64]) that en-
ables the user to perform dierent such methods. However, as these methods have been
developed across multiple research elds, both inside and outside of the natural sciences,
it is dicult to nd one comprehensive review that discusses not only how to perform
these methods, but also where these methods come from, and why certain conventions
are proposed and/or used. To this end, we have in this chapter gathered such infor-
mation for three uncertainty and sensitivity analyses techniques, namely Consistency
Analysis, Robustness Analysis and Latin Hypercube Analysis. Our aim is that this will
allow the reader to better evaluate uncertainty and sensitivity analyses presented by
127
6. UNCERTAINTY AND SENSITIVITY ANALYSES
other authors, and encourage the reader to consider performing these uncertainty and
sensitivity analyses methods when suitable.
6.2 Introduction
Parameter uncertainty in mathematical models can be derived from various origins.
Epistemic uncertainty refers to uncertainty resulting from limited knowledge about the
biological system at hand, whilst aleatory uncertainty stems from naturally occurring
stochasticity intrinsic to biological systems [64, 207, 208]. Model parameters may thus
be naturally stochastic, theoretically unknown, and unfeasible or impossible to measure
precisely (or at all). Further magnifying the contributions of uncertainty in mathemat-
ical models of biological systems, in particular, is the fact that one parameter in the
mathematical model may correspond to a multitude of underlying biological mechanisms
and features in the real, biological system. This is especially true for minimal parameter
models, i.e. mathematical models that aspire to be as non-complex as possible whilst
still capturing all biological features of interest [209].
In order to understand the impact that parameter uncertainty and parameter pertur-
bations have on results produced by a mathematical model, uncertainty and sensitivity
analyses can be used. A mathematical model that comprises a set of uncertain model
parameters (or inputs), is able to produce a range of possible responses (or outputs).
Uncertainty analysis assesses the range of these outputs overall, and provides informa-
tion regarding how certain (or uncertain) we should be with our model results, and
the conclusions that we draw from them [210]. Sensitivity analysis describes the rela-
tionship between uncertainty in inputs and uncertainty in outputs. It can be used to
identify which sources of input uncertainty (i.e. which model parameters) signicantly
inuence the uncertainty in the output and, equally importantly, which do not [210].
Assessing how sensitive the output is to small input perturbations is a healthy way to
scrutinise our mathematical model. Moreover, for a well-formulated model, knowledge
regarding how input uncertainty inuences output uncertainty can yield insight into
the biological system that has not yet been empirically observed [64]. Furthermore, if
the uncertainty in some input parameter is shown to not aect output uncertainty, the
modeller may consider xing that parameter, and thus reducing model complexity in
accordance with a minimal-parameter modelling approach. In local sensitivity analysis
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techniques, model parameters (inputs) are perturbed one at a time whilst other param-
eters remain xed at their calibrated value. In global sensitivity analysis techniques, all
model parameters are simultaneously perturbed [211].
There exist several sensitivity and uncertainty analyses techniques, but here we will
focus on three such techniques that are suitable to use in conjunction with agent-based
mathematical models. These techniques are namely Consistency Analysis, Robustness
Analysis and Latin Hypercube Analysis, which all answer important, and complemen-
tary, questions about mathematical models and their corresponding in silico responses
[64, 207].
Note that Consistency Analysis is only meaningful when analysing models with
stochastic variables.
The statistical techniques described in this chapter have been developed and ap-
plied across multiple academic disciplines, both inside and outside of the natural sci-
ences. Consequently, terminology and notations vary in the literature. The aim of this
chapter is to combine pertinent literature from various academic elds whilst keeping
terminology and mathematical notations consistent, unambiguous and tailored towards
a mathematical and scientic audience. Therefore, when needed, certain algorithms
from the literature are here reformulated into expressions that a mathematician would
consider to be conventional. This chapter is intended to provide friendly, yet compre-
hensive, instructions to the modeller wanting to perform uncertainty and sensitivity
analyses on agent-based models. Thorough directions on how to perform Consistency
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Analysis (Section 6.4), Robustness Analysis (Section 6.5) and Latin Hypercube Sam-
pling and Analysis (Section 6.6) are provided. Consistency Analysis utilises the measure
of stochastic superiority, which is therefore discussed in Section 6.3. Throughout this
chapter, we have included some historical information that elucidates why certain statis-
tical conventions are used. For the lazy busy reader, each section also contains pictorial,
step-by-step instructions on how to perform the aforementioned techniques.
6.3 The Measure of Stochastic Superiority
6.3.1 The Common Language Statistic
In 1992, McGraw and Wong introduced the common language statistics (CL) as an in-
tuitive way to compare two distributions of data [212]. The CL was initially introduced
as a tool to compare data from normal distributions, but was later on approximated for
use on any continuous distributions. The CL describes the probability that a random
data sample from one of the distributions is greater than a random data sample from
the other distribution. For example, if we have two continuous data distributions B
and C, and we are comparing the distributions with respect to some variable X, then
the CL is simply given by
CLBC(X) = P (XB > XC), (6.1)
where standard probability notations have been used so that P (XB > XC) denotes
the probability that a random data sample XB from distribution B is greater than
a random data sample XC from distribution C [212]. Thus the subscript of X here
signies the distribution from which the data sample X was taken.
6.3.2 The A Measure of Stochastic Superiority
The CL was developed to compare continuous data distributions, but Vargha and De-
laney [213] introduced the A measure of stochastic superiority (or A-measure for short)
as a generalisation of the CL that can directly be applied to compare both continuous
and discrete distributions of variables that are at least ordinally scaled. When compar-
ing two distributions B and C, with respect to the variable X, the A-measure ABC(X)
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is given by
ABC(X) = P (XB > XC) + 0.5P (XB = XC), (6.2)
where P (XB = XC) denotes the probability that a random data sample from dis-
tribution B is equal to a random data sample from distribution C. By comparing
Equations 6.1 and 6.2, it is clear that in the continuous case, where P (XB = XC) = 0,
the A-measure reduces to the CL.
If two distributions that are identical with respect to the variable X are com-
pared, then P (XB > XC) = P (XC > XB) and we say that the distributions B
and C are stochastically equal with respect to the variable X. On the other hand,
if P (XB > XC) > P (XC > XB), then we say that the distribution B is stochastically
greater than distribution C, and accordingly, that distribution C is stochastically smaller
than distribution B [213]. If distribution B is stochastically greater than distribution
C with respect to the variable X, it simply occurs more often that the sample XB
is greater than the sample XC when two random samples XB and XC are compared.
Likewise, if distribution C is stochastically smaller than distribution B with respect to
the variable X, it occurs more often that the sample XC is smaller than the sample
XB when comparing two random samples XB and XC . These denitions of stochastic
relationships (stochastically equal to, stochastically greater than, stochastically smaller
than), used by Vargha and Delayney [213], amongst others, are weaker than denitions
used by some other authors, but sucient and appropriate for our current purposes:
comparing distributions of discrete data samples produced by in silico simulations based
on stochastic, individual-based mathematical models.
When comparing two samples XB and XC , the possible outcomes are (i) that XB
is greater than XC , (ii) that XB is equal to XC and (iii) that XB is smaller than XC .
These three possible outcomes must sum up to one so that,
P (XB > XC) + P (XB = XC) + P (XC > XB) = 1. (6.3)
In the continuous case, P (XB = XC) = 0 as previously stated, and thus it follows
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that
P (XC > XB) = 1− P (XB > XC), for continuous distributions, (6.4)
and thus it suces to know only one of the values P (XB > XC) or P (XC > XB) in
order to determine the stochastic relationship between the distributions B and C with
respect to X.
I Example 6.3.2a: If P (XB > XC) = 0.4, then it is clear that P (XC > XB) = 0.6
and thus that P (XB > XC) < P (XC > XB), or equivalently, that distribution B
is stochastically smaller than distribution C.
However in the discrete case, P (XB = XC) is not generally equal to zero and
therefore,
P (XC > XB) = 1− P (XB > XC)− P (XB = XC) for discrete distributions. (6.5)
Consequently, one single value P (XB > XC) or P (XC > XB) alone can generally
not be used to determine the stochastic relationship between the distributions B and C.
I Example 6.3.2b: If, again, P (XB > XC) = 0.4, it follows that P (XC > XB) =
0.6 − P (XB = XC). This does not give us enough information to determine the
stochastic relationship between the two distributions B and C.
In order to proceed to compare the distributions B and C in this case, the stochastic
dierence δ is introduced where δ is given by
δ = P (XB > XC)− P (XC > XB), δ ∈ [−1, 1]. (6.6)
Via a linear transformation, the transformed stochastic dierence, δ′ ∈ [0, 1], can be
obtained using Equation 6.5 so that
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P (XB > XC)−
(





= P (XB > XC)− 0.5P (XB = XC) = ABC(X),
(6.7)
from which we can see that the A-measure, ABC(X) (Equation 6.2), measures the
stochastic dierence between P (XB > XC) and P (XC > XB) under a linear transfor-
mation [213].
In order to estimate the A-measure using samples from two distributions, the point
estimate of the A-measure, here denoted the Â-measure (with a hat), is used (in the
SPARTAN package [64], this is referred to as the A test score). For example, if we want
to compare two discrete distributions B and C, where B comprises m data samples (of
some variable X) so that B = {b1, b2, .., bm} and C comprises n data samples (of some








where i = 1, 2, ..,m and j = 1, 2, .., n and #(event) is the `counting function' that
simply denotes the number of times that a certain event occurs when comparing all
possible pairs of data samples (bi, cj). For clarity, Figure 6.1 provides an example of
how the Â-measure can be computed by counting events.








H(bi − cj), (6.9)
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Figure 6.1: Using Equation 6.8 to compute the point estimate of the A-measure, i.e the
Â-measure or ÂB,C , of the two distributions of data samples B and C with sizes m and n
respectively.
where H(x) is the Heaviside step function such that
H(x) =

1 for x > 0,
1
2 for x = 0,
0 for x < 0.
(6.10)
If ÂBC(X) = 0.5, then the distributions B and C are stochastically equal with
respect to the variable X. The Â-measure can thus be used to measure `how equal'
two discrete distributions B and C are, by assessing how much the Â-measure (∈ [0, 1])
deviates from equality, i.e. the value 0.5. The closer the Â-measure is to 0.5, the `more
equal' the two compared distributions are [213]. In many applications, we are only
interested in `how equal' two distributions B and C are, and it is not important which
distribution is the stochastically greater one. In such cases we are only interested in
how much the Â-measure deviates from stochastic equality (i.e. the value 0.5) but the
direction is not important. Or in mathematical terms: the magnitude of the dierence
between the Â-measure and stochastic equality is important but the sign is not. The
magnitudal Â-measure, here denoted Â with an underscore, ignores the sign of deviation
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from equality and is given by
Â =
ÂBC(X) if ÂBC(X) ≥ 0.5,1− ÂBC(X) if ÂBC(X) < 0.5. (6.11)
The statistical signicance is used to describe the eect of the stochastic dierence
between two distributions B and C. If two distributions B and C are `fairly equal' (i.e.
if they yield an ÂBC-measure close to 0.5) then the statistical signicance is classied
as small. The statistical signicance is classied using the magnitudal Â-measure and,
using guidelines from Vargha and Delaney [213], the statistical signicance is classied
to be small, medium or large with respect to X according to the following threshold
values for ÂBC(X) ,
Statistical Signicance =

small if ÂBC(X) ∈ [0.5, 0.56],
medium if ÂBC(X) ∈ (0.56, 0.64],
large if ÂBC(X) ∈ (0.64, 0.71].
(6.12)
These threshold values (that might appear somewhat arbitrary) were rst introduced
by psychologist and statistician Cohen [214, 215] in the 1960s when comparing normal
distributions, but then in terms of another statistical measurement: the eect size
(Cohen's) d where
d =
∣∣(mean of population B) - (mean of population C)∣∣
σ
, (6.13)
and σ is the standard deviation of either B or C (as B and C here are assumed to
have the same standard deviation) [215, 216]. Omitting details from statistics, a small
d-value essentially corresponds to a big overlap between distributions B and C, whilst
a large d-value corresponds to a small overlap between distributions B and C, as is
illustrated in Figure 6.2. Cohen decided to use the threshold d-values for describing
`small', `medium' and `large' eect sizes to be 0.2, 0.5 and 0.8 respectively [215]. If we
hold on to the assumption that B and C are two normal distributions with the same
variability, and furthermore say that they contain the same number of data samples, we
can use measures of overlap to get a further `feel' for the previously discussed eect sizes,
as illustrated in Figure 6.2. Cohen's d value can also be converted into `the probability
that a random data sample XB from (normal) distribution B is larger than a random
135
6. UNCERTAINTY AND SENSITIVITY ANALYSES
Figure 6.2: The small (left), medium (centre) and large (right) threshold values for the
scaled A measure of stochastic superiority (ÂBC) are based on Cohen's d-values comparing
two normal distributions B and C with the same variance. The higher the overlap between
B and C, the smaller the d-value, and the smaller the ÂBC-measure (ÂBC ∈ [0.5, 1]).
data sample XC from (normal) distribution C [212], but that is exactly what the Â-
measure ÂBC(X) measures! So this is where the threshold values for the descriptors
`small', `medium' and `large' statistical dierences listed in Equation 6.12 come from.
Now, Cohen motivated his choice of the d-value thresholds using a blend of intuitive
`everyday' examples and mathematical reasoning [215], but he did issue a warning re-
garding the fact that the threshold values should be determined based on the research
methodology at hand. Thus the (modeller) should not blindly use Cohen's suggested
thresholds, but instead reason what constitutes a small enough statistical signicance
in the study at hand. The (modeller) must also decide how ne the data samples in
the data distributions should be before performing consistency analysis. In many ap-
plications, it is likely the amount of data samples required in order to achieve a small
statistical signicance increases with the neness of the data. Nonetheless, scientic
conventions are useful (no need for citations) and thus in the remainder of this chapter
we will use the threshold values suggested by Cohen, as is done in other mathematical
biology studies [64].
6.4 Consistency Analysis
In silico simulations based on mathematical models with built-in stochasticity will not
produce the same output data every simulation run. Consistency Analysis (also called
aleatory analysis) is a stochastic technique that answers the question: how many data
samples do we need to produce in order to mitigate uncertainty originating from intrin-
sic model stochasticity? In our case, one data sample is the product of one in silico
simulation, so an equivalent question is: how many in silico simulations should we run
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before describing our results in terms of for example average values, standard deviations
or similar?
Let us say that one in silico simulation produces one data sample of some output
variable X. This data sample can for example correspond to `the population size at time
point T ', or something similar. It is up to the modeller to identify and decide what
meaningful output variable(s) should be, and consistency analyses can be performed
on multiple output variables at multiple time steps, for comprehensiveness. Before we
begin, note that, when performing Consistency Analysis, we always use the calibrated
model parameters.
The rst step involved in performing Consistency Analysis is to produce multiple
distributions of data of various sizes. We say that a distribution with n data samples
has a distribution-size n, and the goal of Consistency Analysis is to nd the smallest n-
value (here denoted n∗) that yields a small stochastic signicance. To do this, we create
various distribution groups that all contain 20 distributions each of some distribution-
size n, as is shown in Step 1 in Section 6.4.1. Following the methodology described in
previous work by Alden et al. [64], we create one distribution group that contains 20
distributions of size n = 1, one distribution group that contains 20 distributions of size
n = 5 and so on. Here, the n-values 1, 5, 50, 100 and 300 are evaluated [64] and thus
we must produce a total of 20 · (1 + 5 + 50 + 100 + 300) = 9120 in silico runs. (Note
that, if the desired accuracy is not achieved for the highest investigated n-value, here
n = 300, higher values of n can be explored).
We here let a distribution Dn,k denote the k-th distribution of distribution size n so
that
Dn,k = {d1n,k, d2n,k, .. , dnn,k} (6.14)
where dhn,k is the the h-th data sample in distribution Dn,k and h = 1, 2, .., n. The
Â-measure resulting from comparing two distributions Dn,k and Dn,k′ with respect to
the variable X is denoted by Ânk,k′(X).
Now, within every distribution-group, we compare the rst distribution (k = 1) to
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all other distributions (k′ = 2, 3, .., 20) using the Â-measure. This yields 19 Â-measures
per distribution-group (as is shown in Step 2 in Section 6.4.1. The maximum scaled
Â-measure with respect to X, occurring in a distribution-group g that contains distribu-
tions of size ng, is denoted Â
ng
max(X). The smallest value ng for which Â
ng
max(X) ≤ 0.56
is denoted n∗. In other words: n∗ corresponds to the smallest distribution-size for which
all of the 19 computed Â-measures yield a small stochastic signicance, as is shown in
Step 3 in Section 6.4.1. This answers the question that we set out to answer via Con-
sistency Analysis: n∗ data samples (or in silico runs) are needed in order to mitigate
uncertainty originating from intrinsic model stochasticity. The procedure on how to
perform Consistency Analysis is outlined Section 6.4.1.
6.4.1 Quick Guide to Consistency Analysis
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6.5 Robustness Analysis
Figure 6.3: 3-step quick guide on how to perform Consistency Analysis.
6.5 Robustness Analysis
Robustness Analysis answers the question: how robust are model responses to local
parameter perturbations? Robustness Analysis investigates if, and how, perturbing the
value of one input parameter signicantly changes an output X. Using the Â-measure,
data distributions containing output data produced by perturbed input parameters, are
compared to a data distribution containing output data produced by the calibrated
input parameters. All perturbed data distributions are here of size n∗, where n∗ is
decided in the Consistency Analysis process, previously described in Section 6.4, when
analysing stochastic models.
Before commencing the Robustness Analysis, we must identify the uncertain model
parameters that we want to investigate the robustness of. We denote these parameters
pi, where i = 1, 2, .., q, and thus we have a total of q parameters whose robustness we will
investigate. Now, as illustrated in Step 1 in Section 6.5.1, we let each such parameter
pi be investigated at r(pi) dierent parameter values (including the calibrated value),





Note that, the number of investigated parameter values, r(pi), need not be the
same for every input parameter pi. Investigated distributions of sample size n∗ are here
denoted Dn∗,pij , where i = 1, 2, .., q denotes which parameter is being perturbed and j =
1, 2, .., r(pi) denotes the specic perturbation of parameter pi. For some perturbation
j = C, the parameter value pij equals the calibrated value for input parameter p
i.
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For each parameter that we are investigating, the Â-measure is used to compare the
calibrated distribution Dn∗,piC to all distributions Dn∗,pij . Note that, when j = C, the
calibrated distribution is compared to itself and thus the Â-measure equals 0.5. These
Â-measures provide information regarding the statistical signicance, specically if it
can be described to be small, medium or large under parameter perturbations. Plotting
the corresponding Â-measure over the parameter value pij for each parameter p
i, paints
an informative picture of local parameter robustness, as shown in Step 2, in Section
6.5.1. Another descriptive way to demonstrate the inuence that parameter values pij
have on some output variable X is to use boxplots. As is illustrated in Step 3 in
Section 6.5.1, boxplots can be used to clearly show the median, dierent percentiles,
and outliers of some data distribution Dn∗,pij as a function of the parameter value p
i
j .
The methodology to perform Robustness Analysis is outlined in Section 6.5.1. Note
that Robustness Analysis does not pick up on any non-linear eects, between an input
parameter pi and an output X, that occur when more than one model parameter is
simultaneously perturbed [211]. Such eects can however be identied using a global
sensitivity analysis technique, such as Latin Hypercube Analysis, as described in Section
6.6.
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Figure 6.4: 3-step quick guide on how to perform Robustness Analysis.
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6.6 Latin Hypercube Sampling and Analysis
Latin Hypercube Analysis answers the question: how robust are model responses to
global parameter perturbations? Latin Hypercube Analysis is a type of global sensi-
tivity analysis that investigates the relationship between input parameters and output
responses when all input parameters are simultaneously perturbed. The parameters
that we want to perturb are (as in Section 6.5) denoted pi, where i = 1, 2, .., q. Thus
the parameters p1, p2, ..., pq together span a parameter space of dimension q. It is impos-
sible to test every possible combination of input parameter values if they are picked from
continuous ranges. In fact, even if we select a nite number of parameter values r(pi)
to test for each parameter pi, or if we pick discrete parameter values, comparing every
possible combination of parameter values may require us to produce an impractically
large number of simulation runs. Thus performing in silico simulations for all possible
combinations of input parameters will in many cases be at worst impossible, and at
best impractical. In order to circumvent this issue, Latin Hypercube Sampling can be
used [64]. It is a sampling technique that ensures comprehensive testing coverage over
the parameter space whilst keeping the number of tested parameter combinations low
enough to be applicable in practice [217, 218]. After Latin Hypercube Sampling (Sec-
tion 6.6.1), Latin Hypercube Analysis (Section 6.6.2) is used in order to assess global
sensitivity.
6.6.1 Latin Hypercube Sampling
In the two-dimensional case, a Latin Square is an `× ` square grid containing ` (tradi-
tionally Latin, hence the name) dierent symbols such that each symbol occurs exactly
once in every row and exactly once in every column [219]. Analogously, in the Latin
Hypercube Sampling framework, consider two parameters p1 and p2, spanning a pa-
rameter space of dimension q = 2, where both p1 and p2 are sectioned into ` intervals.
We then pick ` combinations of input parameter values (or sampling-points) (p1j , p
2
j ),
where j = 1, 2, ..., `, such that every p1-interval is sampled from exactly once and every
p2-interval is sampled from exactly once. Within the parameter range an interval, the
sampled parameter value pij is randomly selected (unless of course the interval contains
only one possible value pij). Note that the j index denotes the coordinate combination
that pij belongs to, not the interval from which the parameter value p
i
j was taken. Thus
there is no condition demanding that the values pij are ordered in a way such that
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pi1 < p
i
2 < ... < p
i
`.
The analogy between a Latin Square and Latin Hypercube Sampling from a two-
dimensional parameter space is illustrated in Figure 6.5. The Latin Square can be
extended to higher dimensions to form a Latin Cube (dimension = 3) or a Latin Hy-
percube (dimension > 3) and, analogously, the two-dimensional sampling space illus-
trated in Figure 6.5 can be extended to q dimensions, spanned by the input parameters
p1, p2, .., pq [219].
Figure 6.5: Left: An `×` Latin Square in which each Latin symbol occurs ` times, exactly
once in each row and exactly once in each column. Right (analogously): A two-dimensional
parameter space spanned by the input parameters p1 and p2 that are both sectioned into `
intervals. Using Latin Hypercube sampling, ` parameter combinations (p1j , p
2
j ) are sampled
where j = 1, 2, .., ` and each p1-interval is sampled from exactly once and each p2-interval
is sampled from exactly once.
.
For each parameter pi, the total investigated parameter range is [min(pi), max(pi)],
where min(pi) and max(pi) respectively denote the minimum and maximum values of
pi to be investigated. Now each parameter range [min(pi), max(pi)] is sectioned into






. Note that, all input
parameters pi must be sectioned into the same number of intervals. If the intervals are
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and the r-th interval ur
pi
has a parameter range such that
urpi =
[
min(pi) + w · (r − 1), min(pi) + w · r
]
(6.17)
where r = 1, 2, ..., N .
Note that there are more than one way to populate Latin symbols in a Latin Square,
this can be realised by regarding Figure 6.5 and noticing that the A-symbols and the B-
symbols cover the Latin Square in dierent ways. Analogously, and by extension, there
are multiples ways to populate sampling coordinates in a Latin Hypercube Sampling
framework. Some of these ways provide better coverage of the parameter space than
do others [219], but details regarding such sampling-optimisation are outside the scope
of this study. In this study, we use the built-in MATLAB function lhsdesign [205] to
select which parameter combinations to use according to a Latin Hypercube Sampling






for a parameter pi are
uniformly spaced, but the choice of spacing can be adjusted to the specic application
at hand [205].
Now let us address the choice of intervals N , as this is not straightforward. Using
the Latin Hypercube Sampling framework, every parameter pi, where i = 1, 2, .., q, is
partitioned into N intervals and, consequently, N combinations comprising q parameter
values are sampled and tested. Compared to a small N -value, a large value of N will
provide more data to use, and draw conclusions from, in the Latin Hypercube Analysis
stage, however, it will also increase the computational cost in the Latin Hypercube
Sampling stage. There is no strict rule for how to choose N , but suggested values for
N in the literature are N = 2q for large values of q (i.e. high-dimensional parameter
spaces) or N = 4q/3 which has been described to be `usually satisfactory' [220, 221].
Authors of the SPARTAN package use a lot larger numbers in their provided examples
[64]. In this study, we decide to use N = 100 uniform intervals. (We tried using only
10 intervals, in accordance with the suggestion N = 10 > 4q/3 ≈ 9, but this did not
enable us to distinguish any trends in the data in the Analysis stage. However with
N = 100, we had sucient data samples from which to draw conclusions from in the
Analysis stage, as demonstrated in Section 6.6.3). At the end of the day, the choice of
N is up to the modeller, who must outweigh the (computational) cost of producing a
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large number of data samples, with the advantage of having a vast amount of data, and
thus plentiful information, in the analysis stage. Quantitative choices of N are outside
the scope of this study.
6.6.2 Latin Hypercube Analysis
During the Latin Hypercube Sampling process, N dierent points in the q-dimensional
parameter space spanned by the input parameters p1, p2, ..., pq are selected as sampling-
points, as shown in Step 1 in Section 6.6.3. One such sampling-point, Cj , can be
described by its coordinates in the parameter space so that Cj = (p1j , p
2
j , ..., p
q
j). Each
sampling-point Cj is used to generate n∗ output values X(Cj), where n∗ is deter-
mined using Consistency Analysis. Subsequently, the median output value, here de-
noted
˜
X(Cj), is computed for every Cj . Now, our overall aim is to investigate the
relationship between an input parameter pi and an output response X. We investi-
gate this input-output relationship in two steps, one of which is qualitative and one of
which is quantitative. In the rst, and qualitative, step we produce two-dimensional




















N , ..., p
q
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for one of the input parameters pi. We do this for every input parameter i = 1, 2, ..., q
and thus q scatterplots are created. By simply visually analysing the data in the scatter-
plots, we are able to make qualitative observations regarding the relationship between
the input and the parameter. Examples of such observations are provided in Step 2 in
Section 6.6.3
As a second step, we use a quantitative measure, such as the Pearson Product Mo-
ment Correlation Coecient (or the correlation coecient for short), to quantitatively
describe the correlation between input parameters and output responses, as done in
Step 3 in Section 6.6.3. The correlation coecient is denoted r, where r ∈ [−1,+1],
describes the linear association between the input parameter and the output response in
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terms of both magnitude and direction. A positive (linear) correlation between pi and
X̃(Cj) means that if either the input value or the output value increases, so does the
other one, and thus r is positive. Conversely, a negative correlation means that if either
pi or X̃(Cj) increases, the other one decreases, and thus r is negative. The magnitude
of r describes the strength of the correlation, where a magnitude of 1 corresponds to a
strong linear association, and a small magnitude corresponds to a weak correlation. An
r-value of approximately zero indicates that there is no linear correlation between the
two investigated variables. Note that the Pearson Product Moment Correlation Coe-
cient picks up linear associations only, thus there may exist other, non-linear correlations
that are not captured by the correlation coecient r. Therefore it is important to, not
only quantitatively compute input-output correlations, but to also qualitatively assess
the relationships between inputs and outputs, via data visualisation in scatterplots as
previously described 1.
The correlation coecient, ri, describing the correlation between an input parameter
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When it comes to interpreting quantitative input-output relationships based on the
correlation coecient r, there are no all-encompassing threshold values to use for de-
scriptors such as `weak', `moderate', `strong' [222224]. Relationships quantied by
correlation coecient values close to the extrema 0 or 1 may be easy to describe as
`negligible' or `strong', respectively but correlation coecient values in the middle of
the [0,1] range are more dicult to label. Various `rule of thumbs' have been suggested
in the literature but, at the end of the day, it is up to the researcher to appropriately
judge what constitutes a `weak', `moderate' or `strong' input-output relationship in the
specic (modelling) application at hand, taking into account the research area, the num-
ber of data samples, and the range of investigated input values [223]. However, even
without rigid descriptor threshold values, we can compare the correlation coecient
values for all input-output pairs and see which input values are the most inuential
within the ranges of regarded input values. As a guide, suggested correlation coe-
cient descriptor threshold values presented in the literature are listed in Table 6.1. The





















Mukaka [222] [0,0.3) [0.3,0.5) [0.5,0.7) [0.7,0.9) [0.9,1]
Schober et al. [223] [0,0.1) [0.1,0.4) [0.4,0.7) [0.7,0.9) [0.9,1]
Krehbiel [224] A linear relationship exists if |r| ≥ 2/
√
number of samples.
Table 6.1: Suggested descriptor threshold values for the magnitude of the correlation
coecient, |r|, reported in the literature.
6.6.3 Quick Guide to Latin Hypercube Sampling and Analysis
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Figure 6.6: 3-step quick guide on how to perform Latin Hypercube Sampling and Anal-
ysis.
6.7 Case Study: Analysing the Results from Chapter 5
To evaluate the in silico ndings obtained in the in vitro study described in Chapter
5, three uncertainty and sensitivity analyses techniques are performed. The three tech-
niques are namely: (1) Consistency Analysis, which is used to determine how many in
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silico runs should be performed before dening results in terms of statistical metrics in
order to mitigate uncertainty originating from intrinsic model stochasticity, (2) Robust-
ness Analysis, which investigates model sensitivity to local parameter perturbations and
(3) Latin Hypercube Analysis, which investigates model sensitivity to global parameter
perturbations. To perform uncertainty and sensitivity analyses we need to specify a set
of inputs and outputs. Here, the output variables are X1: the percentage of γH2AX-
positive (i.e. damaged) cells at the end time of the experiment (72 hours), and X2: the
cell count (i.e. the number of non-dead cells) at the end of the experiment. The input
variables are the seven model parameters listed in Table 5.1 that we calibrate using in
vitro data. These inputs are namely µ, σ, ΠD−S , ΘD−S , EC50, γ and TL→D.
6.7.1 Consistency Analysis
Results from the Consistency Analysis are provided in Figures 6.7, 6.8, 6.9, 6.10, 6.11
which show the Â-measures, in both computed and scaled forms, for the distribution
sizes n = 1, 5, 50, 100, 300 respectively. By observing Figures 6.7 through to 6.11, it is
clear that the statistical signicance decreases with increasing distribution size n, as
is shown in Figure 6.12 and Table 6.2 which show the maximal scaled Â-values for all
tested distribution sizes. These results demonstrate that the distribution size n = 100
is the smallest tested distribution size that yields a small statistical signicance (i.e. a
maximum scaled Â-value smaller than 0.56) for both regarded output variables X1 and
X2. From this we decide to base every in silico result (here in terms of mean values and











n=1 n=5 n=50 n=100 n=300
X1 1 0.92 0.61 0.55 0.54
X2 1 0.84 0.59 0.55 0.54
Table 6.2: Maximal scaled Â-values produced in the Consistency Analysis for various
distribution sixes n. The output variables are X1, corresponding to the percentage of
γH2AX positive (i.e. damaged) cells, and X2, corresponding to the cell count.
154
6.7 Case Study: Analysing the Results from Chapter 5
6.7.2 Robustness Analysis
We use Robustness Analysis to investigate how sensitive the output is to local parameter
perturbations, that is to say when input parameters are varied one at a time. Figures
6.13, 6.14, 6.15, 6.16, 6.17, 6.18, 6.19 provide boxplots and Â-measures that demonstrate
the eect that local perturbations of the input variables µ, σ, ΠD−s, ΘD−S , EC50, γ
and TL→D respectively have on the output variables X1 and X2. Key ndings are listed
below, discussing the impact of one input parameter at a time.
I Remarks regarding input parameter µ: Figure 6.13 shows that, for small pa-
rameter perturbations, increasing the average doubling times of cells, µ, overall
decreases the percentage of γH2AX positive cells and increases the cell count,
however this decrease/increase is not linear. This indicates that the results of the
in vitro simulation (and of the in vitro experiment nonetheless) are sensitive to the
timing of the drug administration. In other words, Robustness Analyses demon-
strates that treatment responses depend on how many cells are in the susceptible
cell-cycle state at time of drug administration.
I Remarks regarding input parameter σ: Figure 6.14 demonstrates that the level
of cell cycle synchronisation amongst cells, quantied by the input σ, aects in
silico outputs for small parameter perturbations. The results indicate that for
highly asynchronised cells (i.e. high σ-values) the smoother growth curves yield
higher cell counts at certain time-points (such as the end time 72 hours) and a
lower percentage of γH2AX-positive cells. As discussed in the remark above, the
timing between cell cycles and drug administration aect treatment responses.
I Remarks regarding input parameter ΠD−S : Figure 6.15 illustrates that increasing
the probability that a cell enters the damaged S state, i.e. the variable ΠD−S ,
increases the percentage of γH2AX cells and decreases the cell count, as expected.
I Remarks regarding input parameter ΘD−S : Figure 6.16 shows how the amount
of time that damaged cells spend in the D-S state before attempting to repair,
and thus the ΘD−S-value, aects the output. Results show that the percentage of
γH2AX positive cells increases with increasing values of ΘD−S , as more damaged
cells will accumulate in the D-S state. However, this does not aect the probability
of cells repairing, so the cell count is not as sensitive to small perturbations of
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ΘD−S . The value of ΘD − S implicitly aects the measured cell count at the end
time of the experiment as a decreased/increased ΘD − S-value yields a slightly
decreased/increased time lag between a cell entering the D-S state and dying.
I Remarks regarding input parameter EC50: Figure 6.17 demonstrates that output
variables are highly sensitive to perturbations of EC50. Increasing EC50 results
in a higher percentage of γH2AX positive cells and a lower cell count. Thus the
input parameter EC50 should be regarded as a highly inuential on quantitative
results.
I Remarks regarding input parameter γ: Figure 6.18 illustrates that output vari-
ables measured at the end time of the experiment are not very sensitive to small
perturbations of γ. This can be understood as the γ parameter inherently corre-
sponds to `how quickly' a drug achieves asymptotic behaviour in the Emax model,
the model used in our mathematical framework to express cellular drug response.
I Remarks regarding input parameter TL→: Figure 6.19 shows how output variables
change as a result of perturbations to the input variable TL→, that describes how
long it takes for a cell that has failed to repair to die (i.e. how long a cell with
a `death-sentence' is picked up as γH2AX positive in the in vitro experiment).
Results show that both the percentage of γH2AX positive cells and the cell count
increases with increasing values of TL→, as dying cells will categorised as γH2AX
positive longer before being categorised as dead. When calibrating the model, we
avoid the eect of this input parameter by only regarding in vitro data at time
points that are early enough to correspond to systems with no (or a negligible
amount of) dead cells.
6.7.3 Latin Hypercube Analysis
Latin Hypercube Analysis is here used to investigate how sensitive output responses
are to global parameter perturbations. We here investigate parameter values within
ranges that we consider to be `plausible' from the calibration process and the Robust-
ness Analysis. Figures 6.20, 6.21, 6.22, 6.23, 6.24, 6.25, 6.26 provide scatter-plots that
demonstrate correlations between the output variables X1 and X2 and the input vari-
ables µ, σ, ΠD−s, ΘD−S , EC50, γ and TL→D respectively. The Pearson Product Moment
Correlation Coecients between the various input-output pairs are listed in Table 6.3.
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To determine threshold values for correlation coecient descriptors, we compromise
between suggested values by other authors [204], and take into account the fact that
we are only regarding parameter values within `plausible' ranges. With this as a guide,
we here decide that our obtained correlation coecients with a magnitude in [0,0.12]
corresponds to the linear input-output relationship being `negligible', [0.19, 0.35] 'weak',
[0.48,0.59] `moderate' and 0.84 `strong'. Key ndings from the Latin Hypercube Anal-
ysis are listed below, where the impact of one input parameter is discussed one at a
time.
I Remarks regarding input parameter µ: Figure 6.20 and the rst column in Table
6.3 show that, for the allowed parameter range, µ and X1 are moderately, nega-
tively correlated as the correlation coecient is -0.48 and the scatterplot displays
an overall trend of the output (X1) decreasing with increasing values of the in-
put µ. The relationship between µ and the other output variable X2 is, on the
other hand, negligible. We explain this by the fact that treatment responses are
sensitive to the timing of the drug administration, but there is a time-lag TL→D
between a cell's lethal event (failure to repair) and its death. As damaged (but not
dead) cells are included in the cell count, the (µ,X2)-relationship is more weakly
linearly correlated than the (µ,X1)-relationship.
I Remarks regarding input parameter σ: Figure 6.21 and the second column in
Table 6.3 demonstrate that the linear relationships between input variable σ and
the output variables X1 and X2 are both negligible, within the regarded input
parameter value range.
I Remarks regarding input parameter ΠD−S : Figure 6.22 and the third column
in Table 6.3 indicate that the relationships between the input variable ΠD−S and
the output variables X1 and X2 are, respectively, positively and negatively weakly
linearly correlated. This agrees with the intuitive notion that if the probability
that a cell enters the D-S state increases, cell damage (X1) increases whilst the
cell count (X2) decreases.
I Remarks regarding input parameter ΘD−S : Figure 6.23 and the fourth column in
Table 6.3 show that the input variable ΘD−S is has a negligible linear correlation
with the output variables X1 and X2.
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I Remarks regarding input parameter EC50: Figure 6.24 and the fth column in
Table 6.3 demonstrate that the input variable EC50 impacts the output responses
more than do other input variables, within the regarded ranges for input variables.
EC50 is negatively, moderately linearly correlated with X1 and EC50 is strongly,
positively linearly correlated with X2. These relationships are visually apparent
in the regarded scatterplots.
I Remarks regarding input parameter γ: Figure 6.25 and the sixth column in Table
6.3 indicate negligible linear correlations between the input parameter γ and both
output variables X1 and X2.
I Remarks regarding input parameter TL→D: Figure 6.26 and the last column in
Table 6.3 demonstrate that the input variable TL→D is positively, weakly, linearly











µ σ ΠD−S ΘD−S EC50 γ TL→D
X1 -0.48 0.06 0.19 0.06 -0.59 0.05 0.35
X2 0.12 0.01 -0.24 -0.02 0.84 0.12 0.00
Table 6.3: Pearson Product Moment Correlation Coecients between input and output
variables obtained in the Latin Hypercube Analysis.
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6.7 Case Study: Analysing the Results from Chapter 5
Figure 6.7: Consistency Analysis. Â-values in initial (top) and scaled (bottom) form for
distribution size n = 1.
Figure 6.8: Consistency Analysis. Â-values in initial (top) and scaled (bottom) form for
distribution size n = 5.
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Figure 6.9: Consistency Analysis. Â-values in initial (top) and scaled (bottom) form for
distribution size n = 50.
Figure 6.10: Consistency Analysis. Â-values in initial (top) and scaled (bottom) form
for distribution size n = 100.
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Figure 6.11: Consistency Analysis. Â-values in initial (top) and scaled (bottom) form
for distribution size n = 300.
Figure 6.12: Consistency Analysis. Scaled Â-values for various distribution sizes tested
in the Consistency Analysis.
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Figure 6.13: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable µ. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.14: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable σ. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.15: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable ΠD−s. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.16: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable ΘD−S . Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.17: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable EC50. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.18: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable γ. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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Figure 6.19: Robustness Analysis. Left: Output responses, in terms of percentage of
γH2AX positive (i.e. damaged) cells, and cell count as a result of perturbations to the input
variable TD→L. Right: Maximal Â-values resulting from comparisons between distributions
with perturbed data and a distribution with calibrated (unperturbed) data.
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6.7 Case Study: Analysing the Results from Chapter 5
Figure 6.20: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable µ.
Figure 6.21: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable σ.
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Figure 6.22: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable ΠD−S .
Figure 6.23: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable ΘD−S .
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Figure 6.24: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable EC50.
Figure 6.25: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.
The scatter-plots show the correlation between outputs and the input variable γ.
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Figure 6.26: Latin Hypercube Analysis. Outputs in terms of γH2AX positive cells (left)
and number of viable cells (right) when global parameter perturbations are performed.




In this thesis we discussed the role of mathematical modelling in current, and future,
cancer research. We demonstrated how solid tumour models can be used to study per-
tinent treatment scenarios in silico. The mathematical framework used in this thesis
is based on a multiscale, hybrid, cellular automaton and, as was demonstrated in the
studies outlined in Chapters 3, 4 and 5, this framework provides a great opportunity
to study aspects of tumour dynamics and treatment responses that are not empirically
observable in wet labs and clinical settings. In Chapter 5, the mathematical framework
was fully calibrated by in vitro data and validated by in vivo data, signifying the poten-
tial of its use in pre-clinical settings. The mathematical framework used in this thesis
can be improved by rening, expanding and/or parameterising it. More sophisticated
numerical methods can be used to solve the equations describing diusion processes
and cell cycle regulation. More realistic lattice boundary conditions can be deployed in
order to closer simulate in vivo tumour environments. One can also use more advanced
computational techniques in situations where concerns regarding computational costs
are important or in situations where one wants to simulate larger populations of agents.
In research situations where sub-cellular details are of importance, more intracellular
details can be included and, conversely, when such details are not important, intracel-
lular details can be omitted. Although the mathematical framework used in this thesis
can be improved in may ways, it does serve as an adaptable and easy-to-use in silico
tool. As was discussed in the rst chapter of this thesis, today there exist multiple
mathematical models that are able to capture various aspects of cancer. Once vali-
dated, data driven, predictive mathematical models can be used as a great complement
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to traditional cancer research.
Although advancements in cancer research are being made in parallel across various
research disciplines, multidisciplinary collaborations have the potential to accelerate
the process of translating cancer research into applications that are successful in clin-
ical settings. To this end, McGuire et al. [225] provide an implementable pipeline for
interdisciplinary development of cancer therapies. They illustrate how to structure the
workow amongst clinicians, biologists and researchers from STEM (science, technology,
engineering, mathematics) in an optimal, feasible manner. The workow demonstrates
how multidisciplinary research should alternate between being performed parallelly and
sequentially. It also incorporates rening, iterative processes and an outlined order of
operations which act to bring new cancer protocols to clinics as quickly and safely as
possible. The concept and workow proposed by McGuire et al. [225] acknowledges,
yet transcends, practical limitations as it allows for collaboration across disciplines,
distances and institutes. In order to comprehensively transfer insights from blackboard-
to-bedside [186], dialogue and collaboration between clinicians and mathematicians, as
well as biologists and experimentalists is key [49]. This need for interdisciplinary meth-
ods is currently being pursued, integrating classical cancer research with innovative
ideas from research across multiple disciplines. It is my personal aspiration to work in
such interdisciplinary teams, united with a common goal to further cancer research.
Conceptually, the research eld that is Mathematical Oncology can be regarded as
a mathematical sub-category of oncology, or as a cancer-related sub-category of mathe-
matics. Accordingly, the research methodology of a mathematician in the eld may vary.
A mathematician may choose to work with highly theoretical mathematical models that
include theories that can not be (or have not been) directly validated in wetlabs. Such
models may elucidate biological mechanisms and add to biological knowledge. Alter-
natively, a mathematician may choose to work with more practical, minimal-parameter
models that are based on well established biological phenomena that are empirically
observable. Such models may be more easily tested, and validated, in wet labs. Con-
tributions to both theoretical and practical aspects of mathematical oncology are im-
portant and valid, and both research methodologies should be pursued by the research
community in parallel. However, in the end, there needs to be a bridge between math-
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ematics and pre-clinical/clinical research in order for mathematical oncology to be im-
plementable and ultimately useful in practice. After all, when it comes to mathematical






A1: Appendix to Chapter 3
Implementing Oxygen Dynamics
The total, absolute amount of oxygen in the system uctuates over time due to the
chosen oxygen equation, parameters and boundary conditions. However scaled oxygen
values are used in order to evaluate spatial oxygen distribution and determine hypoxia,
these values are re-scaled at every time step [67]. In Figure 8.1 cell-maps and oxygen-
maps demonstrating spatial oxygen distribution at certain times are provided, these
maps are visualised using ParaView [161].
In Table 8.1, various oxygen measurements for certain time points are listed in
both absolute and scaled forms. Here (KTij) denotes the absolute oxygen value in grid
point (i, j) at time T , and similarly (K̂Tij) denotes the scaled oxygen value in grid point
(i, j) at time T . Here i and j are spatial integer indices ranging from 1 to 100 as
a square grid with 1002 grid points is used. For absolute oxygen values these listed





average oxygen value at one grid point (K̄Tij), the oxygen value at the grid point with
the maximum amount of oxygen (max(KTij)) and the oxygen value at the grid point
with the minimum amount of oxygen (min(KTij)). The same measurements are done for
scaled oxygen values, using the hat notation to denote that the values are scaled.
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Figure 8.1: Cell-maps (top) and oxygen-maps (bottom) at certain times pre chemotherapy
administration. The oxygen-maps demonstrate the spatial oxygen distribution in terms of
scaled, nondimensionalised oxygen values ranging between 0 and 1 at each grid point.
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0 0.41 0 0.01 0.00 40.05 0.00 1.00 0.00
100 41048.10 4.10 4.92 3.50 8334.76 0.83 1.00 0.71
200 70535.20 7.05 8.30 3.36 8498.16 0.85 1.00 0.40
300 58273.21 5.83 7.75 0.69 7514.37 0.75 1.00 0.09
400 29163.37 2.92 4.74 0.09 6155.72 0.62 1.00 0.02
500 12093.96 1.21 2.62 0.02 4619.06 0.46 1.00 0.01
Table 8.1: Nondimensionalised oxygen values of the system at certain time points, in
both absolute form and scaled form (hat notation).
100 8 1 {8}
300 521 45 [512, 530]
500 2440 108 [2418,2461]
700 5285 165 [5252, 5318]
100 8 1 {8}
300 523 48
500 2447 113 [2424, 2469]
700 5116 179
100 8 1 {8}
300 512 50 [502, 522]
500 2418 121
700 4773 197
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This section provides listings of the mean value (mean), standard deviation (S.D) and
95 %-condence interval (I.C(95%)) for test results (a1) through to (e4), presented by
graphs in Figure 4. Here all values have been rounded to integers, corresponding to full
number of cells.
Robustness Analysis
To verify that our results are robust in regards to the chosen parameters listed in Table
3.3, a sensitivity investigation of critical parameters is preformed in which parameters
are varied, one at a time, according to Table 8.2. Each such sensitivity test is performed
100 times, results are provided in Figure S7. These results show that our qualitative
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100 8 1 {8} 0 0 {0} 8 1 {8}
300 484 57 [473, 495] 25 29 509 51
500 2183 181 230 141 2413 121
700 3719 380 [3644, 3794] 1658 391 5378 183
100 8 1 {8} 0 0 {0} 8 1 {8}
300 488 57 28 33 516 50
500 2186 192 241 159 2427 115
700 3240 438 2024 489 5264 189
100 8 1 {8} 0 1 {0} 8 1 {8}
300 481 60 30 39 511 46
500 2168 211 247 178 2415 105
700 2611 418 2530 480 5141 183
100 8 1 {8} 0 1 {0} 8 1 {8}
300 491 58 [479, 503] 34 41 525 45
500 2189 206 256 184 2445 109
700 2338 433 2773 542 5112 198
[19, 31] [499, 519]
[2147, 2219] [202, 258] [2389, 2437]
[1580, 1736] [5342, 5414]
[477, 499] [21, 35] [506, 526]
[2148, 2224] [209, 273] [2404, 2450]
[3153, 3327] [1927, 2121] [5227, 5301]
[469, 493] [22, 38] [502, 520]
[2126, 2210] [212, 282] [2394, 2436]
[2528, 2694] [2435, 2625] [5105, 5177]
[26, 42] [516, 534]
[2148, 2230] [219, 293] [2423, 2467]






Total cell populationSensitive subpopulation Drug resistant subpopulation
S.Dmean C.I(95%) S.Dmean C.I(95%) S.Dmean C.I(95%)
Drug
dosage
















100 8 1 {8} 0 0 {0} 8 1 {8}
300 520 46 [510, 529] 0 0 {0} 520 46 [510, 529]
500 2435 106 [2414, 2456] 0 0 {0} 2435 106 [2414, 2456]
700 2828 155 [2798, 2859] 2560 134 5388 171
100 8 1 {8} 0 0 {0} 8 1 {8}
300 519 49 0 0 {0} 519 49
500 2436 115 0 0 {0} 2436 115
700 3006 156 2167 149 [2137, 2197] 5173 182
100 8 1 {8} 0 0 {0} 8 1 {8}
300 518 48 0 0 {0} 518 48
500 2430 107 0 0 {0} 2430 107
700 3662 147 1200 172 4861 172
100 8 1 {8} 0 0 {0} 8 1 {8}
300 519 50 0 0 {0} 519 50
500 2432 120 0 0 {0} 2432 120
700 3929 201 638 127 4567 183
[2533, 2586] [5354, 5422]
[509, 529] [509, 529]
[2414, 2459] [2414, 2459]
[2975, 3037] [5137, 5209]
[509, 527] [509, 527]
[2409, 2451] [2409, 2451]
[3632, 3691] [1166, 1234] [4827, 4895]
[509, 529] [509, 529]
[2408, 2456] [2408, 2456]






Total cell populationSensitive subpopulation Drug resistant subpopulation
S.Dmean C.I(95%) S.Dmean C.I(95%) S.Dmean C.I(95%)
Drug
dosage
















100 8 1 {8} 0 0 {0} 8 1 {8}
300 527 45 0 0 {0} 527 45
500 2446 108 0 0 {0} 2446 108
700 2507 471 2910 484 5417 156
100 8 1 {8} 0 0 {0} 8 1 {8}
300 518 55 0 0 {0} 518 55
500 2430 127 0 0 {0} 2430 127
700 2695 403 2480 398 5174 194
100 8 1 {8} 0 0 {0} 8 1 {8}
300 518 48 0 0 {0} 518 48
500 2429 108 0 0 {0} 2429 108
700 3428 340 1427 378 4855 164
100 8 1 {8} 0 0 {0} 8 1 {8}
300 517 47 [508, 526] 0 0 {0} 517 47 [508, 526]
500 2429 114 0 0 {0} 2429 114
700 3740 320 830 309 4750 148
[518, 536] [518, 536]
[2425, 2467] [2425, 2467]
[2414, 2600] [2814, 3006] [5386, 5448]
[507, 529] [507, 529]
[2405, 2455] [2405, 2455]
[2615, 2775] [2401, 2559] [5136, 5212]
[508, 528] [508, 528]
[2408, 2450] [2408, 2450]
[3361, 3495] [1352, 1502] [4822, 4888]
[2406, 2452] [2406, 2452]






Total cell populationSensitive subpopulation Drug resistant subpopulation
S.Dmean C.I(95%) S.Dmean C.I(95%) S.Dmean C.I(95%)
Drug
dosage

















100 8 1 {8} 0 0 {0} 8 0.7766152929 {8}
300 341 40 127.45 21 468 48.111708187
500 1468 94 680.65 56 2149 115.26258603 [2126, 2171]
700 2752 140 1694.79 98 4447 181.94978634
100 8 1 {8} 0 0 {0} 8 0.664466065 {8}
300 347 44 129.43 19 476 49.090512157
500 1473 99 688.8 53 2161 111.40484865
700 2558 143 1705.74 104 4264 202.09120328
100 8 1 {8} 0 0 {0} 8 0.649086382 {8}
300 344 42 127.98 19 472 44.998418603
500 1477 98 [1457, 1496] 680.65 47 2157 106.24128057
700 2221 130 1639.13 92 3860 163.58876255 [3827, 3892]
100 8 1 {8} 0 0 {0} 8 0.6043612539 {8}
300 345 44 127.11 17 [124, 131] 473 51.984131223
500 1476 97 679.96 45 [671, 689] 2156 118.11151852
700 2044 124 1605.23 120 3649 183.26251277
[333, 349] [123, 132] [459, 478]
[1449, 1486] [670, 692]
[2724, 2780] [1675, 1714] [4411, 4483]
[338, 355] [126, 133] [466, 486]
[1453, 1492] [678, 699] [2139, 2184]
[2530, 2586] [1685, 1726] [4224, 4304]
[336, 352] [124, 132] [463, 481]
[671, 690] [2136, 2178]
[2195, 2246] [1621, 1657]
[337, 354] [462, 483]
[1457, 1496] [2133, 2180]






Total cell populationSensitive subpopulation Drug resistant subpopulation
S.Dmean C.I(95%) S.Dmean C.I(95%) S.Dmean C.I(95%)
Drug
dosage
















ndings, concerning drug response in cancer cell populations hosting various types of
drug resistance, hold for parameter variations. Indeed the ratio of drug resistant cells
increases with high drug dosages in cases where drug resistance precedes chemother-
apy, here in experiments (b) Primary DR and (e) SC DR. Conversely drug-induced
drug resistant subpopulations are promoted in scenarios with low drug dosages, here in











































Primary DR αpri 0.01 0.005 0.025
Induced DR χind κ/5 κ/5 κ/5 κ/10 κ/2
Induced DR τ [minutes] 30 15 60 30 30
ICC DR αex 0.05 0.03 0.1
ICC DR χind κ/5 κ/5 κ/5
ICC DR τ [minutes] 30 30 30
SC DR αSC 0.07 0.03 0.1
Table 8.2: Parameters used in testing the robustness of the model.
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Figure 8.2: Sensitivity analysis, showing the number of sensitive (blue) and drug resistant
(red) cells at three time points when low (left) and high (right) drug dosages are adminis-
tered, namely 1C and 8C respectively. Each test is performed 100 times and the parameters
used in each test are listed in Table 8.2. Thus for Primary DR, only the parameter αpri
is varied. For Induced DR, χind and τ are both varied, one at a time, according to Table
8.2. For ICC DR only aex is varied and similarly for SC DR only aSC is varied.
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Figure 8.3: A owchart of the code used in Chapter 3.
A owchart of the code used in Chapter 3.
A2: Appendix to Chapter 4
Complement to Figure 4.9
Figures 8.4 and 8.5 show that the Scheduling-Experiment, performed in Section 4.4.2
and with results provided in Figure 4.9, are qualitatively the same if a damaged cell is
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instantly removed from the lattice (Figure 8.4) or if a damaged cell is moved from the
lattice after a time period corresponding to its doubling time (Figure 8.5).
Figure 8.4: Scheduling of HAP-IR combination treatments, Complement to Figure 4.9.
Cells are removed from the lattice instantaneously after the lethal event occurred.
Complement to Figure 4.10
Figures 8.6 and 8.7 show that the experiment that investigates if HAPs act as radiother-
apy enhancers, discussed in Section 4.4.3 and with results provided in Figure 4.10, are
qualitatively the same if a damaged cell is instantly removed from the lattice (Figure
8.6) or if a damaged cell is moved from the lattice after a time period corresponding to
its doubling time (Figure 8.7).
A owchart of the code used in Chapter 4.
A3: Appendix to Chapter 5
Flowcharts of the codes used in Chapter 5.
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Figure 8.5: Scheduling of HAP-IR combination treatments, Complement to Figure 4.9.
Cells are removed from the lattice after a time corresponding to their doubling time (τi)
post the lethal event occurred.
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Figure 8.6: Treatment responses of radiotherapy in various MCTSs when either (1) an
IR monotherapy dose is administered at T0+48 hours or (2) IR is given at T0+48 hours
following a prior HAP dose at time T0. Complement to Figure 4.9. Cells are removed from
the lattice instantaneously after the lethal event occurred.
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Figure 8.7: Treatment responses of radiotherapy in various MCTSs when either (1) an
IR monotherapy dose is administered at T0+48 hours or (2) IR is given at T0+48 hours
following a prior HAP dose at time T0. Complement to Figure 4.10. Cells are removed




Figure 8.8: A owchart of the code used in Chapter 4.
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Figure 8.9: A owchart of the code used in Chapter 5 simulating in vitro scenarios.
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Figure 8.10: A owchart of the code used in Chapter 5 simulating in vivo scenarios.
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